Understanding and Manipulating AAV-Glycan Interactions by Shen, Shen
UNDERSTANDING AND MANIPULATING AAV-GLYCAN INTERACTIONS 
Shen Shen 
A dissertation submitted to the faculty of the University of North Carolina at Chapel Hill in 
partial fulfillment of the requirements for the degree of Doctor of Philosophy in the 
Department of Biochemistry and Biophysics. 
Chapel Hill 
2013 
 
 
 
Approved by: 
Aravind Asokan, Ph.D. 
Ronald Swanstrom, Ph.D. 
Hengming Ke, Ph.D. 
Jian Liu, Ph.D. 
Nikolay Dokholyan, Ph.D. 
ii 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
© 2013 
SHEN SHEN  
ALL RIGHTS RESERVED 
iii 
 
ABSTRACT 
SHEN SHEN: Understanding and Manipulating AAV-Glycan Interactions 
(Under the direction of Dr. Aravind Asokan) 
 
Viral infections generally begin with virus-glycoconjugate interactions on the host 
cell surface. Adeno-associated Virus (AAV) serotypes have been shown to bind to 
sialylated glycans and heparan sulfates for cellular attachment. However, the underlying 
molecular mechanism and its impact on AAV tropism in hosts have not been well 
understood. In this dissertation, terminal N-linked galactose was identified as the primary 
receptor for AAV serotype 9 (AAV9). Moreover, recombinant sialidase was explored as 
an adjuvant to dramatically enhance AAV9 gene transfer both in vitro and in vivo. More 
in-depth analysis of the effects of sialidase on the transduction, tropism, and 
pharmacokinetics profiles of AAV9 indicates that higher binding avidity between AAV9 
and galactose alters its tropism, shifting it from a systemic towards a hepatic phenotype. 
Using AAV9 as a model system, the functions of glycan receptors in determining AAV 
transduction efficiency in vitro and its tropism in vivo were elucidated. In addition, it was 
also showed that the blood circulation kinetics of AAV vectors are tightly regulated by 
their binding avidities with cognate glycan receptors on tissues and blood components. In 
parallel, key amino acids in the galactose binding footprint on the AAV9 capsid were 
identified by screening of a random mutagenesis library of AAV9. Furthermore, grafting 
of the galactose binding footprint from AAV9 onto other AAV strains yields a series of 
novel AAV variants with enhanced transduction efficiency, as well as a rapid on-set of 
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transgene. This work also demonstrates the orthogonality and modularity of glycan 
binding motifs from several naturally occurring AAV serotypes, as well as the 
adaptability of the AAV capsid for the incorporation of new functionalities. By 
establishing the link between the first step of AAV infection and its tissue targeting 
profiles, a novel strategy was proposed to design and construct AAV vectors with organ-
targeting or detargeting phenotypes. In conclusion, this dissertation sheds light on the 
crucial roles of glycan receptors in AAV infectious pathways, and paves a new avenue 
for vector development for gene therapy applications. 
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CHAPTER 1  
Introduction 
1.1 Glycans in Viral Infection 
The glycocalyx on cell surface is composed of complex glycoconjugates that are 
critical in physiological and pathological conditions. It plays important roles in maintaining 
the integrity of cellular morphology, intracellular signaling, cell adhesion and migration, 
regeneration and differentiation, as well as mediating immune responses and tumor 
metastasis. While glycocalyx forms a shield against microbial invasion, pathogens also 
exploits these glycans on the host cell surface as anchoring points to initiate infection.   
Three major classes of glycoconjugates on the cell surface are utilized by viruses as 
primary receptors 1. The first class is glycosphingolipid (also called glycolipid), a 
polysaccharide chain covalently linked to the terminal hydroxyl group of the ceramide lipid 
anchored in the cellular membrane. The second type is glycoprotein, formed by 
oligosaccharides covalently linking to the extracellular domains of polypeptide backbones. 
Glycoproteins can be classified as N-glycans and O-glycans based on the amino acid residues 
the sugar chains attach to. An N-glycan forms when an asparagine residue of an Asn-X-
Ser/Thr motif on the polypeptide chain is attached by an oligosaccharide molecule. An O-
glycan is linked to the polypeptide backbone via the hydroxyl group of a serine or threonine 
residue. The third class of glycoconjugates is proteoglycan, which is formed by covalently 
linking glycosaminoglycans (GAGs) to serine residues on a peptide backbone via xylose 
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moieties. Glycolipids and glycoproteins contain linear or branched oligosaccharide chains 
that are usually capped with sialic acids. These sugar chains often consist of repeating 
disaccharide units Galβ1-4GlcNAcβ1- or GalNAcβ1-4GlcNAcβ1-, and are modified with 
sulfate groups, fucose (Fuc), or β-GalNAc. In contrast, GAG are linear polysaccharide chains 
composed of repeating disaccharide units, including GalNAcβ1-4GlcA (in chondroitin), 
GalNAcβ1-4IdoA (in dermatan sulfate), GlcNAcα1-4GlcA (in heparin), GlcNAcα1-4IdoA 
(in heparan sulfate), or GalNAcβ1-4GlcNAc (in keratin sulfate). 
What forces drive the virus-glycan interactions? Since the sulfate groups on GAGs 
and the carboxyl groups of the terminal sialic acid moieties are negatively charged, these 
glycans usually bind to basic patches on the exterior surface of viral structural proteins. 
Especially in the case of heparan sulfate-recognizing proteins, common motifs with 
continuous positive charges XBBXBX or XBBBXXBX (B: lysine or arginine; X: any other 
amino acid) were proposed 2.  Therefore, electrostatic forces are the key forces involved in 
virus-glycan interactions. In addition, direct hydrogen bonding as well as H2O mediated 
hydrogen bonding between hydroxyl groups on glycan residues and hydrophobic or aromatic 
amino acids contribute to the specificity of glycan-virus interactions. 
Although the interactions between viruses and their cognate glycan receptors are 
highly specific, it is noteworthy to mention that the binding affinity (Kd) between a single 
viral particle and a single glycan receptor is very low, sometimes within the micromolar (µM) 
to millimolar (mM) range 3. Therefore, avidity, the cooperative synergy of multiple virus-
glycan interactions, increases the affinity and specificity of this binding event 4. This 
multivalency of virus-glycan binding is attributed to the icosahedral symmetry of identical 
viral protein (VP) subunits, and the multiantennary glycan structures. The spatial symmetry 
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of icosahedral viruses allows for the presence of 12, 20, 30, or even more identical receptor 
footprints on one macromolecule assembly.  
The first step of viral infection is the virion-receptor interactions on cell surface, 
usually mediated by carbohydrates. Once attached by cell surface glycans, viruses are 
concentrated on cell membrane. At the same time, this virus-glycan interaction primes the 
viral particles for protein receptor recognition by inducing global conformational changes on 
viral proteins. Then the surface bound viruses are guided into cytoplasm and hijack the 
cellular replication machinery. Because these virus-glycan interactions are very specific, the 
distribution and presence of the corresponding glycans plays a determining role in the 
permissibility of viruses in different cell types, tissue types, and species.  
 An example of how glycan binding ability impacts the species specificity of viral 
infection and the antigenic drift among species is influenza viruses. Influenza A viruses, the 
major cause of annual flu epidemics (www.cdc.gov/flu), infect several animal species, 
including birds, swine, and humans 5-7. Although all influenza A strains recognize terminal 
sialic acids (SA) as primary receptors, it was not until 1983 that Rogers and Paulson 
discovered that the influenza hemagglutinin (HA) possesses specificity towards different 
linkage forms between sialic acid and the penultimate galactose 8. Tumpey et al. further 
demonstrated that by mutating two amino acids, A/South Carolina/1/18 (SC18), specific to 
α2-6 SA, can switch to a α2-3 SA preference displayed by AV18 (avianized 1918 influenza 
virus). This altered glycan recognition pattern of SC18 completely abrogates its transmission 
between ferrets, a model for human respiratory system 9. X-ray crystallography and high-
throughput glycan array screening revealed that α2-6 SA adopts an umbrella-like topology, 
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allowing for human-adapted HA binding. The cone-topology, displayed by α2-3 SA and 
short α2-6 SA chains, is more amenable towards avian or swine-adapted HAs 10,11.  
 Other examples of viruses binding to sialylated glycans for infection include 
Adenovirus type 37 12, Coronavirus OC43 13,14, Measle virus 15, Sendai virus 16, Newcastle 
disease virus 17, Enterovirus 70 18 and Rhinovirus 87 19,20 in the Picornavirus family, 
Reovirus 3 21-23, as well as Rotavirus 24-26, JC 27 and BK viruses 28 in Polyomaviridae (Table 
1). The distribution and availability of their cognate sialylated glycan receptors on tissues 
partially determine the tropism and transmissibility of these viruses in hosts. For examples, 
Norovirus, the causative agent for acute nonbacterial gastroenteritis, binds to ABO(H) histo-
blood group antigens on red blood cells (RBCs) and intestinal mucosa to infect hosts 29. A 
key enzyme in the biosynthesis pathways of histo-blood group antigens in the intestines is 
FUT2, which transfers fucose to galactose through an α1-2 covalent bond 30. Due to a FUT2 
deficiency in ~20% of Caucasians and Africans, these populations lack the glycan receptor 
Fucα1-2Gal for most Noroviruses in gut. Therefore, the same populations also possess a 
natural resistance to most Noroviruses transmission 30.  
 Glycoaminoglycans (GAGs) is another group of carbohydrate receptors for viral 
infections as shown in Table 1.  The differentiated degree of sulfation on heparan sulfates in 
major organs partially explains the hepatic tropism of hepatitis A, B, D, E, and hepatitis C 
virus (HCV). According to a study led by Vongchan et al., heparan sulfate in human liver has 
an elevated level of sulfation compared to that in other human organs, porcine liver, or 
HepG2 cell culture 31. In vitro GAG inhibition assays demonstrate that HCV binds 
preferentially with highly sulfated heparan sulfates or heparin 32. In addition, only the 
heparan sulfates isolated from liver, not kidney, can efficiently blocks HCV binding. It 
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prompted us to speculate that the preferential binding of HCV on highly sulfated heparin 
sulfate prevents HCV from being absorbed in other organs and ultimately leads to its hepatic 
accumulation. Although HCV belongs to a different viral family different from HAV and 
HBV, they all requires heparan sulfates for efficient binding and cellular uptake of viruses 33-
36. Therefore, analogy is likely to be drawn among them with regards to the tropism-
determining role of heparan sulfates. 
1.2 Glycan Receptors for Parvoviruses  
Parvoviruses are small, non-enveloped, single-stranded DNA viruses 37. Its members 
include canine parvovirus (CPV), feline parvovirus (FPV), goose parvovirus (GPV), porcine 
parvovirus (PPV), bocavirus (BoV), B19, AAV, and minute virus of mice (MVM), etc. 
Similar to all other pathogens, interactions with glycan receptors is a prerequisite for efficient 
infection by parvoviruses.  
Two parvoviruses, bovine AAV (BAAV) and B19 are the only strains known to bind 
to glycosphingolipid (GSL) to engage productive infection 38,39. Schmidt and Chiorini 
showed that the transduction and binding of BAAV is SA-dependent as sialidase treatments 
abolish its infection and binding in vitro 38. On the other hand, incorporation of GSL in GSL-
depleted CHO cells or C6 cells restored BAAV infection and binding, while disruption of 
glycoprotein using trypsin and dispase does not alter its infection profiles. Cryo-EM structure 
of B19-globoside complex published in 1996 suggests that globosides bind to the depression 
around the three-fold axes 39. Mutations around the globosides binding footprints yield 
mutant B19 that can escape neutralizing antibodies.  
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Parvoviruses that bind to heparan sulfates for infection include AAV2 40, 
AAV3B  41,42, and AAV6  43. In addition, AAV1 44, AAV5  45, and AAV6 44 use N-linked 
sialic acids to attach to cell surface. It is noteworthy to mention that AAV6 is the only 
naturally occurring strain of parvovirus that is known to bind alternatively to two types of 
glycan receptors, heparan sulfate and sialic acid. With a difference of six amino acids (AAV6 
VP1 numbering: F129, D418, K531, L584, V598, H642) out of more than 700 residues on 
AAV6 VP3, AAV1 shows suppressed heparan sulfate binding profiles and the subsequential 
inability to transduce liver parenchymal cells. Interestingly, a single lysine-to-glutamate 
(K531E) mutation on AAV6 attenuates its heparan sulfate binding efficiency, while the 
converse mutation (E531K) on AAV1 imparts its heparan sulfate binding ability. 
Furthermore, this E531K also bestows AAV1 the ability to transduce liver parenchymal cells. 
This hepatotropism induced by AAV-heparan sulfate interactions echoes the aforementioned 
phenotype displayed by HCV. 
Another AAV serotype that engages with sialoglycans is AAV4, a cardiopulmonary 
tropic isolate. AAV4 utilizes O-linked sialylated glycoprotein, mucin, to initiate 
infection 46,47. The molecular mechanism of how sialylated glycans in heart and lung 
contribute to its cardiopulmonary phenotype is discussed in detail in Appendix I of this 
dissertation. Briefly, intravenous injection of sialidase disrupts the transduction of AAV4 in 
murine heart and lung, which prerents abundant O-linked sialylated glycans on cell surface. 
AAV4 mutants that are deficient in SA binding also demonstrate loss-of-transduction in the 
cardiopulmonary system.  Blood circulation assay of the parental and mutant AAV4 reveals 
that attenuated SA binding ability leads to reduced binding on erythrocytes and other blood 
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cells. It is the formation of AAV-erythrocytes in circulation and high affinity towards O-lined 
SA in heart and lung that eventually result in the cardiopulmonary tropism of AAV4. 
Previous studies on the prototype MVM (MVMp) and immunosuppressive MVM 
(MVMi) also imply the determining roles of SA in viral tropism. A battery of biophysical 
characterizations revealed that high binding affinity between MVMi and sialylated glycans 
contributes to the neurotropism of MVMi 48,49. Specifically, mutations on residues 399, 460, 
553, and 558 of MVMp confer a fibroblast-tropism similar to that of MVMi. X-ray 
crystallography structure suggests that the “shoulder” region of the spikes surrounding the 
three-fold axes of MVM and the “dimples” along the two-fold axes harbors the residues 
involved in SA binding and fibrotropism 50.  
Recent studies from our group and others discovered that terminal N-linked galactose 
is the primary receptor for AAV9, and the binding avidity between AAV9 and galactose 
drives the systemic tropism of AAV9 in animal 51-53. Details are discussed in Chapters 2 
and 3 of this dissertation. Enzymatic desialylation on a spectrum of cell lines demonstrates 
elevated AAV9 binding and transduction profiles. This observation was corroborated by 
transduction and cell surface binding assays on CHO-Pro5 and CHO-Lec2 cells. In 
conjunction with lectin inhibition and biophysical assays, this led to the conclusion that the 
penultimate galactose moiety is the glycan receptor for AAV9. In a murine model, enhanced 
availability of galactose in major organs shifts the systemic tropism of AAV9 towards liver, 
while both its blood distribution and blood retention time are shortened due to absorption into 
tissues. The scarcity of free terminal galactose residues in physiological conditions prevents 
AAV9 particles from being depleted by a single major organ like AAV2. As a result, AAV9 
tends to circulate longer in blood stream, allowing for non-specific low-affinity interactions 
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with sialylated glycoconjugates or secondary receptors. Ultimately, AAV9 are evenly 
distributed into all major organs, and displays its unique systemic transduction profiles in 
animals. Molecular simulation, together with alanine-scanning on AAV9 VP3, indicates that 
N470, D271, N272, Y446, and W503 form a three-dimensional binding pocket for galactose 
recognition. Grafting of this pocket and flanking residues enables multiple AAV serotypes to 
bind to galactosyl-glycans, suggesting the modularity of this glycan receptor footprint and 
the adaptability of AAV capsid for new functionalities. The engineering of G mutants (G 
represents galactose) is presented in Chapter 4 of this dissertation. 
1.3 Genomic Composition of AAV 
AAV genome is a single-stranded DNA, 4,679 bases in length 54. At each end of the 
AAV genome, there is a 145-base long inverted terminal repeat (ITR) flanking the rest of the 
DNA sequence. Due to its high GC content, ITRs form secondary hairpin structures, 
discernible using tungsten-shadowing EM 55. These ITRs are the minimal requirement for 
AAV genome packaging 56, and also play critical roles in genome integration and second-
strand DNA synthesis 57.  
As shown in Figure 1, there are two Open Reading Frames (ORFs) between the two 
ITRs in AAV genome. They encode replication components and viral protein of AAV, 
respectively. The Rep region on AAV genome encodes four Rep proteins that are 
instrumental in wild-type AAV life cycle. Alternative splicing of the mRNA transcribed from 
p5 promoter yields Rep78 and Rep68. P19 drives the transcription of two smaller Rep 
proteins, Rep52 and Rep40. While Rep78 and Rep68 facilitate genome replication and 
integration into chromosome 19 of the human genome 58, Rep52 and Rep40 are required for 
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efficient encapsidation of AAV genome 59. Both p5 and p19 promoter regions contain Rep 
Binding Elements (RBEs), which bind to Rep proteins in order to self-regulate 
transcription 60.  
The Cap ORF encodes two mRNAs, one of which translates into VP1. The second 
mRNA can be translated into VP2 from an alternate start codon (ACG), or VP3 from a 
conventional start codon (ATG). Due to the leakiness of the ACG start codon, the ratio 
between VP2 and VP3 is 1:10. VP1, VP2, and VP3 share the same C-terminus, while VP1 
unique region (VP1u) harbors a phospholipase A2 (PLA2) domain and nuclear localization 
sequence (NLS), necessary for endosomal escape and nuclear entry during AAV infectious 
pathway(s) 61-63. The alternate start codon also encodes for a 23 kD assembly-activating 
protein (AAP), which targets newly synthesized VPs from cytoplasm into nucleus and 
facilitates the assembly of AAV particles 64-66.  
1.4 Icosahedral Structures of Viral Capsids  
Viruses are small bionanoparticles. To generate a protective protein shell for nucleic 
acids with minimal structural information, only a few types of protein capsid morphologies 
are constructed by viruses, including helical tubes and icosahedral shells 67. Crick and 
Watson first proposed the hypothesis that construction of identical subunits in an ordered 
form is the most efficient way to use the limited amount of structural information provided 
by viral genome 68,69. This hypothesis has been verified by X-ray crystallography and cryo-
EM structures of many viruses. It was in 1957 that the first icosahedral viral structure, tomato 
bushy stunt virus (TBSV), was solved by X-ray crystallography 70, followed by another 
icosahedral capsid of turnip yellow mosaic virus 71. From then, a series of nonevenloped 
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RNA viruses were claimed to adopt the same icosahedron shape of capsid assembly, 
including turnip crinkle virus (TCV), picornavirus, rhinovirus, and reovirus 3,72,73. The 
collection of icosahedral viruses further expands to DNA viruses, for example, SV40 and 
murine polyomaviruses. At the same time, it was also shown by geometrical theorems that 
icosahedral symmetry is the most efficient form of packing with the lowest energy 74.  
1.5 Capsid Structures of AAV  
Parvoviruses have a common icosahedral protein shell with a triangulation number 
T=1, and AAV is no exception. A 5:5:50 ratio of VP1 (87kD), VP2 (83kD), and VP3 (61kD) 
constitutes this icosahedral capsid with a size of 25 nm in diameter. There are 12 
representative members of AAV serotype, AAV1-12. Due to high amino acid sequence 
homology (60-90%), VPs of these 12 AAV serotypes adopt similar 3D structures. With 
technological advancements over the past decades, atomic structures of most representative 
AAV serotypes are available in RCSB Database as shown in Table 2. The core structure of 
AAV VP is an eight-stranded jelly-roll β-barrel, observed in many icosahedral viral capsids. 
As depicted in Figure 2A and 2B, βBIDG and βCHEF constitute two antiparallel β-sheets. A 
short β-strand A (βA) is located at the N-terminal region of VP3, in antiparallel interactions 
with βB. There is also a short α-helix facing the interior of viral capsid. All eight β strands 
and the α helix are conserved among all AAV serotypes. In contrast, the loops connecting 
neighboring β strands are highly dynamic in both amino acid sequence and structural 
morphology. These loops are named by the two β strands they connect. For instance, the loop 
that links βH and βI is called the HI loop. The shortest loop is the FG loop, only 2-3 amino 
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acids in length.  The longest loop is the GH loop (~230 amino acids), where most sequence 
variation resides.  
When 60 subunits assemble into an intact AAV capsid, these dynamic loops 
demonstrate their pivotal roles in intra-subunit interactions and the formation of exterior 
surface topology. First of all, the five-fold axes of symmetry are formed by DE loops and HI 
loops from five adjacent monomers. The most prominent feature of the pentamers is their 
iris-like five-fold pores in the center. Extensive mutagenesis of the amino acid constituting 
the five-fold pore reveals that it is not only instrumental in packaging single-stranded DNA 
into AAV capsid, but also critical for extrusion of VP1u during post-entry steps in 
infection 75-77. Bleker S. et al. further demonstrated that the interactions between the five-fold 
pores and Rep proteins promote the encapsidation of AAV genomes in preformed capsid 
shells 78. Deletion, insertion, and substitution mutations on the HI loop by DiPrimio et al. 
shed light on the functional roles of the canyon structures surrounding the five-fold pore 79. 
F661 on the HI loop and P373 on the EF loop of AAV2 are critical residues involved in the 
incorporation and activity of the VP1 unique domain. Substitution of the HI loop with a 
hexa-histidine stretch yields AAV2 particles that are amenable to nanogold labeling and 
purification through nickel column 80.  
According to structural analysis of subunit interfaces, the two-fold axes of symmetry 
of AAV hold the least energy among three types of interfaces 81,82. This area with dimple 
structures was also proposed to contain heparan sulfate binding motif as well as high 
tolerance of peptide insertion 77,83. Site-directed mutagenesis of tyrosine-to-phenylalanine 
changes of all seven Tyr residues clustered near two-fold axes of AAV2 (Y252F, Y272F, 
Y444F, Y500F, Y700F, Y704F, Y730F) showed enhanced transduction profiles both in vivo 
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and in vitro. The underlying mechanism is that these Tyr mutants are able to avoid the 
phosphorylation by epidermal growth factor receptor protein tyrosine kinase (EGFR-PTK) 84. 
Similar results were observed with two tyrosine-to-phenylalanine mutations on AAV6 
(Y445F, Y731F), indicating a ubiquitous function of tyrosine residues in AAV life cycle 85. 
Chemically crosslinking Y704 from two adjacent monomers on AAV2 results in dityrosine 
adducts with reduced flexibility of both the two-fold depression and five-fold interface 86. 
The reduction of transduction and nuclear entry induced by this artificial constrain further 
supports the notion that the two-fold axes on AAV capsid play a role in VP1u extrusion. In 
addition, amino acids along the dimple structure of the two-fold axes of symmetry on AAV2 
are also implicated in the neutralizing antibody (NAb) recognition as well as affinity towards 
skeleton muscles. An AAV1-AAV2 hybrid variant, AAV-221-IV, first drew the attention 
towards the aa213-423 region on AAV1. Swapping this domain from AAV1 onto AAV2 
promotes higher transduction of AAV1 in skeleton muscles. Later on, Bowles D.E. et al. 
constructed AAV2.5, an AAV2 mutant with five amino acids swapped from AAV1 87. 
Although no changes were observed in in vitro transduction profiles, AAV2.5 demonstrates 
elevated transduction efficiency in skeleton muscles in mice and attenuated cross-reactivity 
with NAbs. More in-depth mutagenesis focused on two specific amino acids (Q263A, and 
265T insertion) in this area 88. It implies a functional role of the 265 region in stimulating 
humoral immune response. Given its unique antibody-neutralizing profile, AAV2.5 can serve 
as a candidate for repetitive administration of AAV vectors.  
The three-fold axes of symmetry on AAV capsids are the hot spot of structural 
variance, which further dictates AAV functionalities. As mentioned earlier, the GH loops 
forming the three-fold axes are the longest loop on AAV VP. On the trimeric assembly, GH 
13 
 
loops constitute three mounds of spike protrusions, the inner loops, middle loops, and outer 
loops. Glycan and protein receptor binding footprints disseminate among these surface 
exposed loops.  
Extensive mutagenesis studies discovered the heparan sulfate binding site on AAV2, 
constituted with R484, R487, K532, R585, and R588 at the walls and valleys of the three-
fold spikes 77,89-91. The three-dimensional footprint has a positive electrostatic potential and 
concaved structure, readily accommodating highly negatively charged heparan sulfate 
oligosaccharide chains. The repetitive appearance of this footprint on the icosahedral AAV 
capsid allows the flexible heparan sulfate chains to wrap around the virions with enhanced 
binding avidity. Further cryo-EM study on the AAV2-heparan sulfate complexes visualizes 
conformational shifts at the three-fold and five-fold area of AAV2 92. Our knowledge of the 
glycan receptor footprint on AAV surface is expanded with co-crystal structure of AAV3b 
and heparan sulfate 93. In addition to conserved residues R475, R485, R488, K533 from 
AAV2, R447 and the AAV3b-unique R594 are also in contact with heparan sulfate on 
AAV3b capsids. The N500 also contributes to the positive electrostatic potential in close 
proximity of three-fold spikes. A similar continuous basic patch is also conceivable on the 
three-fold spikes of AAV6 43. K531 on AAV6 three-fold axes, which is absent on AAV1, 
connects residues R487, K528, K533, and K567 to compose a positively-charged surface 
exposed region. K531E mutation on AAV6 not only reduces its retention time on heparin 
columns, but also diminishes its transduction efficiency in hepatocytes.  
In case of SA binding AAV serotypes, their glycan receptor footprints are also 
located in close proximity to the three-fold axes of symmetry. Our recent studies on AAV4 
identified K492, K503, M523, G581, Q583, N585 as key residues in contact with sialylated 
14 
 
glycans on CV-1 cell culture and murine erythrocytes. Three-dimensional structural 
alignment of AAV4 and AAV2 trimers showed that the heparan sulfate and SA binding 
pockets occupy similar regions on AAV capsids. In addition, site-saturation mutagenesis and 
alanine-scanning confirmed the notion that M569, Y583, and L585 on the inner loop of 
AAV5 three-fold area are indispensable for productive infection of AAV5 on cell culture 
(Shen Shen and Aravind Asokan, unpublished data). 
On the exterior surface of AAV9, galactosylated glycans are indicated to bind to 
amino acids in close proximity to the three-fold axes. With a combination of molecular 
simulation, site-directed mutagenesis, and cell-surface binding assays, N470, D271, N272, 
Y446, and W503 were identified as the galactose binding site on AAV9 94. In parallel, 
screening of a random mutagenesis library on AAV9 GH loop reveals that single mutations 
of W503 or N498 are sufficient to abrogate its galactose binding ability 95. Further 
investigation of transduction and pharmacokinetics profiles of these individual AAV9 
mutants confirms that mutations on W503 and N498 are also detrimental to the systemic 
tropism of AAV9 51,95.  
Interestingly, AAV2 and AAV9 also engage with their cognate protein receptors via 
domains on the trimer protrusions. Integrins αVβ5 and α5β1 recognize AAV2 through 
specific interactions with its conserved binding domain NGR/RGD (residues 511-513 on 
AAV2 VP1) 96. Located on the outer loops, this domain is conserved across several AAV 
serotypes (except AAV4, AAV5, and AAV11) as shown by sequence alignment. Akache et 
al. discovered that 37/67 kD laminin receptors mediates transduction of AAV8, AAV2, 
AAV3, and AAV9 97.  Coincidentally, the structure on AAV capsids that interact with LamR 
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were mapped onto the GH loops---stretches 491-547 and 593-623 (AAV8 VP1 amino acid 
numbering). 
The protrusions surrounding the three-fold axes of AAV serotypes not only contain 
receptor binding sites, but can also be attached by monoclonal NAbs. Cryo-EM and 3D 
reconstruction of AAV8 virion, together with docking simulation of a generic Fab model, 
provide the structural hint that residues 586-591 on AAV8 (VP1 numbering) interact directly 
with the neutralizing monoclonal antibody ADK8 98. In-depth biochemical analysis reveals 
that binding of ADK8 prohibits AAV8 intracellular trafficking. With the recent discovery of 
ADK9 66, whether residues 586-591 on the inner loops of other AAV serotypes are in direct 
contact with their corresponding NAbs are yet to be determined. 
1.6 Infectious Pathways of AAV  
Upon attachment to its cognate glycan receptors on the cell surface, AAV undergoes 
conformational changes to prime for interactions with its secondary receptors 92. A spectrum 
of growth factor receptors, integrins, and LamR are claimed to be the co-receptors for AAV 
serotypes (listed in Table 2). Specifically, AAV2 utilizes αVβ5 and α5β1 Integrins, 
hepatocyte growth factor receptor (HGFR), fibroblast growth factor receptor (FGFR), LamR 
to engange infection 96,97,99,100. Similarly, AAV3b also exploits HGFR and LamR for 
infection 97,101. Bioinformatics technologies and cell-based assays discovered that AAV5 and 
AAV6 interact with platelet-derived growth factor receptor (PDGFR) and epidermal growth 
factor receptor (EGFR) as co-receptors for transduction, respectively 102,103. As described 
earlier, AAV8 and AAV9 also uses LamR 97. Recent study in our lab indicates that αVβ3 
integrins are indispensable for efficient gene transfer by AAV9 both in vitro and in vivo 
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(Shen Shen and Aravind Asokan, unpublished data). This work also shed light on the roles of 
co-receptors in AAV life cycles in animals.  
Receptor binding of AAV serotypes triggers signaling pathways in the cytoplasm to 
embark efficient uptake of virions, which is a rate-limiting step for most viral infection 104. 
Most AAV serotypes enter cells through dynamin-dependent budding of clathrin-coated 
vesicles 105-107. A recent study in Thomas Weber’s group incorporates the CLIC/GEEC 
pathway in the picture of AAV2 internalization 108. This cellular entry step is both serotype- 
and cell-type dependent. For instance, in well-differentiated human airway epithelial cells 
(HAE), AAV tends to infect the basolateral side 200-fold more efficiently than from the 
apical side of polarized cells 109. AAV5 is an exception. It employs both clathrin- and 
caveoli-dependent routes of cellular uptake to enter primary human embryo fibroblasts 110. 
Another study from John Engelhardt’s group demonstrated distinct transduction pathways of 
AAV1 and AAV6 on polarized HAE, supporting the notion that receptor recognition of 
individual AAV serotype also plays an role in post-entry steps of AAV lifecycle 111.  
Following cellular entry is the cytoplastic processing of AAV particles. 
Colocalization of AAV virions with endosomal compartments highlighted by fluorescent 
markers reveal that AAV travels through early, late, and recycling endosomes before nuclear 
entry 112-114. In HeLa cells, AAV2 traffics through the late endosome marked by Rab7 at low 
multiplicity of infection (MOI). When excessive AAV virions are present, Rab11-positive 
routes serve as the express highways for AAV2 transduction 112.  During this endosomal 
trafficking, AAV capsids also undergo structure alterations and chemical modifications. As 
described earlier, VP1u with a PLA2 domain and an NLS externalize from the five-fold axes 
of symmetry prior to endosomal escape. This conformational rearrangement in post-entry 
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steps is paramount for effective AAV transduction as microinjections of intact AAV particles 
do not guarantee infection 115. Later, Arun Srivastava’s group discovered that epidermal 
growth factor receptor protein tyrosine kinase (EGFR-PTK) phosphorylates some tyrosine 
residues on AAV2 capsids by casein kinase II (CKII), which is further proven to be an 
prerequisite step for nuclear entry 84,116,117. AAV2 mutants evading tyrosine phosphorylation 
have higher transduction efficiency in vitro. Other components in signaling pathways 
involved in AAV2 intra-cellular trafficking include, but not limited to, rac1 and 
phosphatidylinositol-3 kinase activation, phosphorylate FKBP52 protein, and ubiquitin-
proteasome pathways 114,118,119.  
Cytoskeleton is the key player facilitating the translocation of AAV from cellular 
membrane to perinuclear region, as demonstrated in HeLa cells using quantitative 3D 
imaging techniques 108,119-122. Direct visualization of the intact AAV particles in the nucleus 
indicates that uncoating and genome replication of AAV occur inside the nucleus 106,118,123. 
1.7 Reengineering AAV Capsids  
A prominent advantage of AAV vectors in gene therapy applications is its broad 
collection of tissue tropism, attained by its ever-growing collection of naturally occurring and 
artificially generated variants. In murine models, AAV2 and AAV8 are highly hepato-centric, 
while AAV1 transduces skeleton muscle ~100-fold more efficiently 124,125. AAV4 is 
prevalent in transducing the cardiopulmonary system after systemic administration, while it 
targets astrocytes in the rostral migratory stream (RMS) if injected intraventrically into the 
brain. AAV5 transduces the hippocampus after CNS administration 126. AAV6 demonstrates 
high transduction efficiency in both liver and skeleton muscle. AAV9 has a systemic 
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transduction profile after intravenous administration. Intriguingly, AAV9 is also able to cross 
the blood-brain barrier besides its systemic phenotype. Recently, AAV.rh8 and AAV.rh10, 
isolated from rhesus monkey tissues, show compelling brain transduction efficacy similar or 
greater than AAV9 in CNS 127-129. Although the arsenal of naturally occurring AAV strains is 
expanding, pre-existing NAbs in human population, cross-species disparity of tropism, and 
dose-related toxicity still hurdles its transition from bench to bedside into clinical 
applications. To conquer these issues, the next generation of AAV vectors was introduced by 
viral protein engineering and directed evolution of AAV libraries. 
In 2003, Muller and colleagues generated the first AAV capsid library by inserting a 
random peptide library on AAV2 capsid 130. Panning and selection on human coronary artery 
endothelial cells gave rise to AAV mutants with cell line specific transduction profile. The 
next breakthrough in AAV library construction and screening took place in 2006. In this 
study led by N. Maheshri, random mutations were introduced to AAV2 VP1-3 by combining 
error-prone PCR and staggered extension process 131-133. High-throughput screening of this 
library with >106 individual clones successfully isolate mutants with altered affinities 
towards heparan sulfates and acquired ability to evade antibody-neutralization compare to the 
parental AAV2. AAV libraries based on other serotypes sprout since then. Based on different 
selection strategies, AAV mutants with specific tissue-targeting properties were characterized. 
Directed evolution of a chimera library of AAV2 and AAV5 yields a novel AAV vector 
(AAV2.5T) efficient in transducing well-differentiated polarized human airway epithelium 
(HAE), projecting a promising candidate for cystic fibrosis treatment 134,135.  Mechanistic 
studies of AAV2.5T indicates that its increased infectivity on HAE is due to its higher 
affinity towards α2,3-N-linked SA on the respirotary airway than AAV5 and AAV2. Other 
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studies form David Schaffer’s group developed AAV vectors targeting retina glia, Müller 
cells, pig airway epithelium, and neural stem cells for cell type specific applications 136-140. 
Another strategy to construct AAV capsid library is DNA shuffling. Li W. et al. 
shuffled the VP sequences from AAV1-9 with exception of AAV7 to generate an AAV 
shuffling library 141. Directed evolution of this library on the ciliated HAE resulted in two 
variants, HAE-1 and HAE-2, both of which possess higher transduction efficiency on HAE 
compared to the parental strains. Selection and screening of the same library further yielded 
AAV isolates capable of crossing seizure-compromised blood brain barrier 142.  
During the endeavor to decipher AAV9 structure-function relation, Pulicherla et al. 
created an AAV9 capsid library with random mutations on the GH loop by error-prone 
PCR 95. 10 out of 96 individual AAV9 clones were isolated and characterized in mice. Three 
variant, 9.24, 9.45, and 9.61, were identified as class II mutants displaying liver-detargeted 
phenotype. These vectors are well suitable for clinical applications to evade liver toxicity. In 
vitro analysis of the glycan binding property of each mutant also discovered that W503 and 
N498 are key residues involved in AAV9-galacotse interactions, as mentioned earlier. 
Despite the prevalence of AAV libraries with random swaps/mutations/insertions, 
rational engineering based on receptor usage information has been an important strategy 143. 
By substitute partial heparan sulfate binding footprint on AAV2 (585-RGNRQA-590) with 
corresponding residues from AAV8 (585-QQNTAP-590), AAV2i8 is unable to bind to 
heparan sulfate. The same variant also demonstrates muscle-tropic phenotype both in mice 
and non-human primates. Results from this study not only showed the versatility of AAV2 
capsid, but also correlate AAV-receptor interactions with hepatotropic phenotype of AAV in 
general. 
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1.8 AAV in Gene Therapy 
AAV2 was first discovered in an Adenovirus type 12 preparation as contaminant in 
1965 144. AAV1, AAV3, and AAV4 were sequentially isolated from a simian Adenovirus 15 
stock, an Adenovirus 7 stock, and African green monkey 145-147. AAV5 and AAV9 were 
discovered from humans, while AAV7 and AAV8 were isolated from rhesus monkeys 124,148. 
In addition, AAV10 and AAV11 were cloned from cynomolgus monkeys 149. In 2004, a 
study led by Gao G. expand the collection of naturally occurring AAV to more than 100 
members 124. The pursuit of more naturally occurring AAV strains and reengineered variants 
is fueled by AAV’s encouraging successes as gene therapy vectors. 
The idea of using AAV to package transgene traces back to 1982 150,151. The era of 
gene therapy flourishes when therapeutic genes can be introduced to target cells or organs. 
Compared to other viral vectors, AAV has the advantage of no currently-known 
pathogenicity, prolonged transgene expression kinetics, and the ability to transduce both 
dividing and non-dividing cells.  Transition of AAV vectors from bench-to-bedside was 
enabled by the extensive knowledge of the basic virology of the vectors described earlier.  
Preclinical and clinical trials have been carried out with many AAV strains and 
emerging AAV variants 152. For instance, AAV8 has been tested in nonhuman primates and 
dog models to express factor IX in liver, with the hope of alleviating hemophilia symptoms. 
AAV1 packaging the SERCA2a gene is in phase I/II clinical trial to treat cardiac failure. As 
described earlier, AAV5, HAE-1/2, and AAV2.5T have been investigate to develop cures for 
pulmonary diseases, such as cystic fibrosis. In the past few years, extremely exciting results 
of recombinant AAV vectors come from clinical trials of Leber’s congenital amaurosis. 
AAV4 and AAV8 restoring retinal pigmented epithelium (RPE) functions showed success in 
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expression RPE65 gene into RPE65-deficient dogs and nonhuman primate models. Patient 
treatments demonstrated over five orders of magnitude of progression in rod photoreceptor 
function. Using AAV as delivery machinery into the brain also saw encouraging results in 
treating Canavan’s, Parkinson’s, and Batten’s diseases in long-term assessments.  
Despite persistent successes in the clinical front, there are still concerns and 
challenges regarding to the pre-existing humoral immunity, cross-species difference in 
tropism, immune response to both AAV vector cassette and transgene products. Further 
improvement of existing vectors and development of new AAV vectors counts on a 
persistent accumulation of basic knowledge about AAV biology. 
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Table 1. Examples of Viruses and Their Cognate Glycan Receptors1 
Virus Family Virus Type Glycan Receptor 
Adenoviridae Adeno 37 
Adenovirus 2,5 
α2-3 SA 
Heparan Sulfate 
Arenaviridae Lassa Virus Dystroglycan Glycans 
Caliciviridae 
      Noroviruses 
 
Norwalk and others 
 
Histo-blood group 
Coronaviridae Coronavirus OC43 9-O-acetyl SA 
Flaviviridae 
      Hepaciviruses 
      Flavivirus 
 
Hepatitis C 
Dengue Virus 
Japanese encephalitis Virus 
West Nile Virus 
 
Heparan Sulfate 
Heparan Sulfate 
Heparan Sulfate 
Herpesviridae 
      α-herpesviruses 
      β-herpesviruses 
 
      γ-herpesviruses 
Herpes simplex virus types 1 & 2 
Varicella-zoster virus 
Cytomegalovirus 
Human Herpesvirus Types 6 & 7 
Human Herpesvirus type 8 
Heparan Sulfate  
Heparan Sulfate 
Heparan Sulfate 
 
Heparan Sulfate 
Ortomyxoviridae Influenza A virus 
Influenza B virus 
Influenza C virus 
α2-3 SA, α2-6 SA 
α2-3 SA, α2-6 SA 
9-O-acetylsialic acid 
Papillomaviridae 
      Papillomavirus 
Human papillomavirus 
types 11, 16, 33 
Heparan sulfate 
Paramyxoviridae 
      Respirovurus 
      Pneumovirus 
 
 Metapneumov. 
 
Paramyxovirus 1-3 
Respiratory syncytial virus 
 
Human metapneumovirus 
 
Sialic acid 
Heparan sulfate 
(chondroitin sulfate) 
Heparan sulfate 
Parvoviridae 
      Erythrovirus 
       
      Dependovirus 
(see section 1.2) 
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Adeno associated virus 
(AAV) types 4 & 5 
AAV type 2 
 
Globoside/Histo-blood 
group P substance 
SA 
 
Heparan sulfate 
Picornavirus 
      Enterovirus 
      Rhinovirus 
 
Enterovirus 70 
Rhinovirus 87 
 
SA 
SA 
Polyomaviridae 
      polyomavirus 
 
JC and BK virus 
 
SA 
Poxviridae 
     Ortopoxvirus 
     Reoviridae 
 
Vaccinia virus 
 
Heparan Sulfate 
(Chondroitin Sulfate) 
Ortoreovirus Reovirus 3 SA 
Rotavirus Rotavitus SA 
Retroviridae HIV-1 Sulfatide; Galactosylceramide, HS 
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Table 2 Structure, Receptor, and Tropism of AAV1-9 
AAV Serotype 
VP 
Structure 
(PDB#) 
Glycan Receptor Protein Receptor Tropism 
1 3NG9 N-linked SA  Muscle, Lung 
2 1LP3 Heparan Sulfate αVβ5 & α5β1 
Integrins, 
HGFR, FGFR, 
LamR 
Liver, Neuron 
3B 3KIE Heparan Sulfate LamR Liver 
4 2G8G O-linked SA  Heart, Lung, 
Astrocytes 
5 3NTT N-linked SA PDGFR Muscle 
6 3OAH N-linked SA 
Heparan Sulfate 
EGFR Muscle 
7    Muscle, Liver 
8 2QA0   Liver 
9 3UX1 N-linked Galactose LamR Systemic 
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Figure 1. Genomic Map of AAV. There are two ORFs between ITRs, coding non-structural 
and structural proteins of AAV. The p5 promoter initiates transcription of Rep78 and Rep68, 
while p19 drives that of Rep52 and Rep48. Transcripts of non-structural protein, AAP, and 
structural proteins, VP1, 2, and 3, are driven by p40 promoter. Alternative splicing results in 
mRNAs coding for VP1 and VP2. Leaky scanning of the stop codon in the middle of VP2 
yields VP3. 
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Figure 2. Structural Components of AAV Capsid. (A) Schematic diagram of the eight-
strand jelly-roll β-barrel structure displayed by many icosahedral viral capsids. Adapted from 
reference 153. Eight β strands are sequentially numbered B-I. Loops connecting the 
neighboring two strands are named by numbers of the two connecting strands. (B) Ribbon 
rendering of AAV2 VP3 (PDB# 1LP3) showing β strands corresponding to (A) in blue. The 
conserved short α-helix is colored in red. DE loop and HI loop forming the five-fold axes of 
symmetry, and GH loop on the three-fold axes are labeled. Two-, three-, five-fold axes of 
symmetry are marked by oval, triangle, and pentagon, respectively to orient the view. (C) A 
trimer model of AAV2 VP3, with individual chain colored in palecyan, bluewhite, and 
lightorange in PyMOL. (D) A pentamer model of AAV2 VP3, showing the five-fold axes of 
symmetry. Each VP monomer is colored wheat, palegreen, lightblue, paleyellow, and light 
pink, respectively. (E) Visualization of a full capsid model of AAV2, looking into the five-
fold axes of symmetry. 
 
CHAPTER 2  
Terminal N-linked Galactose is the Primary Receptor for AAV91 
2.1 Overview 
A broad range of pathogens engage with cell surface sialoglycans to initiate infection, 
and parvoviruses are no exception. In the current study, we discovered that asialoglycans, 
instead of sialylated glycoconjugates, mediate cell surface binding and infectivity of AAV 
serotype 9, an isolate with systemic tropism in animals. Enzymatic removal of sialic acid, but 
not heparan sulfate or chondroitin sulfate, increased AAV9 transduction on multiple cell 
types. Viral binding and transduction assays on a series mutant Chinese Hamster Ovary 
(CHO) cell lines defective in glycan chain synthesis or translocation, revealed a pivotal role 
of core glycan residues beneath sialic acid moieties in AAV9 transduction. Treatment with 
chemical inhibitors of N- or O-glycosylation and competitive inhibition studies with a 
spectrum of lectins suggest that N-linked glycans with terminal galactosyl residues facilitate 
cell surface binding and transduction by AAV9. In addition, resialylation of galactosylated 
glycans on the sialic acid-deficient CHO Lec2 cell line with different sialyltransferases 
partially blocked AAV9 transduction. Quantitative binding curves of AAV9 on parental, 
sialidase-treated or sialic acid-deficient mutant CHO cells revealed a 3 to 10-fold increase in 
relative binding potential of AAV9 particles upon desialylation. Lastly, pretreatment of well-
                                                 
1This chapter includes the original publication: Shen, S., Bryant, K.D., Brown, S.M., Randell, 
S.H., Asokan, A. Terminal N-linked Galactose is the Primary Receptor for Adeno-associated 
Virus 9, Journal of Biological Chemistry, 2011, 286(15):13532-40 (PMID: 21330365). 
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differentiated human airway epithelial cultures and intranasal instillation of recombinant 
sialidase in murine airways enhanced transduction efficiency of AAV9 by over an order of 
magnitude. In corollary, the studies described herein provide a molecular basis for low 
infectivity of AAV9 in vitro and a biochemical strategy to enhance gene transfer by AAV9 
vectors in general.   
2.2 Introduction 
Cell surface glycans have been shown to play a critical role in the infectious pathways 
of viruses 1. Detailed studies of virus-glycan interactions have yielded significant insight into 
mechanisms underlying emergence and transmission of viral pathogens in different hosts. 
Amongst various glycolipids, glycoproteins or proteoglycans anchored to the plasma 
membrane, sialylated glycans and heparan sulfate proteoglycans appear to serve as 
predominant substrates for viral attachment to the cell surface. For instance, heparan sulfate 
serves as a primary receptor for Herpesviridae 154 as well as certain adenoviruses 155 and 
parvoviruses 40,156. Interactions between sialylated glycans and members of the 
Orthomyxoviridae 157, Reoviridae 158, Polyomaviridae 159 families and certain parvoviruses 
are also well known 45,48,160.  
Adeno-associated viruses (AAV) are small, single-stranded DNA viruses that belong 
to the genus Dependovirus of the Parvoviridae family 144. Recombinant AAV vectors, by 
virtue of their lack of pathogenicity and low immunogenicity, are currently being evaluated 
as lead candidates in clinical gene therapy trials 161. The discovery of a large number of AAV 
isolates over the past decade has accelerated efforts to exploit tissue tropisms displayed by 
different strains for therapeutic gene transfer applications 162,163. Successful translation from 
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bench to bedside will require a thorough understanding of molecular mechanisms underlying 
AAV infection. As with other viruses, attachment to cell surface glycans constitutes the first 
step in the AAV infectious pathway. For instance, several AAV serotypes have been shown 
to bind heparan sulfate proteoglycans (AAV2 40; AAV6 44), while others utilize sialic acid for 
cell surface binding and entry (AAV4 46; AAV5 45; AAV1/6 44; Bovine AAV 38).  
Sialylated glycans that serve as primary receptors for the latter AAV strains vary at 
the level of N-acetylneuraminic acid (Neu5Ac) linkage to underlying sugars, i.e., N-2,3 or N-
2,6 linked to galactose residues 44,46. Further receptor specificity has been demonstrated at the 
level of N-linked or O-linked glycans displayed on the cell surface 44,46. Selective recognition 
of such linkages and underlying core glycan types 164 is likely enabled by differences in the 
capsid surface topology of AAV serotypes 82,165. In general, dependence of AAV infectivity 
on sialic acid has been demonstrated using a battery of chemical, biochemical and genetic 
tools to desialylate cell surface glycans. The current study is focused on glycan interactions 
of a human AAV isolate, AAV serotype 9/Hu.14 (Clade F; 124). Recombinant AAV9 vectors 
display widespread and robust transduction following systemic administration in animal 
models, but fail to infect cells in culture 124,125. We demonstrate that efficient gene transfer by 
AAV9 vectors requires an atypical interaction with non-sialylated cell surface glycans. The 
results described herein provide a molecular basis for the low infectivity of AAV9 observed 
in cell culture.   
2.3 Materials and Methods   
Plasmids and viruses. All plasmids were obtained from the UNC vector core. The 
triple plasmid transfection protocol 166 utilized for production of AAV9 vectors, includes (i) 
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the AAV helper plasmid, pXR9, containing AAV2 Rep and AAV9 Cap genes, (ii) the 
Adenoviral helper plasmid, pXX6-80 and (iii) the vector genome cassette, pTR-CBA-Luc or 
pHpa-trs-SK, containing the firefly luciferase gene driven by the chicken beta-actin (CBA) 
promoter or self-complementary GFP cassette driven by the cytomegalovirus (CMV) 
promoter, respectively. The vector genome cassette is flanked by inverted terminal repeats 
(ITRs) required for packaging. The ITRs are the only elements within the vector genome 
cassette derived from the wild-type AAV genome, thereby eliminating 96% of viral elements. 
Recombinant AAV9 vectors generated thus allow quantitation of viral infectivity (or 
transduction efficiency) through luciferase transgene expression assays. HEK293 cells 
utilized for production of recombinant AAV9 vectors were obtained from the UNC vector 
core. Sonicated cell lysates and PEG8000 precipitates from supernatant were pooled and 
subjected to cesium chloride ultracentrifugation as described earlier 166. Dialyzed peak 
fractions were subjected to quantitative PCR using a Roche Light Cycler instrument with luc 
transgene-specific primers to determine viral vector titers (forward 5'-AAA AGC ACT CTG 
ATT GAC AAA TAC-3'; reverse 5'-CCT TCG CTT CAA AAA ATG GAA C-3').   
Cell lines. All cell lines were cultured in DMEM supplemented with 10% fetal 
bovine serum (FBS) and 1% penicillin, streptomycin, amphotericin B (Sigma) and 
maintained in 5% CO2 at 37°C unless mentioned otherwise. COS-1 (monkey kidney), 
Neuro2a (mouse neuroblastoma), U87 (human glioma) and Huh7 (human hepatocarcinoma) 
were obtained from the UNC tissue culture facility and utilized in viral transduction assays. 
Chinese hamster ovary (CHO) Pro5 and mutant Lec1, Lec2 cell lines were a gift from Dr. 
Jude Samulski (UNC-Chapel Hill) and the CHO Lec8 cell line purchased from ATCC. All 
CHO cells, utilized for viral binding and transduction assays, were cultured in α-MEM 
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(GIBCO) supplemented with 10% FBS and penicillin, streptomycin, amphotericin B as 
outlined above. Well-differentiated human airway epithelial (HAE) cultures (4-6 weeks) 
grown on permeable membrane supports (Millipore, Corning, NY) at the air-liquid interface 
were provided by the Cell Culture Models Core and the UNC Cystic Fibrosis/Pulmonary 
Research Center.  
Transduction assays. Different cell lines were seeded at 105 cells/well in 24-well 
plates and allowed to adhere overnight at 37°C. Plates were then pre-chilled at 4°C for 30 
min and incubated with AAV9 vectors at a multiplicity of infection (MOI) of 1000 vector 
genomes per cell (vg/cell) to allow binding to the cell surface for 1.5 hrs at 4°C. Unbound 
virus was then removed by washing three times with ice cold 1x phosphate-buffered saline 
(1xPBS) and 0.5mL of DMEM added to each well. Luciferase transgene expression levels 
were quantitated after incubation for 24 hrs from cell lysates using a Victor 2 luminometer 
(Perkin Elmer). For studies with HAE, well-differentiated cultures were pretreated with 1.25 
U/ml of sialidase A (Prozyme #GK80040) at 37°C for 3hrs followed by three washes with 
ice-cold 1xPBS. Cultures were then incubated with scAAV9-CMV-GFP vectors (MOI = 105 
vg/cell) as outlined above. Fluorescence micrographs of green fluorescent protein (GFP) 
expression in HAE cultures at 2 weeks post-transduction were obtained using an Olympus 
epifluorescence microscope equipped with a 20x objective and a Hamamatsu camera. 
Enzymatic desialylation assays. Different cell lines were treated with Heparinase I 
and III (from Flavobacterium heparinum; Sigma #H2519 and #H8891), Chondroitinase ABC 
(from Proteus vulgaris Sigma #C2905), Neuraminidase Type III (from Vibrio cholerae 
Sigma #N7885), endo-β-galactosidase (from Pseudomonas sp., Sigma #G6920) and α-
fucosidase (from bovine kidney, Prozyme #GKX-5006) to determine the role of cell surface 
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glycans in AAV9 infection. Briefly, Cos1 cells were seeded at a density of 1x105 cells/well 
in 24-well plates and pretreated with 50mU/ml neuraminidase, 3 U/ml heparinase I, 1.5 U/ml 
heparinase III, 1.5 U/ml chondroitinase ABC, 80 mU/ml endo-β-galactosidase, and 50 
mU/ml α-fucosidase in DMEM at 37 °C for 2 hrs. Neuro2a, U87, HEK293 and Huh7 cells 
were treated with neuraminidase alone. Cells were then washed three times with 1xPBS and 
subjected to AAV9 infection at an MOI of 1000 vg/cell. Luciferase transgene expression 
assays were carried out as described earlier at 24 hrs post-infection.  
Internalization assays. Human glioma U87 cells were untreated or pretreated with 
Neuraminidase Type III from Vibrio Cholerae followed by incubation with AAV1 or AAV9 at 
MOI = 1x105 vg/cell. At 60 min post incubation on ice, unbound virions were removed with 
three 1xPBS washes. Cells were then incubated at 37°C for 30 min to allow uptake of AAV9 
particles. Cells were then treated with 100μl/well of 0.05% Trypsin EDTA (Cellgro #25-052-
CI) for 5min at 37°C to remove cell surface bound virions. Cells were then pelleted by 
centrifugation and washed thrice with 1xPBS.  Cell lysates were further analyzed using Q-
PCR to quantitate cell-associated (internalized virions) as described earlier. Internalized 
virions are expressed as vector genome copy numbers (vg) per cell. All experiments were 
carried out at n=5 and error bars represent standard error mean. 
Chemical inhibition assays. CHO Lec2 cells were seeded at 105 cells/well in 24-well 
plates and pretreated for 24 hrs with small molecule inhibitors of glycosylation, Swainsonine 
(10µM; Sigma, #S8195) and α-benzyl-GalNAc (1µg/mL; Sigma, #B4894) to determine the 
role of N- and O-glycans in AAV9 infection. Cells pretreated with chemicals were subjected 
to AAV9 infection at an MOI of 1000 vg/cell and luciferase transgene expression assays 
carried out as described earlier.   
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Enzymatic resialylation assays. The sialic acid-deficient cell line, CHO Lec2 was 
treated with 50mU/mL each of α2,3-(N)-sialyltransferase (Calbiochem #566218), α2,6-(N)-
sialyltransferase (Calbiochem #566222) or α2,3-(O)-sialyltransferase (Calbiochem, #566227) 
and 1mM CMP-sialic acid (Sigma) in serum-free media for 3 hrs at 37°C. Untreated CHO 
Pro5 cells with endogenous sialic acid were included as control. Cells were then rinsed three 
times with 1xPBS and subjected to AAV9 infection at an MOI of 1000 vg/cell and luciferase 
transgene expression assays carried out as described earlier.    
Lectin inhibition and staining assays. Competitive inhibition of AAV9 infection 
was carried out using a panel of lectins, Concanavalin A (Con A), Wheat germ agglutinin 
(WGA), Maackia amurensis lectin (MAL I), Sambucus nigra lectin (SNA) and Erythrina 
cristagalli lectin (ECL) obtained from Vector Labs (Burlingame, CA). Briefly, prechilled 
CHO Pro5 or mutant Lec2 cells were incubated with 100mg/mL FITC-conjugated lectin 
(fluorescent labeling assay) in serum-free α-MEM media or along with AAV9 particles 
(transduction assay at MOI = 10,000 vg/cell) for a period 1.5 hrs at 4°C.  After three washes 
with ice cold 1xPBS to remove unbound virus and/or lectins, cells were imaged using an 
Olympus epifluorescence microscope equipped with a Hamamatsu camera or incubated for 
24 hrs at 37°C prior to luciferase transgene expression analysis. 
Cell surface binding assays. CHO Pro5 cells were seeded at a density of 104 
cells/well in 96-well plates prior to treatment with with 50mU/mL neuraminidase type III 
from Vibrio cholerae for 2 hrs at 37°C. Untreated Pro5 and Lec2 cells were included as 
negative and positive controls respectively. Cells were then pre-chilled at 4°C for 30 minutes, 
followed by incubation with AAV9 particles at MOI of 1x102, 5x102, 1x103, 5x103, 1x104, 
5x104, 1x105, 5x105 vg/cell for 1.5 hrs at 4°C. Cells were then subjected to three washes with 
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ice cold 1xPBS to remove unbound virions. Cell surface-bound virions were collected along 
with cell lysates following three freeze-thaw cycles and vector genome copy numbers per 
cell determined using Q-PCR as outlined earlier. Binding curves were generated using 
GraphPad Prism 5 software by applying the single site binding model (Y = Bmax*X/(Kd + 
X)), where Y represents number of bound virions/cell determined by Q-PCR; X represents 
MOI; Bmax is the maximum binding capacity and Kd’, the observed disassociation constant. 
Animal studies. All experiments were carried out with 6-8 week old female BALB/c 
mice (Jackson Labs, Bar Harbor, ME) maintained and treated in accordance with National 
Institutes of Health guidelines and as approved by IACUC at UNC-Chapel Hill. Mice were 
administered via intranasal instillation with either 100 µl PBS (50 ul/nostril) or 100 µl 
Neuraminidase Type III from Vibrio cholerae (200 mU, Sigma, St. Louis, MO). At 2 hrs 
post-treatment, a dose of 5x1010 AAV9 particles in 1xPBS (50 µl/nostril) was administered. 
Luciferase transgene expression in live animals was obtained using an Xenogen IVIS 
Lumina® imaging system (Caliper Lifesciences, CA) after intranasal instillation of luciferin 
substrate (120 mg/kg; Nanolight). Image analysis was carried out using the Living Image 
software® (Caliper Lifesciences) and luciferase expression reported in relative light units 
(photons/sec/cm2/sr).  
2.4 Results 
Neuraminidase treatment selectively increases AAV9 transduction in different cell 
types. Enzymatic removal of different cell surface glycans was achieved by treating cells 
with different glycosidases. Removal of terminal sialic acid residues using neuraminidase 
(from V. Cholerae) enhanced AAV9 transduction by > 1 log unit when compared to virus 
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alone on COS1 cells (Figure 3A). In contrast, hydrolysis of cell surface heparan sulfate or 
chondroitin sulfate proteoglycans using heparinase I/III or chondroitinase ABC, respectively 
had no effect on viral transduction compared to control. Neuraminidase treatment abrogated 
AAV1 transduction, while AAV2 remained unaffected under these conditions (Figure 4A). 
In addition, treatment of cell lines derived from different tissues with neuraminidase (grey 
bars) prior to AAV9 infection enhanced transduction efficiency by nearly 2 log units in 
contrast to infection with virus alone (white bars) (Figure 3B). These results were 
corroborated by increased binding and internalization of AAV9, but not AAV1 vectors upon 
sialidase treatment in these cell lines (Figure 4B & 4C). Thus, sialic acid appears to mask 
cell surface glycans that selectively facilitate AAV9 infection in vitro. Further, enzymatic 
desialylation might serve as a facile biochemical strategy to enhance transduction efficiency 
of AAV9 vectors in vitro and might enable detailed analysis of intracellular trafficking 
pathways.    
Mutant CHO Lec2 cells lacking terminal sialic acid are highly permissive to AAV9 
infection. Analysis of cell surface binding and infectivity of AAV1 and AAV9 on parental 
(Pro5) and mutant CHO cell lines was carried out to further understand the role of core 
glycans under sialic acid in AAV9 infection. The CHO Lec2 cell line lacks terminal sialic 
acid due to a defect in CMP-sialic acid transport 167, while Lec8 and Lec1 cell lines are 
defective in translocation of UDP-galactose and N-acetylglucosaminyl transferase 
activity 168,169, respectively. Correspondingly, cell surface glycans on CHO Lec2 cells contain 
terminal galactosyl residues, while Lec8 and Lec1 cell lines predominantly display terminal 
N-acetylglucosamine and mannosylated glycans, respectively (Figure 6). As seen in Figure 
6B & C, cell surface binding and transduction of AAV9 particles (grey bars) on Lec2 cells is 
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significantly increased (> 1 log unit) when compared to the parental Pro5 cell line. In contrast, 
AAV1 (white bars), which requires sialic acid for infection shows ~ 10-fold decrease in 
binding and transduction in all CHO Lec mutant cell lines. In addition, no major changes in 
binding and infectivity are observed in case of Lec8 and Lec1 cells for AAV9 particles. 
These results suggest that galactosylated glycans immediately underlying sialic acid can 
facilitate AAV9 cell surface binding and entry. The results also support the notion that 
AAV9 particles might exploit an inefficient and non-specific uptake mechanism in the 
parental Pro5, mutant Lec8 and Lec1 cell lines.  
Sialylation of N-linked glycans blocks AAV9 infection. In order to further elucidate 
the nature of glycans required for AAV9 infection, we utilized small molecule inhibitors of 
glycosylation and sialyltransferases to modify terminal galactosyl residues on the sialic acid-
deficient Lec2 cell surface. Swainsonine 170 and α-benzyl-O-GalNAc 171 are chemical 
inhibitors of N-linked and O-linked glycosylation, respectively. Treatment with these 
reagents results in a corresponding decrease in cell surface expression of N-linked glycans 
and O-linked glycans. As seen in Figure 7A, AAV9 infection is significantly blocked by 
swainsonine (~ 75%), while α-benzyl-O-GalNAc has a modest inhibitory effect (~25%). 
These results suggest that AAV9 prefers N-linked cell surface glycans for infection. In 
addition, resialylation of the sialic acid-deficient Lec2 cell surface was carried out to 
understand the nature of the sialic acid linkage that blocks AAV9 infection (Figure 7B). The 
abilities of different sialyltransferases to partially block AAV9 infection was observed to 
follow the order, α2,3-N-sialyltransferase (3’NST) > α2,6-N-sialyltransferase (6’NST) > 
α2,3-Osialyltransferase (3’OST). Alteration of cell surface glycans upon resialylation was 
confirmed by staining with lectins recognizing different glycan residues and linkages (Figure 
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7C). As expected Pro5 expressing sialylated glycans and Lec2 cells expressing asialoglycans 
demonstrate preferential staining by FITC-MAL I and FITC-ECL, respectively. Resialylation 
of Gal(β1,4)GlcNAc residues with 3’NST, but not 3’OST partially restores FITC-MAL-I 
staining concurrent with decrease in AAV9 transduction. The lack of MAL I staining in 
6’NST-treated Lec2 cells is expected due to lack of recognition of α2,6-sialylated glycans by 
MAL I. Taken together, these results not only corroborate the important role played by core 
N-linked glycans in AAV9 infection, but also the potential for α2,3- and α2,6-sialic acid 
linkages to block infection by masking underlying glycoconjugates on the cell surface.  
Terminal galactosyl residues are critical for AAV9 infection. To better understand the 
nature of AAV9-glycan interactions that mediate infection, we carried out competitive 
inhibition studies with lectins that recognize different glycan linkages on the cell surface 
(Figure 8A & B). Specifically, we utilized (i) Maackia amurensis lectin (MAL I), which 
recognizes native, N-2,3-sialylated or sulfated glycoconjugates having Gal-(β1,4)-N-GlcNAc 
structures 172,173; (ii) Sambucus nigra lectin (SNA), which binds preferentially to α2,6-
sialylated galactose residues 174; (iii) Erythrina cristagalli lectin (ECL), which demonstrates 
specificity towards galactose residues, in particular, galactosyl-(β1,4)-N-acetylglucosamine 
(Gal-(β1,4)-N-GlcNAc) 175; (iv) Wheat germ agglutinin (WGA), which binds N-
acetylglucosamine (N-GlcNAc) and also tolerates glycoconjugates containing sialic acid with 
different linkages 176 and (v) Concanavalin A (Con A), which recognizes mannose 
residues 177. The SNA lectin had no effect on AAV9 infection and can be explained by low 
levels of α2,6-sialylated glycans in both cell lines of rodent (hamster) origin 177. On the other 
hand, the MAL I lectin demonstrated 5 to 10-fold inhibition of AAV9 infection in both Pro5 
and Lec2 cell lines. More importantly, a striking difference in AAV9 transduction was 
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observed in case of ECL-treated cells with 5-fold inhibition in parental Pro5 cells and nearly 
200-fold inhibitory activity in the Lec2 cell line demonstrating the importance of core Galβ1-
linked residues. The ConA and WGA lectins demonstrated broad inhibitory activity in both 
parental Pro5 cells and the sialic acid-deficient Lec2 cell line suggesting that underlying N-
GlcNAc and core mannose residues might contribute to AAV9-glycan interactions.  
These results were corroborated by fluorescent staining of Pro5 and Lec2 cell lines 
with aforementioned lectins (Figure 8C). As expected, MAL I and WGA lectins, which bind 
to α2,3-sialylated glycans, preferentially label Pro5 cells. In contrast, preferential ECL 
staining is noted in Lec2 cells. The SNA lectin, which recognizes α2,6-sialic acid does not 
stain either Pro5 or Lec2 cells confirming the lack (or modest expression) of α2,6-sialylated 
glycans on these hamster-derived cell lines. Further evidence supporting the important role of 
galactose in mediating AAV9 infection was obtained by treatment of CHO Pro5 cells with 
endo-β-galactosidase (Figure 7A & B). Removal of galactose residues, but not fucose 
abrogated AAV9 transduction. Taken together, these results suggest that terminal galactosyl 
residues serve as the primary receptor for AAV9. 
Desialylation increases the cell surface binding potential of AAV9 particles. Cell 
surface binding curves were generated to establish a quantitative biochemical rationale for 
the observed increase in AAV9 transduction following desialylation. Binding of AAV9 
particles to the surface of parental CHO Pro5 cells, sialidase-treated Pro5 cells or sialic acid-
deficient Lec2 cells was carried out over a range of multiplicities of infection (genome-
containing viral particles (vg) per cell). As seen in Figure 9, enzymatic removal of sialic acid 
partially recapitulates the effect of genetic desialylation by increasing the number of cell 
surface-bound AAV9 particles. Non-linear regression analysis of binding data was carried 
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out using the single site binding model (Y = Bmax*X/(Kd’ + X)), where X and Y represent 
multiplicity of infection  and number of bound AAV9 particles, respectively; Bmax is the 
maximum binding capacity and Kd’ is the relative (observed) binding affinity. Calculation of 
aforementioned parameters reveals Bmax values averaging 375 vg/cell on wild type Pro5 cells, 
a ~3-fold increase to 1075 vg/cell on sialidase-treated Pro5 cells and a ~5-fold increase to 
1971 vg/cell on the sialic acid-deficient Lec2 cell line. These results support the observation 
that AAV9 prefers asialo N-glycans with terminal Galβ1-linked residues.    In addition, an 
apparent decrease in Kd’ (~3-fold) is observed in Lec2 cells as well as a corresponding 10-
fold increase in relative binding potential (Bmax/Kd’; Table 3). These results support the 
notion that enhanced avidity plays a role in mediating AAV9 binding to asialo N-glycans.                        
Sialidase pretreatment increases AAV9 gene transfer efficiency in HAE and murine 
airways. To evaluate the potential of enzymatic desialylation as a strategy to enhance gene 
transfer by AAV9 vectors, we evaluated the effect of sialidase pretreatment on AAV9 
transduction efficiency in well differentiated HAE cultures and murine airways. A marked 
increase in GFP positive HAE was observed upon treatment with neuraminidase from 
Arthrobacter Ureafaciens (recombinant Sialidase A) prior to infection with scAAV9/CMV-
GFP vectors (Figure 10A & B). Further, quantitation of live animal bioluminescent images 
of Balb/c mice following intranasal instillation of sialidase showed ~ 10-fold increase in 
luciferase transgene expression in murine airways mediated by AAV9/CBA-Luc vectors 
(Figure 10C & D). These results further validate the role of asialo N-glycans as the primary 
receptor for AAV9 in mouse and human species as well as provide a novel adjuvant strategy 
to enhance AAV9 gene transfer.    
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2.5 Discussion 
Glycomic profiles of major N-and O-glycans expressed in the parental CHO Pro5 and 
the CHO Lec2 mutant 178,179 were instrumental towards delineating the nature of glycans that 
play a role in cell surface binding and infection by AAV9 vectors. The N-glycan profile of 
CHO Pro5 cells has been shown to possess complex bi-, tri-, and tetra-antennary structures 
bearing multiple N-acetyllactosamine (LacNAc) extensions, capped with sialic acid (NeuAc) 
residues. In addition, the O-glycan profile contains Gal-(β1,3)-GalNAc core structures that 
are mono- or di-sialylated. In contrast, the most abundant glycans produced by the sialic 
acid-deficient Lec2 cell line are asialo N-glycans, possessing between 2 and 7 LacNAc units. 
The O-glycan profile is known to be similarly affected by altered sialylation 179. These 
observations suggest that LacNAc units might serve as cell surface attachment factors for 
AAV9. Treatment of the Lec2 cell line with chemical inhibitors and sialyltransferase 
enzymes confirmed that Galβ1-linked N-glycans rather than O-glycans were the preferred 
substrate for attachment. These results were further corroborated by competitive inhibition 
studies with the LacNAc-specific Erythrina cristagalli lectin (ECL). In addition, ConA and 
WGA lectins revealed a potential contributing role for mannose and GlcNAc residues 
underlying terminal galactose in mediating AAV9 infection. Further evidence supporting the 
aforementioned results was also obtained from competitive inhibition studies of AAV9 
particles co-incubated with different glycan residues. Although only a modest inhibitory 
effect was observed potentially due to low affinity interactions, monomeric LacNAc (LN) 
units, but not α2,3-sialylated LN (3’-SLN) or α2,3-sialylated di-LN (3’-S-Di-LN) glycans 
appear to selectively block AAV9 infection 52.  
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Cell surface binding studies constitute a direct approach to determine the relative 
binding potential (Bmax/Kd’) of AAV9 particles under physiological conditions. Upon 
desialylation, the observed increase in number of binding sites (Bmax) is likely due to 
increased availability of asialo N-glycans on the cell surface. The increase in relative binding 
affinity (Kd’) is potentially a consequence of the increased number of binding sites and can 
be explained by enhanced avidity arising from multivalent interactions. The aforementioned 
results suggest that the relatively low abundance of asialo N-glycans provides a molecular 
basis for the low transduction displayed by AAV9 in cell culture. In contrast to in vitro 
assays, studies in rodent, canine and primate models have demonstrated robust and 
widespread systemic gene transfer using AAV9 vectors following intravenous 
administration 125,180,181. As such, the nature of AAV9-glycan interactions does not provide 
sufficient rationale for the observed lack of in vitro-in vivo correlation outlined above. As 
seen in case of other viruses, potential interactions with blood components 182 or co-receptors 
such as integrins 183 might play an important role in dictating the transduction profile 
observed in animal models. Nevertheless, it is tempting to speculate that the relative 
abundance of asialo N-glycans in various animal tissues likely contributes to the broad 
biodistribution pattern and tissue tropism displayed by AAV9 vectors in vivo. Studies with 
animal models lacking sialyltransferases 184,185 might provide further insight into the 
mechanism(s) underlying tissue tropism displayed by AAV9. 
Carbohydrate receptors utilized by members of different AAV clades appear to fall 
under two classes, namely, heparan sulfate proteoglycans and sialylated glycans 186. For 
instance, AAV2, a Clade B member utilizes heparan sulfate proteoglycan as a primary 
receptor 40. The closely related strains, AAV1 and AAV6 of Clade A appear to equally prefer 
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for α2,3- and α2,6- N-linked sialic acid for infection 44. Further, AAV6 has been shown to 
bind heparin implying a potential dual mechanism of interaction with cell surface glycans 43. 
Serotypes AAV4 and AAV5, which have not been assigned to any clade thus far, require 
α2,3-O- and α2,3-N-linked sialic acid for cell surface binding, respectively 46. The current 
study identifies a third class of glycan receptors with terminal galactose utilized by the AAV 
strain Hu.14/AAV9 for infection. The latter serotype has been classified under Clade F 
within the AAV phylogenetic tree 124. The major capsid protein (VP3, viral protein subunit 3) 
of other AAV isolates within Clade F is largely similar to Hu.14/AAV9 (GenBank# 
AY530579.1). Specifically, isolate Hu.31 (GenBank# AY530596.1) differs from 
Hu.14/AAV9 by 2 amino acid residues (S386G, N716S), while the VP3 subunit of isolate 
Hu.32 (GenBank# AY530597.1) is identical to Hu.14/AAV9. These observations suggest 
that at least one other member of Clade F (Hu.32) might utilize non-sialylated glycans for 
cell surface binding and entry. Lastly, Akache et al. 97 have previously reported the role of 
laminin receptor (LamR) in mediating transduction by AAV9. Whether the 2.5-fold increase 
in AAV9 transduction mediated by LamR in the previous report within transfected NIH 3T3 
cells is due to enhanced binding or internalization is unknown. Nevertheless, low levels of 
LamR expressed in CHO cells 187 might account for residual transduction of AAV9 seen in 
the current study.  
Recombinant sialidase has been proposed as a therapeutic agent in several clinical 
modalities. For instance, a sialidase fusion protein has been proposed as an antiviral agent for 
protection from influenza viruses 188,189. The latter approach hinges on the inhibition of cell 
surface binding by influenza viruses due to desialylation of cell surface glycans. In another 
recent study, intrathecal infusion of recombinant sialidase, which reverses inhibition of axon 
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outgrowth in neurons, has been proposed as a candidate therapy for spinal cord injury 190. In 
the current study, enzymatic desialylation was found to markedly enhance binding and 
transduction of AAV9 across different cell types regardless of host or tissue type. In addition, 
intranasal instillation of sialidase markedly enhanced gene transfer efficiency of AAV9 in 
murine airways supporting the potential application of recombinant sialidase as an adjuvant 
in therapeutic gene transfer applications in the lung/airways. Specifically, co-administration 
or pretreatment of different tissue types such as the lung, CNS or eye with recombinant 
sialidase might serve as (i) a strategy to expose high avidity glycan receptors and 
consequently restrict AAV9 transduction to these specific tissue types; (ii) a facile 
biochemical strategy to increase gene transfer efficiency of AAV9 vectors and (iii) a method 
to evaluate AAV9 vectors in desialylated preclinical models eliminating cross-species 
variation in sialylation patterns. 
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Table 3. Binding Parameters for AAV9 Interactions with Cell Surface Glycans 
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Figure 3. Enzymatic desialylation enhances AAV9 infectivity on multiple cell lines. (A) 
A series of glycosylases (heparinase I; heparinase III, neuraminidase from Vibrio Cholerae 
and chondroitinase ABC) were utilized to modify the glycoconjugates prominently expressed 
cell surface glycans on COS-1 cells. Transduction assays with AAV9 vectors (MOI = 1000 
vg/cell) were carried out 2 hrs post-enzymatic treatment. (B) Different cell lines (HEK293, 
U87, Huh-7 and Neuro2a) were untreated (white bars) or pretreated with neuraminidase from 
Vibrio Cholerae (grey bars) followed by subsequent infection with AAV9 vectors (MOI = 
1000 vg/cell). Luciferase transgene expression (Relative Light Units, RLU) was quantified 
for both studies at 24 hrs post-infection. All experiments were carried out in triplicate. Error 
bars represent standard error mean. Statistical significance was analyzed using the one-tailed 
Student’s t-test (* p < 0.05; ** p < 0.01). 
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Figure 4. Effects of enzymatic desialylatoin on transduction, binding, and 
internalization of AAV9 on mammalian cell cultures. (A) COS-1 cells were pretreated 
with PBS or neuraminidase prior to infection with AAV1, AAV2 or AAV9 vectors (MOI = 
1000 vg/cell). 24 hrs post infection, luciferase assays were carried out to demonstrate 
serotype-specific effects of enzymatic desialylation on transduction efficiency. (B) Effect of 
enzymatic desialylation on AAV9 binding to different human cell lines. Briefly, U87 and 
Huh-7 cells were seeded at a density of 1x105 cells/well on a 24-well plate. Cells were 
untreated (white bars) or pretreated with 50 mU/ml of Neuraminidase Type III from Vibrio 
Cholerae (grey bars) prior to pre-chilling and incubation with AAV9-CBA-Luciferase vectors 
(MOI = 1000 vg/cell) at 4°C for 1.5 hrs. Unbound virions were removed by three washes 
with ice-cold 1xPBS. The amount of cell surface-bound AAV9 virions was quantified using 
Q-PCR. The amount of bound virions was expressed as vector genome copy numbers (vg) 
per cell. All experiments were carried out in quadruplicate. Error bars represent standard 
error mean. (C) Effect of desialylation on the internalization of AAV1 and AAV9 in U87 cells. 
U87 cells were untreated (white bars) or pretreated with Neuraminidase Type III from Vibrio 
Cholerae (grey bars) followed by incubation with AAV1 or AAV9 at MOI = 105 vg/cell. At 
60 min post incubation on ice, unbound virions were removed with three 1xPBS washes. 
Cells were then incubated at 37°C for 30 min to allow uptake of AAV9 particles. Incubation 
with 100 μl/well of 0.05% Trypsin EDTA (Cellgro #25-052-CI) for 5 min at 37°C to remove 
cell surface bound virions. Cells were then pelleted by centrifugation and washed thrice with 
1xPBS.  Cell lysates were then analyzed using Q-PCR to quantitate cell-associated 
(internalized virions). Internalized virions are expressed as vector genome copy numbers (vg) 
per cell. Data are shown as mean ± s.e.m. (n=5). Statistical significance was analyzed using 
the one-tailed Student’s t-test (* p < 0.05; ** p < 0.01). 
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Figure 5. Glycan chain composition on cell surface affects binding and transduction of 
AAV9. (A) Schematic representation of N-glycan compositions of the parental CHO Pro5 
cell line and mutants Lec2, Lec8 and Lec1 using nomenclature proposed by the Consortium 
for Functional Glycomics nomenclature committee. (B) Binding of AAV1 (white bars) and 
AAV9 (grey bars) particles to wild type and parental CHO cell lines was analyzed using Q-
PCR as described in Materials and Methods. Number of bound virions is expressed as vector 
genome copy number (vg) per cell. (C) Transduction efficiency (Relative Light Units, RLU) 
of AAV1 (white bars) and AAV9 (grey bars) particles (MOI = 1000 vg/cell) on parental and 
mutant CHO cell lines were analyzed by quantifying luciferase transgene expression at 24 
hrs post-infection. All binding experiments were carried out in quadruplicate and infectivity 
assays in triplicate. Error bars represent standard error mean. 
 47 
 
 
Figure 6. Endo-β-galactosidase and α-fucosidase decreases AAV9 transduction 
efficiency on cell culture. Cos-1 cells were untreated (-) or pretreated (+) with 
Neuraminidase Type III from Vibrio Cholerae followed by no treatment (-) or treatment (+) 
with (A) endo-β-galactosidase (80 mU/ml, from Pseudomonas sp., Sigma #G6920) and (B) 
α-fucosidase (50 mU/ml, from bovine kidney, Prozyme #GKX-5006). Transduction of 
AAV9 were carried out with MOI = 1000 vg/cell. Transduction efficiency (RLU) was 
quantified at 24 hrs post-infection. All experiments were carried out in triplicate. Error bars 
represent standard error mean. 
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Figure 7. N-linked galactosylated glycans are prerequisite for AAV9 transduction. (A) 
Effect of glycosylation inhibitors on AAV9 transduction. Prior to infection with AAV9 
vectors (MOI = 1000 vg/cell), CHO Lec2 cells were cultured in media containing α-Benzyl-
GalNAc (1 μg/mL) or Swainsonine (10 μM), inhibitors of O- and N-glycosylation, 
respectively. (B) Effect of enzymatic resialylation on AAV9 transduction. CHO Lec2 cells 
were treated with 50 mU/mL each of α2,3-(N)-sialyltransferase (α2,3NST), α2,6-(N)-
sialyltransferase (α2,6NST) or α2,3-(O)-sialyltransferase (α2,3OST) and 1 mM CMP-sialic 
acid (Sigma) to resialylate cell surface asialo glycans. Luciferase transgene expression was 
quantified at 24 hrs post-infection and expressed as % infectivity with respect to untreated or 
wild type (CHO Pro5) control. All experiments were carried out in triplicate. Error bars 
indicate standard error mean. (C) Lectin staining of CHO cell lines subjected to enzymatic 
resialylation. CHO Lec2 cells treated with CMP-sialic acid alone or with CMP-sialic acid 
and different sialyltransferases were subjected to lectin staining using FITC-labeled ECL, 
which exclusively recognizes Gal(β1,4)GlcNAc or FITC-labeled MAL, which recognizes 
α2,3-Sialylated Gal(β1,4)GlcNAc. Untreated wild type CHO Pro5 cells, which show high 
levels of FITC-MAL I staining and untreated Lec2 cells, which show high levels of FITC-
ECL staining were included as control.   
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Figure 8. Galactose-specific lectin competitively inhibits AAV9 transduction on Lec2. 
Wild type CHO Pro5 (A) and sialic acid-deficient Lec2 (B) cell lines were co-incubated with 
lectins recognizing different glycan linkages (100 mg/mL) and AAV9 vectors (MOI = 10,000 
vg/cell). Briefly, ConA lectin recognizes mannose residues, while WGA lectin recognizes 
GlcNAc residues as well as sialic acid residues. MAL and SNA lectins recognize α2,3- and 
α2,6-linked sialic acid residues, respectively, while ECL exclusively recognizes 
Gal(β1,4)GlcNAc residues. Luciferase transgene expression (% Infectivity) was quantified at 
24 hrs post-infection. All experiments were carried out in triplicate. Error bars represent 
standard error mean (n=4). (C) Lectin staining of Pro5 and Lec2 cell lines were carried out 
using FITC-labeled lectins and fluorescent images obtained as described in Materials and 
Methods. 
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Figure 9. Effect of desialylation on cell surface binding of AAV9 particles. Sialic acid-
deficient Lec2 cells (■); untreated wild type Pro5 cells (●) and sialidase-treated Pro5 cells (○) 
were prechilled and incubated with AAV9 particles at different MOI ranging from 100 to 
500,000 (across 4.5 orders of magnitude) at 4˚C to allow binding, without cellular uptake. 
Quantitative analysis of dose-dependent AAV9 binding to cell surface asialo N-glycans was 
carried out by generating binding curves using a single-site binding model as described in 
Materials and Methods. Inset shows linear range of the binding curve from X-axis values 
ranging from 100 to 10,000 vg/cell. Calculated binding parameters are listed in Table 1. All 
experiments were carried out in triplicate. Error bars represent standard error mean. 
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Figure 10. Enzymatic desialylation enhances AAV9 transduction efficiency in HAE 
cultures in vitro and murine airways in vivo. Well differentiated human airway epithelial 
(HAE) cells were untreated (A) or pretreated with recombinant sialidase A (B) followed by 
subsequent infection with self-complementary (sc) AAV9-CMV-GFP vectors (MOI = 105 
vg/cell). Representative fluorescence micrographs of GFP transgene expression were 
obtained using an Olympus microscope equipped with a 20x objective and a Hamamatsu 
camera. (C) Representative live animal bioluminescent images of luciferase expression in 
Balb/c mice pretreated with intranasally administered PBS or neuraminidase (200 
mU/50μl/nostril). Intranasal instillation of AAV9-CBA-Luciferase vectors (5x1010 
vg/50μl/nostril) was carried out 2 hrs post-sialidase treatment and bioluminescent images 
obtained at 4 weeks post-administration. (D) Bioluminescence intensity was quantified using 
Living Image ® software and expressed as relative light units (RLU). Error bars represent 
standard error mean.  
 
CHAPTER 3  
Glycan Binding Avidity Determines the Systemic Fate of AAV92 
3.1 Overview 
Glycans are key determinants of host range and transmissibility in several pathogens. 
In the case of adeno-associated viruses (AAV), different carbohydrates serve as cellular 
receptors in vitro; however, their contributions in vivo are less clear. A particularly 
interesting example is adeno-associated virus serotype 9 (AAV9), which displays systemic 
tropism in mice, despite low endogenous levels of its primary receptor (galactose) in murine 
tissues. To understand this further, we studied the effect of modulating glycan binding 
avidity on the systemic fate of AAV9 in mice. Intravenous administration of recombinant 
sialidase increased tissue levels of terminally galactosylated glycans in several murine tissues. 
These conditions altered the systemic tropism of AAV9 into a hepatotropic phenotype, 
characterized by markedly increased sequestration within the liver sinusoidal endothelium 
and Kupffer cells. In contrast, an AAV9 mutant with decreased glycan binding avidity 
displayed a liver-detargeted phenotype. Altering glycan binding avidity also profoundly 
affected AAV9 persistence in blood circulation. Our results support the notion that high 
glycan receptor binding avidity appears to impart increased liver tropism, while decreased 
avidity favors systemic spread of AAV vectors. These findings may not only help predict 
                                                 
2This chapter includes the original publication: Shen, S., Bryant, K.D., Sun, J., Brown, S.M., 
Troupes, A., Pulicherla, N., Asokan, A. Glycan Binding Avidity Determines the Systemic 
Fate of Adeno-associated Virus 9, Journal of Virology, 2012 (PMID: 22787229). 
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species-specific differences in transduction profile for AAV9 on the basis of tissue 
glycosylation profile, but also provide a general approach to tailor AAV vectors for systemic 
or hepatic gene transfer by reengineering capsid-glycan interactions.  
3.2 Introduction 
The cell surface glycocalyx contains many glycans terminated with sialic acid 
moieties. Variability in the extent, type and linkage of sialylation between different hosts is 
exploited by several pathogens during infection 191,192. Sialo/asialoglycans have also been 
implicated as cell surface receptors for different strains of adeno-associated virus (AAV) in 
vitro 193,194. The latter are non-pathogenic, helper-dependent parvoviruses, currently being 
evaluated in phase I-III clinical trials as vectors for gene therapy 195. Over 150 different 
strains have been isolated from human and primate tissues till date and these AAV isolates 
display striking differences in capsid structure, receptor usage and tissue tropism within 
different hosts 152,193,196. A better understanding of the mechanisms underlying AAV tropism 
in different hosts could help guide the selection of preclinical animal models for evaluating 
AAV vectors and possibly predict outcomes in human gene therapy clinical trials. 
Glycan receptors for different AAV serotypes include heparan sulfate for AAV2 40, 
N-linked α2,3-/α2,6-sialic acid for AAV1/AAV6 44, N-linked α2,3-sialic acid for AAV5 45, 
O-linked α2,3-sialic acid for AAV4 46 and β1,4-galactose for AAV9 52,53. In addition, various 
co-receptors such as integrins and growth factor receptors have been implicated in AAV 
infection in vitro 193,194. Structural analysis of AAV capsids in conjunction with mutagenesis 
studies has provided a better understanding of the molecular determinants of AAV capsid-
glycan interactions. For instance, crystallographic and/or cryoelectron microscopy-based 
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analysis have enabled mapping the role of critical amino acid residues involved in heparan 
sulfate recognition by AAV2, AAV-DJ, AAV3B and AAV6 capsids 83,92,93,165,197,198. 
Recently the binding site of galactose on AAV9 capsids was mapped using a combination of 
mutagenesis and computational modeling tools 94. The structural/molecular basis for 
recognition of sialo/asialoglycans by the corresponding AAV serotypes is currently unknown.  
Despite the accruing knowledge of AAV-glycan interactions in vitro, the underlying 
molecular basis for differential tissue tropisms displayed by AAV serotypes in vivo is not 
well understood. For instance, AAV2, which utilizes heparan sulfate proteoglycans for cell 
surface attachment is a hepatotropic strain, while AAV1, which binds N-linked α2,3-/α2,6-
sialic acid displays cardiac/muscle tropism 152. In contrast, AAV9, which displays systemic, 
multi-organ tropism within different hosts 125,180,199 utilizes terminal galactose as its primary 
receptor 52,53. The current study seeks to understand exactly how variations in host 
glycosylation patterns can affect AAV tissue tropism in mice, using AAV9-galactose 
interactions as a model. The study hinges on a two-pronged approach, the first of which 
exploits our preliminary observation that tissue sialo/asialoglycan levels can be readily 
modulated by enzymatic treatment in vivo. Briefly, intravenously administered sialidase 
afforded a dramatic increase in the density of asialoglycans (terminal galactose residues) 
across multiple tissues, which markedly altered the systemic behavior of AAV9 in mice. In 
the second part of this study, we carried out the systemic evaluation of a mutant AAV9 
displaying low glycan binding avidity in normal mice. Our results demonstrate that altered 
tissue glycosylation patterns and/or glycan binding affinity can result in sharply contrasting 
liver uptake and blood circulation profiles of AAV in vivo.  
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3.3 Materials and Methods 
Biochemical reagents. Recombinant sialidase (neuraminidase type III from V. 
cholerae) was obtained from Sigma-Aldrich (St. Louis, MO). Erythrina Cristagalli (ECL) 
and Maackia Amurensis I (MAL-I) lectins were purchased from Vector Labs (Burlingame, 
CA). Monoclonal antibodies (MAb) against endothelium-specific marker FcγRII/III/IV (rat 
2.4G2 anti-CD16/CD32) 200 was obtained from BD Biosciences (San Jose, CA), and Kupffer 
cell-specific marker (rat anti-F4/80) 200 was obtained from Abcam (Cambridge, MA). 
Fluorophore-conjugated secondary antibodies (goat anti-rat or anti-mouse) were obtained 
from Invitrogen (Carlsbad, CA). The ADK9 mouse anti-capsid MAb recognizing intact 
AAV9 capsids was a kind gift from Dr. Jürgen Kleinschmidt (German Cancer Research 
Centre, DKFZ, Heidelberg, Germany).    
AAV production. HEK293 cells were maintained at 37˚C in 5% CO2 in Dulbecco’s 
modified Eagle’s medium supplemented with 10% fetal bovine serum and penicillin-
streptomycin-amphotericin B. The following plasmids were generated in the lab as described 
earlier 95 or obtained from the UNC vector core facility: (1) the pXR9 plasmid encoding rep2 
and cap9; (2) the plasmid pXX6-80 containing adenoviral helper genes; and (3) the vector 
cassettes, pTR-CBA-Luc or pTR-CBA-tdTomato, encoding the Chicken beta-actin (CBA) 
promoter and luciferase or tdTomato reporter transgene, respectively. AAV9 vectors 
packaging TR-CBA-Luc or TR-CBA-tdTomato were produced by the triple transfection 
method 166 followed by cesium chloride density gradient ultracentrifugation and dialysis 
against 1x phosphate buffered saline (PBS) overnight with two changes. Viral titers were 
determined by quantitative PCR using primers (IDT Technologies, Ames, IA) specific for the 
CBA promoter (forward 5′-CGT CAA TGG GTG GAG TAT TT-3′; reverse 5′-GCG ATG 
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ACT AAT ACG TAG ATG-3′) or Luc transgene region (forward 5′-AAA AGC ACT CTG 
ATT GAC AAA TAC-3′; reverse 5′-CCT TCG CTT CAA AAA ATG GAA C-3′). Viral 
titers for different vector preps typically ranged from 2-5 x 1012 vector genome-containing 
particles per mL (vg/ml).   
Cell surface binding assay. CHO Lec2 cells deficient in terminal sialic acid moieties 
were seeded at a density of 104 cells/well in 96-well plates and maintained in an incubator at 
37 ˚C and 5% CO2 overnight. Prior to adding virus particles, cells were pre-chilled to 4°C 
for 30 min, followed by incubation with AAV9 or AAV9-W503R particles at MOI of 1x102, 
5x102, 1x103, 5x103, 1x104, 5x104, 1x105, 5x105 vg/cell for 1.5 hrs at 4°C. Cells were then 
subjected to three washes with ice-cold 1x PBS to remove unbound virions. Cell surface-
bound virions were collected along with cell lysates following three freeze-thaw cycles and 
vg copy numbers/cell determined using quantitative PCR as outlined earlier. Binding curves 
were generated using GraphPad Prism 5 software by applying the single site binding model 
(Y=Bmax*X/(Kd’+X)), where Y represents the number of bound virions/cell determined by 
quantitative PCR; X represents MOI; Bmax is the maximum binding capacity, and Kd’, the 
observed disassociation constant. Binding potential is defined as Bmax/Kd’ and serves as a 
measure of glycan binding avidity.  
Live animal studies. All in vivo experiments were carried out using 6–8-week old 
female BALB/c mice (Jackson Laboratories, Bar Harbor, ME) maintained and treated in 
accordance with National Institutes of Health guidelines and as approved by IACUC at 
UNC-Chapel Hill. Sialidase (neuraminidase type III from V. cholerae, 200 milliunits) or PBS 
was administrated through intravenous injection 3 hrs prior to AAV9-CBA-Luc (5x1010 vg) 
through the same route. Luciferase transgene expression in live animals was monitored at 
 57 
 
indicated time points for each experiment using an Xenogen IVIS Lumina® imaging system 
(Perkin Elmer/Caliper Life Sciences, Waltham, MA) following intraperitoneal injection of D-
luciferin substrate (120 mg/kg; Nanolight, Pinetop, AZ). Bioluminescent image analysis was 
conducted using the Living Image software® (Perkin Elmer/Caliper Life Sciences, Waltham, 
MA) and luciferase expression reported in relative light units (photons/s per cm2 per 
steradian).  
Quantitation of luciferase expression. The same group of mice was sacrificed at 
indicated time points and the heart and liver harvested. Approximately 50 mg of each tissue 
was homogenized in 150 μl of passive lysis buffer (Promega, Madison, WI) using a Tissue 
Lyser II system (Qiagen, Valencia, CA). Tissue lysates were centrifuged at 8,000 rpm for 2 
min to pellet debris and 50 μl of the supernatant transferred to 96-well plates for 
luminometric analysis using a Victor2® luminometer (Perkin Elmer, Waltham, MA). Total 
protein concentration in tissue lysates was determined using the Bradford assay (BioRad, 
Hercules, CA).  
Quantitation of viral genome biodistribution. Approximately 100 μl of supernatant 
from tissue lysates obtained as mentioned above was processed using a DNeasy kit (Qiagen, 
Valencia, CA) to extract host and vector genomic DNA. Vector genome (Luc) and mouse 
lamin gene (housekeeping gene serving as internal standard) copy numbers were determined 
from 100 ng of total extracted DNA using quantitative PCR as described earlier. 
Immunohistology. For lectin staining studies, sialidase (neuraminidase type III from 
V. cholerae, 400 milliunits) in 150 μl of PBS or PBS alone was first administrated via tail 
vein injection. At 3 hrs post-administration, mice were anesthetized with intraperitoneal 
injection of avertin (0.2 ml/10 g of a 1.25% solution) and perfused transcardially with 20 ml 
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of PBS, then 20 ml of freshly prepared 4% paraformaldehyde (Sigma-Aldrich, St. Louis, MO) 
in PBS. Cardiac, liver, brain, and musculartissues were fixed at 4°C overnight, and then 
sectioned into 40 μm slices using a Leica vibrating blade microtome (Leica Microsystems, 
Buffalo Grove, IL). The sections were blocked in 10% goat serum in 1xPBS containing 0.1% 
Triton X-100 (PBS-T) for 1 hr at room temperature prior to incubation with primary 
antibodies (10 μg/ml CD16/CD32 or F4/80 MAb and 1:10 dilution of ADK9 in hybridoma 
media) for 24 hrs at 4°C. Antibody binding was localized using fluorophore-conjugated 
secondary antibodies diluted 1:1000 in 3% goat serum in PBS-T for 1 hr at 4°C. Specifically, 
Alexa Fluor 647 goat anti-rat IgG (H+L) (Invitrogen A21247, 2 mg/ml, 1:500 dilution) was 
used to recognize rat anti-mouse-CD16/CD32 and rat anti-mouse-F4/80, and Alexa Fluor 594 
goat anti-mouse IgG (H+L) (Invitrogen A11005, 2 mg/ml, 1:500 dilution) was utilized to 
detect ADK9 MAb, which binds to intact AAV9 capsids. When indicated, the sections were 
further stained in 30 μg/ml of FITC-labeled ECL or MAL-I lectins in 3% blocking solution. 
After three washes with PBS to get rid of unbound antibodies and lectins, the sections were 
mounted under cover slips in Prolong® gold anti-fade reagent with DAPI (Invitrogen 
P36935). Tissues harvested from untreated mice were utilized as controls. Four color 
fluorescence images were acquired using a Zeiss 710 confocal laser scanning microscope 
equipped with a spectral detection system for finer separation of fluorochromes. Image 
processing was carried out using LSM viewer and Image J® softwares.  
To compare the transduction profile of AAV9 and AAV9-W503R in live animals, 
PBS (mock treatment), AAV9-CBA-tdTomato (5x1010 vg), and AAV9-CBA-tdTomato 
(5x1010 vg) were injected to BALB/c mice through tail vein. 2 weeks post infection, animals 
were anesthetized using intaperitoneal avertin (0.2 ml/10 g of a 1.25% working solution), 
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followed by transcardial perfusion with 20 ml of PBS and 20 ml of 4% paraformaldehyde in 
PBS. Tissues were fixed in 4% paraformaldehyde in PBS for overnight at 4˚C, and sectioned 
into 40 μm slices using a Leica vibrating blade microtome. Tissue sections were mounted 
under cover slips using Prolong® gold anti-fade reagent with DAPI. Red fluorescent images 
were taken using an Olympus epifluorescence microscope equipped with a 10x objective and 
a Hamamatsu digital camera. 
Pharmacokinetic analysis. Sialidase (neuraminidase type III from V. cholera, 200 
milliunits) or 100 μl of PBS was injected through intravenous injections via the mouse tail 
vein. AAV9-CBA-Luc (5x1010 vg) was injected through the same route 2 hrs later. For 
pharmacokinetic analysis, 10 μl of blood was drawn from the tail vein through nicking at the 
different time intervals into heparinized glass capillary tubes (Fisherbrand Hematocrit®). 
Viral DNA was extracted from the blood samples using a DNeasy kit (Qiagen, Valencia, CA) 
and further quantified by qPCR as described earlier. Blood clearance of viral genomes was 
plotted as a function of viral genome copy number vs. time and the data fit into a bi-
exponential model using least-square regression analysis in GraphPad Prism® software. 
Distribution and elimination half-life as well as different rate constants based on a two 
compartment pharmacokinetic model were calculated using equations outlined in Table 4 as 
described earlier 201. Pharmacokinetics parameters, standard errors, and goodness of fit from 
curve-fitting are listed in Table 5 and Table 6. 
Statistics. All data are expressed as mean ± s.e.m. unless indicated otherwise. The 
two-tailed unpaired t test was utilized for all statistical analysis and P values < 0.05 were 
considered significant unless indicated otherwise. Statistical evaluation of pharmacokinetic 
parameters and goodness of fit are provided in Table 5. 
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3.4 Results 
Intravenous sialidase alters tissue surface glycosylation patterns in mice. Using lectin 
staining, we analyzed the endogenous constitution of sialylated glycans in major mouse 
organs as well as the effect of administering intravenous sialidase on tissue surface 
glycosylation patterns. First, BALB/c mice were intravenously injected with PBS or 
recombinant sialidase from V. cholerae 3 hrs prior to tissue harvesting/fixation. Sections of 
major organs were then stained with FITC-labeled lectins, specifically, ECL, which 
recognizes terminal galactose moieties on Gal(β1,4)N-GlcNAc or MALI, which binds both 
α2,3-sialylated and sulfated forms of Gal(β1,4)N-GlcNAc. As shown in Figure 11A, FITC-
ECL staining is barely discernible, while substantial FITC-MALI staining is observed in 
murine heart, liver, brain and muscle. These observations suggest that the endogenous 
expression of asialoglycans containing terminal galactose is low when compared to that of 
α2,3-sialylated glycans in normal mouse tissues. In contrast, intravenous injection of 
recombinant sialidase markedly enhanced FITC-ECL staining intensity in heart, liver and 
muscle tissue, while MALI staining showed a modest decrease (Figure 11B). Interestingly, 
murine brain displayed ECL staining potentially localized to blood vessels alone, while 
MALI staining remained more or less unaffected upon sialidase treatment (Figure 11B). 
These results correlate well with earlier in vitro studies 52 and suggest that intravenous 
sialidase can effectively desialylate glycoproteins and glycolipids revealing the underlying 
β1,4-galactose moiety in major organs in vivo. We then exploited these observations to 
further evaluate the impact of increasing cognate glycan receptor density on AAV9 tropism 
in vivo. 
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High glycan binding avidity redirects systemic AAV9 to the liver. We analyzed the 
effect of enzymatic desialylation on the transduction profile of AAV9 vectors packaging a 
chicken β-actin (CBA) promoter-driven firefly luciferase transgene in vivo. Briefly, AAV9 
vectors were injected into the tail vein at 3 hrs following intravenous administration of 
recombinant sialidase. To track the kinetics of luciferase transgene expression, live animal 
bioluminescence images were taken at different time intervals post-injection (Figure 12A). 
As seen in Figure 12A, AAV9 displays a systemic transduction profile in the PBS treated 
mouse group (left panel), consistent with previous reports 95,125,202. In the sialidase treated 
group (Figure 12A, right panel), a predominantly liver-centric bioluminescent signal is 
observed, accompanied by decreased signal in other systemic regions. Luciferase transgene 
expression and viral genome copy number in different tissue lysates were quantified at 2 
weeks and 3 days post-injection, respectively. As shown in Figure 12B, the transduction 
efficiency of AAV9 in the liver is ~5-fold higher upon sialidase treatment. Further, a 
substantial decrease in transduction efficiency within the heart (~10-fold) and skeletal muscle 
(~14-fold) is observed. Transgene expression levels in the murine brain are relatively low in 
comparison with other organs and show no significant change upon sialidase treatment. 
Consistent with these observations, the biodistribution of viral genomes in the liver is 
increased by ~7-fold in the liver (Figure 12C). Correspondingly, viral genome copy numbers 
are decreased in the brain, heart and skeletal muscle are decreased (ranging from 2 to 5-fold) 
upon sialidase treatment. These results suggest that surface glycan density in host tissues 
strongly influences AAV tissue tropism. In particular, increased availability of the galactose 
receptor in host tissue appears to redirect AAV9 capsids from major systemic organs towards 
the liver.  
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High glycan binding avidity results in AAV9 sequestration within liver endothelial 
and Kupffer cells. To understand the mechanism(s) underlying increased liver accumulation 
of AAV9, we analyzed liver sequestration of viral capsids through immunohistology. Briefly, 
mice were injected with AAV9 vectors 3 hrs post-sialidase or PBS treatment. At 15 minutes 
post-vector administration, liver and heart were harvested and processed as described in 
materials and methods. Following PBS pre-treatment, we observed sporadic immunostaining 
for AAV9 capsids partially overlapping with endothelial cells defined by FcγRII/III/IV 
staining (anti-CD16/CD32) or other cell types within the liver (Figure 13A). In contrast, 
sialidase pre-treatment resulted in increased liver uptake of AAV9 capsids consistent with 
increased galactose density (Figure 13A). Further, increased immunofluorescence associated 
with AAV9 capsids almost completely co-localized with liver sinusoidal endothelial cells 
upon sialidase treatment (Figure 13A). We also observed substantially increased co-
localization of AAV9 capsids with Kupffer cells (anti-F4/80) in addition to sinusoidal 
endothelial cells within the liver (Figure 13B). These results confirm the earlier observation 
that high glycan density in host tissues redirects AAV9 from systemic organs to the liver. 
The underlying mechanism can be attributed to markedly increased sequestration of AAV9 
capsids within the liver sinusoidal endothelium and Kupffer cells.   
Decreased glycan binding avidity detargets AAV9 from the liver. We previously 
engineered a class of AAV9 mutants, which have selectively lost their ability to transduce the 
liver 95. As shown in the previous study, one such mutant, AAV9-W503R displays markedly 
lower transduction efficiency (> 1 log unit) in liver when compared to wild type AAV9. In 
the current study, we evaluated the ability of this mutant to bind surface-exposed galactose 
residues on Chinese hamster ovary (CHO) Lec2 cells, which are permissive to AAV9 
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infection in vitro 52,53. As seen in Figure 14A, the AAV9-W503R mutant is deficient in cell 
surface binding, with a binding potential (Bmax/Kd’) that is ~4.5-fold lower than that 
observed for wild type AAV9. Correspondingly, this mutant displays transduction efficiency 
that is several orders of magnitude lower when compared to wild type AAV9 in CHO Lec2 
cells at different multiplicities of infection (MOI) (Figure 14B). We then investigated the 
impact of such decreased glycan binding avidity on liver sequestration of AAV9 and the 
W503R mutant following intravenous administration. As seen in Figure 14C, 
immunohistological analysis reveals markedly lower immunostaining for AAV9-W503R in 
comparison with AAV9 capsids. Moreover, while AAV9 capsids co-localized with 
FcγRII/III/IV (anti-CD16/CD32 staining), which is specific for endothelial cells as well as 
liver parenchyma, the AAV9-W503R mutant weakly co-localized with endothelial cells 
alone (Figure 14C). In addition, consistent with earlier studies in our lab 95, we observed a 
lack of tdTomato reporter gene expression in hepatocytes for AAV9-W503R in contrast to 
wild type AAV9 (Figure 14D). Taken together, these results suggest that decreased glycan 
binding is the underlying basis for the liver-detargeted phenotype displayed by the AAV9-
W503R mutant. 
Vascular endothelium constitutes a limiting barrier for cardiac uptake of AAV9. We 
also evaluated the impact of altering glycan binding avidity on cardiac tropism of AAV9 in 
mice. As seen in Figure 5, immunostaining for AAV9 capsids (MAb ADK9, red) as well as 
the endothelial marker FcγRII/III/IV (anti-CD16/CD32 staining) is markedly lower in 
comparison to that observed in liver sections (Figure 13). Moreover, unlike liver, where viral 
particles are dispersed amongst parenchymal and non-parenchymal cell types, AAV9 capsids 
predominantly co-localize with the vascular endothelium in the murine heart. This 
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observation supports the notion that transvascular transport is a likely prerequisite for viral 
entry into cardiomyocytes as proposed earlier 203. Interestingly, despite the dramatic increase 
in galactose receptor density as demonstrated by FITC-ECL staining throughout cardiac 
tissue following sialidase pre-treatment, no changes in the pattern or extent of cardiac uptake 
of AAV9 capsids were observed when compared to PBS-treated control. Instead, AAV9 
capsids co-localized with cardiac endothelium in a manner similar to PBS-treated control 
animals. In addition, immunostaining for the low binding affinity mutant (AAV9-W503R) 
was significantly lower at this early time interval potentially due to decreased endothelial 
surface interactions.   
Altered glycan binding avidity affects the blood circulation profile of AAV9. Several 
reports have demonstrated that AAV9 displays prolonged blood circulation in comparison 
with other AAV strains in mice 125,203. We hypothesized that the latter phenomenon could 
arise from low endogenous levels of terminal galactose residues in murine tissue. To test this 
hypothesis, we first treated mice with intravenous sialidase prior to AAV9 administration in 
order to increase galactose receptor density in murine tissues as described earlier. Viral 
genome copies in blood were then collected at different time intervals, quantitated by Q-PCR 
analysis and the data fit to a bi-exponential, two compartment model (Table 4) to obtain 
different pharmacokinetic parameters (Table 5 and Table 6). As seen in Figure 16A, high 
glycan binding avidity results in rapid clearance of AAV9 from the blood (solid circles), 
while the low binding avidity mutant AAV9-W503R appears to persist longer in blood 
circulation in comparison to AAV9 circulating under normal conditions. Specifically, 
increasing tissue glycan density by sialidase treatment results in ~4 times faster elimination 
half-life (t1/2,e). In contrast, the AAV9-W503R mutant, which is deficient in galactose 
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binding, is eliminated twice as slowly (~10 hrs) from the blood circulation when compared to 
AAV9 alone (~4.7 hrs). Further, while the half-life of viral dissemination from blood to 
tissue (t1/2,dis) is reduced by ~2-fold upon sialidase treatment, this parameter is extended from 
~0.4 hrs to ~1 hr (2.5-fold increase) for the W503R mutant. Consistent with these 
observations, we note that the blood-to-organ distribution rate constant (k12) and organ-to-
blood distribution rate constant (k21) are comparable in mice injected with AAV9 alone. In 
contrast, k12 for AAV9 is ~7-fold higher than k21 in mice pretreated with sialidase supporting 
rapid tissue dissemination of injected virus particles. Further, for the AAV9-W503R mutant, 
both the aforementioned rate parameters are lower in comparison with AAV9, consistent 
with prolonged blood residence time. Taken together, these results confirm that the capsid-
glycan interactions profoundly affect the pharmacokinetics of AAV9.  
3.5 Discussion 
The liver is a prominent systemic organ featuring hepatocytes as well as a large 
proportion of cells belonging to the reticuloendothelial system. Due to the large volume of 
circulating blood that filters through the liver, the sinusoidal endothelial and Kupffer cells in 
this organ play a major scavenging role in the uptake of various macromolecules and 
pathogens 204,205. A particularly well-studied example in this regard is the adenoviral 
sequestration within the liver 200,206-208. Most, if not all naturally occurring isolates of AAV 
studied to date, display a moderate-to-high transduction efficiency within the liver 125. 
However, whether liver sequestration mechanisms similar to those observed for adenoviruses 
prevail in the case of AAV is not known.   
 66 
 
In the current study, we investigated the potential role of glycan receptor binding 
avidity on AAV liver sequestration and systemic spread using AAV9-galactose interactions 
as a model. Notably, the transduction profile and in vivo biodistribution of AAV9 were 
altered from systemic to hepatotropic under high glycan binding avidity conditions. These 
observations are corroborated by immunostaining studies, which revealed that increasing 
glycan receptor binding avidity potentiates AAV9 sequestration within the liver sinusoidal 
endothelium and Kupffer cells. In corollary, the AAV9-W503R mutant displays low 
galactose binding affinity and displayed decreased liver uptake in mice. Further, our results 
suggest that high affinity receptor sites for AAV9 in mice are constitutively low. This 
observation is not surprising, since it is well known that glycans containing β1,4-linked 
galactose are extended by sialylation or sulfation, although formation of poly-N-
acetyllactosamine (Galβ1,4GlcNAcβ1-) units has also been demonstrated earlier 209. The 
resulting modest glycan binding avidity could explain the underlying basis for widespread, 
systemic tropism and prolonged blood circulation displayed by AAV9 in comparison to other 
AAV serotypes in vivo. Strikingly, high glycan binding avidity appears to adversely affect 
AAV9 uptake and transduction in peripheral tissues such as cardiac and skeletal muscle. This 
effect can likely be attributed to the rapid blood clearance of AAV9 under such conditions 
and highlights the limiting role of vascular endothelium in viral dissemination. Our 
conclusions are further supported by earlier studies by Nakai and others 203, which 
demonstrate that trans-endothelial transport of AAV9 is a capacity-limited process that 
constitutes a significant barrier towards viral uptake by cardiomyocytes, but not hepatocytes. 
Why is the AAV9-W503R mutant selectively detargeted from the liver, while 
transduction in peripheral tissues such as the heart and skeletal muscle remain unaffected 95? 
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In the current study, we determined that this mutant (as well as other liver-detargeted AAV9 
mutants, Shen and Asokan, unpublished) displays low galactose binding avidity in vitro and 
reduced endothelial binding in vivo. These results are consistent with W503R being recently 
identified as one of the key residues involved in galactose recognition by AAV9 capsids 94. A 
potential explanation for this phenomenon is that low glycan binding avidity results in the 
doubling of distribution half-life (t1/2,dis ~1 hr) as well as elimination half-life (t1/2,e ~9 hrs) of 
the mutant when compared to wild type AAV9 (Table 3). Thus, it is likely that the AAV9-
W503R mutant significantly benefits from repeated circulation through cardiac tissue, where 
traversing the vascular endothelium appears to be a capacity-limited process. Such 
transendothelial transport of viral particles might be redundant for transduction in liver, 
which contains open fenestrae that allow free exchange of material between blood and the 
space of Disse 204. These results are further corroborated by earlier studies with AAV 
serotype 2, wherein, abrogation of capsid binding to heparan sulfate yields liver-detargeted 
AAV2 mutants 89. One such mutant, AAV2i8, which persists longer in blood than other AAV 
strains, displays robust cardiac and skeletal muscle tropism with ability to traverse the 
vascular endothelium 143. Based on a collective interpretation of results, we propose 
mathematical models that will help predict the impact of capsid-glycan interactions on AAV 
blood clearance as well as transport between the central (blood) compartment and major 
peripheral (liver) compartment (Figure 16B and Figure 16C). High glycan receptor binding 
avidity will likely increase the rate of viral dissemination from blood to liver (k12) as well as 
rapid viral elimination from blood (ke) by excretory mechanisms (Figure 16B). In contrast, 
when glycan binding avidity is low, both dissemination and elimination rate constants are 
decreased resulting in significantly longer blood circulation times (Figure 16C). Although 
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virus-glycan interactions alone are unlikely to provide a complete understanding of the 
biology of AAV, it is tempting to speculate that the latter models could potentially help 
predict liver sequestration of AAV in different species on the basis of their respective 
glycosylation patterns.   
In summary, our studies offer new insight into the role of glycans in determining 
AAV tropism in vivo. In addition to resolving the mechanistic basis of liver-detargeted AAV 
vectors, we provide a potential general strategy for engineering any AAV strain by 
modulating capsid-glycan interactions. Further, the results described herein underscore the 
importance of understanding species-specific variation in glycosylation patterns. For instance, 
striking differences in sialylation patterns between different tissues in mice, rats, 
chimpanzees and humans have been reported 210. Such information could guide rational 
selection of preclinical animal models for evaluating AAV vectors and might help better 
predict clinical gene therapy outcomes. 
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 Table 4. Pharmacokinetic Equations for a Two Compartment Model a   
 Bi-exponential equation describing AAV9 pharmacokinetics:     
Tissue-to-blood compartment distribution rate constant:            
Blood elimination rate constant:                                                  
Blood-to-tissue compartment distribution rate constant:             
Distribution half-life:                                                                     
Elimination half-life:                                                                     
 a Cp is the viral genome copy number in plasma, x is the time interval  
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Table 5. Pharmacokinetic Parameters and Goodness of Fit from Curve-fitting Blood 
Circulation Data to a Bi-exponential Two-compartment Model 
Treatment PBS Sialidase PBS 
Virus AAV9 AAV9 AAV9-W503R 
Y0 6.86x10
10  9.81x109 9.89x1010  1.65x1010 8.62x1010  2.46x1010 
A 3.75x10
12  5.55x1010 8.79x1012  2.49x1010 3.94x1012  8.83x1011 
B 3.11x10
12  5.55x1010 1.10x1012  2.49x1010 4.68x1012  8.83x1011 
α 3.509  1.12 4.602  0.7836 1.752  3.566 
β 6.826x10
-2  4.874x10-3 7.055x10-2  7.696x10-3 3.884 x10-2  6.423x10-2 
R2 0.9995 0.9999 0.7250 
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Table 6. Parameters Describing the Pharmacokinetics of AAV9 Under Different 
Glycan Binding Avidity Conditions In Vivo 
Treatment AAV9 AAV9+Sialidase AAV9-W503R 
Glycan binding avidity ++ +++ + 
k21 (h-1) 1.63 0.57 0.97 
ke (h-1) 0.15 0.57 0.07 
k12 (h-1) 1.80 3.53 0.75 
t1/2,dis (h) 0.38 0.20 0.92 
t1/2,e (h) 4.72 1.22 9.87 
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Figure 11. Intravenous sialidase alters endogenous tissue glycosylation patterns in vivo. 
(A) Fluorescent lectin staining of heart, liver, brain and skeletal muscle tissue harvested from 
Balb/C mice. FITC-ECL was used to detect tissue glycans containing terminal β1,4-
Galactose and FITC-MALI detects α2,3-sialylated glycans. Confocal micrographs were 
obtained using a Zeiss 710 Confocal Laser Scanning Microscope with a 40x objective at 
zoom 0.6. Scale bar = 50 μm. (B) Fluorescent lectin staining of heart, liver, brain and skeletal 
muscle harvested from Balb/C mice administered intravenous sialidase to enzymatically 
remove α2,3-sialic acid residues in vivo. 
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Figure 12. High glycan binding avidity redirects systemic AAV9 to the liver. (A) Live 
animal bioluminescence images of AAV9-mediated luciferase transgene expression in 
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Balb/C mice injected prior with PBS (control, upper panel) or recombinant sialidase (lower 
panel) at 2 weeks post-administration (n=3). Images were obtained using a Xenogen IVIS 
Lumina system. Rainbow scale represents relative light units (RLU) expressed in photons per 
sec per cm2 per steradian. Kinetics of luciferase transgene expression on days 2, 4 and 7 was 
also recorded through live animal bioluminescence imaging (See Supplementary Figure S1). 
(B) Luciferase transgene expression in brain, heart, liver, skeletal muscle tissue lysates 
harvested from mice injected with PBS (white bars) or sialidase (grey bars) prior to AAV9 at 
2 weeks post-administration. Luciferase transgene expression (RLU) is normalized to total 
cellular protein in tissue lysate (n=3). Data are represented as mean ± s.e.m.. (C) AAV9 
vector genome biodistribution in brain, heart, liver and skeletal muscle tissues harvested from 
Balb/c mice pre-treated with PBS (white bars) or sialidase (grey bars) at 3 days post-
administration (n=3). Viral genome copy numbers in different tissues/animals were obtained 
using quantitative PCR and normalized to total copy number of the constitutive mLamin 
gene in host genomic DNA. Primer sequences utilized for QPCR are listed under 
experimental procedures. Data are represented as mean ± s.e.m.. 
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Figure 13. High glycan avidity potentiates AAV9 sequestration by liver sinusoidal 
endothelium and Kupffer cells. (A) Liver sections were obtained 15min post-injection of 
AAV9 in Balb/C mice pre-treated with intravenous PBS (middle row) or sialidase (bottom 
row). Tissue sections were stained with fluorescent lectin to detect β1,4-galactose, FITC-
ECL (green); anti-AAV9 capsid antibody, ADK9 (red) and anti-CD16/CD32 endothelial cell 
marker antibody (magenta). Color images were merged along with nuclear DAPI staining 
(blue) to generate the overlay panel. Untreated mouse liver is shown as control (top row). 
Large white arrows indicate liver sinusoidal endothelial cells and small white arrows indicate 
non-endothelial cells. Fluorescent micrographs were obtained using a Zeiss 710 Confocal 
Laser Scanning Microscope with a 63x objective. Scale bar = 50 μm. (B) Liver sections 
obtained from Balb/C mice pre-treated with intravenous PBS or sialidase and immunostained 
with FITC-ECL (green), ADK9 (red), anti-F4/80 Kupffer cell marker antibody (magenta) 
and nuclear DAPI staining (blue). Large white arrows indicate liver sinusoidal endothelial 
cells and small white arrows indicate Kupffer cells. 
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Figure 14. Low glycan binding avidity detargets AAV9-W503R from the liver. (A) The 
AAV9-W503R mutant displays decreased binding affinity to terminal galactose residues on 
the surface of CHO Lec2 cells lacking sialic acid (n=4). Curve fitting based on a single-
binding site model was utilized to obtain binding potential values (Bmax/Kd’) for the mutant 
and parental AAV9. Data are represented as mean ± s.e.m.. (B) Transduction efficiency of 
AAV9 and AAV9-W503R on CHO Pro5 (constitutive glycan composition) and Lec2 cells 
(sialic acid-deficient) at different multiplicities of infection (n=4). Luciferase transgene 
expression in cell lysates was analyzed 24 hrs post-infection **p < 0.01; ***p < 0.005. Data 
are represented as mean ± s.e.m.. (C) AAV9 and AAV9-W503R accumulation in the liver of 
Balb/C mice at 15 min post-intravenous administration. Immunostaining was carried out 
using anti-AAV9 capsid antibody, ADK9 (red); anti-CD16/CD32 endothelial cell marker 
(magenta) and nuclear DAPI staining (blue). Fluorescent images were collected as described 
earlier. Large white arrows indicate liver sinusoidal endothelial cells and small white arrows 
indicate non-endothelial cells. Scale bar = 20 μm. (D) Transgene expression (tdTomato 
reporter) mediated by AAV9 and AAV9-W503R in liver and heart in BALB/c mice (n = 3). 
Tissues were harvested and imaged 2 weeks post-infection with a 10× objective.  
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Figure 15. Vascular endothelial cells limit cardiac uptake of AAV9 capsids. Confocal 
micrographs of cardiac tissue sections harvested from Balb/C pre-treated with PBS (second 
row) or sialidase (third row) obtained at 15min post-intravenous AAV9 injection. 
Immunostaining was carried out using FITC-ECL (green), ADK9 (red), anti-CD16/CD32 
(magenta) and nuclear DAPI staining (blue). Co-localization of mutant AAV9-W503R with 
vascular endothelium in the heart (bottom row) and cardiac tissue sections from untreated 
Balb/C mice (top row) are also shown. Large white arrows indicate cardiac endothelium. 
Scale bar represents 50 μm.  
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Figure 16. Glycan binding avidity affects the blood circulation profile of AAV9. (A) 
Blood circulation kinetics of the AAV9-W503R mutant (●) or AAV9 in Balb/c mice pre-
treated with PBS (o) or sialidase (▲). Viral genome copy numbers in blood obtained at 
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15min, 30min, 1 hr, 3 hrs, 6 hrs and 24 hrs post-administration were obtained by quantitative 
PCR (n=3). Curve fitting based on a bi-exponential, two-compartment model was utilized to 
obtain pharmacokinetic parameters listed in Table 4. Data are represented as mean ± s.e.m.. 
Equations, goodness of fit and statistical analysis are listed in Tables 5 and 6. (B) Proposed 
mathematical model for predicting the impact of high glycan binding avidity on viral blood 
clearance and liver sequestration. Rates of viral elimination from blood (ke), viral 
dissemination from blood-to-liver (k12) and liver-to-blood (k21) are shown. Bold arrows 
indicate faster rates of dissemination and clearance from blood. This model specifically 
explains the pharmacokinetics of wild type AAV9 following enzymatic desialylation in mice. 
(C) Proposed mathematical model for predicting the impact of low glycan binding avidity on 
viral blood clearance and liver sequestration. Different rates (k values) are shown as above. 
Dotted arrows indicate slower rates of dissemination and clearance from blood. This model 
specifically explains the pharmacokinetics of mutant AAV9-W503R in mice. 
 
 
CHAPTER 4  
Engineering Novel Dual Glycan Binding AAVs for Enhanced Gene Transfer3 
4.1 Overview 
New viral strains can be evolved to recognize different host glycans through 
mutagenesis and experimental adaptation. However, reassortants generally harbor mutations 
that affect viral binding to a single class of carbohydrate receptors. We describe the rational 
design and synthesis of a novel class of adeno-associated viruses (AAV) that exploit two 
distinct glycan receptors for cell entry. A prototypical dual glycan binding AAV strain was 
engineered by “grafting” an orthogonal galactose (Gal) binding footprint from AAV serotype 
9 onto the heparan sulfate (HS) binding AAV serotype 2. The resulting chimera, AAV2G9, 
interchangeably exploits Gal and HS as evidenced by competitive inhibition assays with 
lectins and glycans. Further, AAV2G9 mediates rapid onset and sustained, higher transgene 
expression in vivo compared to parental AAV serotypes. In addition to demonstrating the 
modularity of glycan receptor footprints on viruses, our approach provides design parameters 
to upgrade the current AAV vector toolkit for clinical gene therapy. 
                                                 
3This chapter includes the original manuscript in preparation: Shen, S., Horowitz, E.D., 
Troupes, A., Brown, S. M., Asokan, A. Engineering of a Dual-glycan Binding Aden-
associated Virus Variant Using Molecular Grafting. 
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4.2 Introduction 
Virus-glycan interactions are critical determinants of host cell invasion. Cell surface 
carbohydrates such as sialic acids, gangliosides or heparan sulfate are exploited by a vast 
number of viruses such as influenza, herpesvirus, SV40, polyomavirus, papillomavirus and 
other pathogens 1,192. In most cases, a single class of glycans primarily serves as the cell 
surface attachment factor for viruses, leading to sequential or parallel engagement of other 
receptors/co-receptors for cell entry. Adeno-associated viruses (AAV) are helper-dependent 
parvoviruses that exploit heparan sulfate (HS), galactose (Gal) or sialic acids (SA) as primary 
receptors for cell surface binding 152,193. For instance, AAV serotypes 2 and 3b utilize HS; 
AAV1, 4 and 5 bind SA with different linkage specificities; while AAV9 exploits Gal for 
host cell attachment. Different AAV strains also require subsequent interaction with co-
receptors such as integrin αVβ5 or α5β1, fibroblast growth factor receptor (FGFR), platelet-
derived growth factor receptor (PDGFR), epidermal growth factor receptor (EGFR), 
hepatocyte growth factor receptor (HGFR) or the laminin receptor for cellular uptake 152,193.  
A notable exception to the monogamous relationship between a specific AAV strain 
and a single class of carbohydrates is AAV serotype 6, which recognizes both SA and HS 211. 
However, only SA has been shown essential for viral transduction. Structural studies have 
now established that the K531 residue in conjunction with R488, K528 and K533 in the VP3 
subunit of the AAV6 capsid form a continuous basic patch for electrostatic recognition of HS 
glycosaminoglycans 43,165,198. Similarly, the structural basis for HS recognition by AAV2 and 
AAV3b is well known and attributed to similar clusters of basic amino acid residues located 
at the three-fold axis of symmetry 83,90,92,93. The SA binding footprints for AAV1, AAV4, 
AAV5 and AAV6 remain to be determined. More recently, key amino acid residues involved 
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in Gal recognition by AAV9 capsids were identified by using a combination of molecular 
docking and site-directed mutagenesis 94. This abundance of structural information and 
knowledge pertaining to host receptor usage by AAV serotypes provided the rationale for 
designing new dual glycan binding AAV strains.    
In the current study, a new, prototypical dual glycan binding strain, AAV2G9 was 
generated by incorporating the Gal binding footprint from AAV9 onto the AAV2 VP3 
backbone using structural alignment and site-directed mutagenesis. In vitro binding and 
transduction assays confirmed the exploitation of both HS and Gal receptors by AAV2G9 for 
cell entry. Subsequent in vivo characterization of the kinetics of transgene expression and 
viral genome biodistribution profiles indicate fast, sustained and enhanced transgene 
expression by this novel rationally engineered chimera. 
4.3 Materials and Methods 
Structural modeling. Coordinates for the AAV2 and AAV9 viral protein (VP) 
crystal structures were obtained from RCSB Protein Databank (PDB accession# 1LP3 and 
3UX1, respectively) 81,212. Using the SWISS-MODEL protein structure modeling server 
(http://swissmodel.expasy.org/) 213, homology models of the 2G9 VP3 monomer were 
generated with crystal structures of AAV2 VP3 as template. A three-dimensional icosahedral 
model of an intact 2G9 capsid was created using the Oligomer Generator utility in VIPERdb-
Virus Particle ExploreR2 (http://viperdb.scripps.edu/) 214. Similarly, illustration of the AAV2 
VP3 trimer, 2G9 trimer, and AAV9 trimer were obtained using the Oligomer Generator 
utility. All structural models were visualized using PyMOL with residues forming the 
galactose binding site (AAV9 VP3 numbering: D271, N272, Y446, N470, A472, V473, 
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W503) 94 and heparan sulfate binding site (AAV2 VP3 numbering:R487, K527, K532, R585, 
R588) 83,89,90,92 highlighted in orange and purple, respectively. Different VP3 monomers were 
colored in pale green, light blue and light pink.  
Generation of dual glycan binding AAV strains. Helper plasmids pXR1, 2, 6, 8 
and 9 were obtained from UNC vector core. The prototypical pXR2G9 chimera plasmid 
construct was generated by substituting amino acid residues directly involved or flanking the 
Gal recognition site on the AAV9 VP3 capsid protein subunit onto corresponding residues on 
the VP3 subunit of AAV2 (AAV2 VP3 numbering: A266S, Q464V, A467P, D469N, I470M, 
R471A, D472V, S474G, Y500F, S501A). Substitutions were generated using the 
QuikChange® Lightning site-directed mutagenesis kit (Agilent) using the following primers 
(IDT): 5’- GGAACCACCACGCAGTCAAGGCTTCAGTTTTCTGTGGCCGGACC 
CAGTAACATGGCTGTCCAGGGAAGGAACTGGCTTCCTGGACCCTGTTACCGC-3’ 
and 5’- GACATCTGCGGATAACAACAACAGTGAATTTGCTTGGACTGGAGCTACC 
AAGTACCACCT-3’. Recombinant AAV vectors packaging the CBA-Luc transgene 
cassettes were generated as described previously 166. Viral titers were obtained by 
quantitative PCR.  
In vitro binding, transduction and competitive inhibition assays. CHO Lec2 cells 
were cultured in αMEM (Thermo Scientific) supplemented with 10% fetal bovine serum 
(FBS), 100 U/ml of penicillin (Cellgro), 100 µg/ml of streptomycin (Cellgro), and 2.5 µg/ml 
of amphotericin B (Sigma). Cells were seeded at a density of 1x105 cells/well in 24 well 
plates. For competitive inhibition assays, cells were pre-chilled at 4ºC for 30 minutes and 
incubated with 100 µg/ml of FITC-labeled Erythrina Cristagalli Lectin (FITC-ECL, Vector 
Labs) in αMEM at 4ºC for 1 hr. Alternatively, different viral capsids were incubated with 
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100µg/ml of soluble heparin (Sigma) or 1xPBS (control) at room temperature for 1 hr. Mock-
treated or FITC-ECL treated cells were then infected with HS-bound or mock-treated AAV2, 
AAV2G9, or AAV9 capsids packaging a CBA-Luc transgene cassette at an MOI of 1000 
vector genome (vg) copies/cell. Following incubation in the cold room for 1 hour, unbound 
virions were removed by three washes with ice cold 1xPBS. For cell surface binding assays, 
the number of bound virions was measured by quantifying vector genome copy numbers/cell 
in each well using quantitative PCR. For transduction assays, infected Lec2 cells were moved 
to 37ºC and incubated for 24 hrs prior to quantitation of luciferase transgene expression from 
cell lysates. 
For competitive inhibition with parental AAV2 or AAV9 capsids, vectors packaging 
CBA promoter-driven tdTomato transgene cassette were utilized. Briefly, Lec2 cells were 
seeded in 24 well plates overnight at a density of 1x105 cells/well. After being pre-chilled at 
4ºC for 30 minutes, Lec2 cells were pre-incubated with either AAV2-tdTomato or AAV9-
tdTomato vectors at multiplicities of infection (MOI) ranging from 500 to 100,000 vg/cell at 
4ºC for another 30 minutes. Cells were then super-infected with AAV2G9-CBA-Luc at an 
MOI of 1000 vg/cell for 45 minutes at 4ºC, followed by removal of unbound virions using 
ice cold PBS. Infected cells were then incubated at 37ºC for 24 hrs prior to luciferase 
expression analysis. Controls included AAV2-CBA-Luc or AAV9-CBA-Luc vectors.  
Kinetics of transgene expression in vivo. Female BALB/c mice (6-8 weeks old) 
were purchased from Jackson Laboratories and handled in accordance with NIH guidelines 
using IACUC approved protocols at UNC Chapel Hill. Different AAV vectors packaging the 
CBA-Luc cassette were injected intravenously into the tail vein at a dose of 1x1011 vg/mouse. 
At indicated time intervals post-administration (3, 7, and 18 days), mice were 
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intraperitoneally injected with luciferin (120 mg/kg; Nanolight) and bioluminescent images 
obtained using an Xenogen IVIS® Lumina system (Caliper Lifesciences). Quantitation of 
light output from liver and whole animal images was carried out using Wavemetrics® 
software. Further quantitation of luciferase transgene expression and vector genome 
biodistribution in different tissues was carried out in two different groups of mice that were 
sacrificed at days 3 and 18 post-vector administration. Luciferase transgene expression was 
monitored in different tissue lysates as described earlier. Vector genome biodistribution was 
determined by first extracting genomic DNA from tissue lysates using a DNeasy® Kit 
(Qiagen). Luciferase transgene copy number was determined using qPCR and normalized to 
the number of copies of the mouse lamin gene to determine vg/cell in each tissue. Specific 
primer sets were 5’-AGG GCA CCT CCA TCT CGG AAA C-3’ / 5’-GGA CCC AAG GAC 
TAC CTC AAG GG-3’ (for mouse lamin) and 5’-AAA AGC ACT CTG ATT GAC AAA 
TAC-3’/ 5’-CCT TCG CTT CAA AAA ATG GAA C-3’(for CBA-Luc) , respectively. 
Statistical Analysis. All data is expressed as mean ± standard error mean and the 
number of replicates for each experiment is provided in the corresponding figure legends. 
Statistical significance was determined using the unpaired one-tail student’s t-test and p-
values less than 0.05 considered statistically significant for different experiments unless 
indicated otherwise.  
4.4 Results 
Construction of the dual glycan binding prototype strain 
To explore the feasibility of “grafting” the Gal footprint of AAV9 onto several AAV 
strains, we first compared the three-dimensional structures of VP3 subunit trimers of AAV 
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serotypes 1, 2, 6 and 8 in alignment with that of AAV9 (Figure 18). Amino acid residues on 
the template capsids that overlapped with corresponding AAV9 VP3 residues directly 
involved in binding or immediately flanking the Gal receptor footprint were modified by 
multiple rounds of site-directed mutagenesis. All of the chimeric AAV strains generated were 
prepared as recombinant vectors packaging a chicken beta-actin promoter driven firefly 
luciferase (CBA-Luc) reporter transgene cassette using previously established protocols 166. 
Amino acid residues involved in Gal recognition and other flanking residues from AAV9 
were remarkably well tolerated on different AAV serotype capsids as the packaging 
efficiencies of these AAV chimeras are comparable with parental strains. Multiple AAV 
chimeras based on AAV serotypes 1, 2, 6, 8 and the previously engineered AAV2i8 
mutant 143 were obtained (at titers ranging from 5×1011 to 5×1012 viral genome copies/mL) 
and observed to exploit Gal as a novel primary receptor in transducing CHO Lec2 cells in 
vitro (Figure 20). We then carried out a detailed characterization of a prototypical dual 
glycan binding AAV chimera, dubbed AAV2G9 (where G stands for the Gal footprint and 
the numbers identify the recipient and donor capsid serotypes, respectively). 
Three-dimensional models of synthetically engineered AAV2G9 (full capsid in 
Figure 17A and VP3 trimer in Figure 17D) with the putative dual glycan receptor binding 
sites (HS and Gal) highlighted in purple and orange were generated by homology modeling 
using Swiss Model®. The molecular model of AAV2G9 full capsids demonstrates the 
geometrical distribution and orthogonality of HS and Gal binding sites located around the 
three-fold symmetry axis on the icosahedral capsid. Close-up views of HS and Gal receptor 
footprints from the three-fold axes further support the observation that grafting orthogonal 
Gal binding sites on the backbone of AAV2 capsid can be tolerated with regard to capsid 
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assembly. Three-dimensional structures of the AAV2 VP3 subunit trimer with side chains of 
positively charged residues involved in HS recognition (highlighted in purple, Figure 17A) 
as well as the side chains of amino acid residues comprising the Gal recognition site on the 
AAV9 VP3 subunit trimer (highlighted in orange, Figure 17C) are also shown. 
AAV2G9 exploits HS and Gal receptors interchangeably in vitro 
The first line of evidence supporting the usage of dual glycan receptors by AAV2G9 
was obtained from competitive inhibition assays of virus binding on cell surface involving 
soluble heparin and Erythrina Cristagalli lectin (ECL), which selectively binds terminally 
galactosylated glycans. As seen in Figure 19A & Figure 19B, HS, but not ECL significantly 
inhibits AAV2 transduction in CHO Lec2 cells (dark grey bars), while ECL selectively 
blocks AAV9 transduction by nearly two log units (white bars). These results are consistent 
with the expected transduction profiles for AAV2 and AAV9 40,52,53. In contrast, AAV2G9 
can only be effectively neutralized by pre-treatment with a combination of both ECL and HS 
(light grey bars, Figure 19C). A small, yet significant inhibitory effect is observed for ECL.  
Transduction profiles for AAV2 and AAV9 were further corroborated by inhibition 
of cell surface binding by each strain using ECL or HS (Figure 19D & Figure 19E). The 
unique cell surface attachment of the chimeric AAV strain is further supported by 
competitive inhibition of cell surface attachment of AAV2G9 exclusively by a combination 
of ECL and HS, but neither reagent alone (Figure 19F). In addition, confocal 
immunofluorescence micrographs (Figure 22) obtained using monoclonal antibodies against 
different AAV capsids suggest that AAV2G9 binds more robustly to the surface of CHO 
Lec2 cells than AAV2 or AAV9. Such a scenario can be expected based on the apparent 
ability of AAV2G9 to bind two different glycans interchangeably.  
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In order to further interrogate the exploitation of alternate transduction pathways by 
AAV2G9, we conducted competition assays with the parental serotypes, AAV2 and AAV9. 
As shown in Figure 21A & Figure 21B, pre-incubation with AAV2-CBA-tdTom or AAV9-
CBA-tdTom competing vectors at MOIs ranging from 500 to 100,000 vg/cell efficiently 
blocks transduction by AAV2-CBA-Luc or AAV9-CBA-Luc, respectively as measured by 
luciferase transgene expression. However, both AAV2 and AAV9 are unable to effectively 
block AAV2G9 transduction at 10-fold excess multiplicities of infection (MOI). At higher 
MOI (100-fold excess), AAV2 appears to compete less effectively than AAV9 in 
neutralizing AAV2G9 transduction. Taken together, these results support the notion that 
AAV2G9 is indeed a novel, dual glycan binding strain with the unique ability to exploit both 
HS and Gal as primary receptors for transduction. 
AAV2G9 mediates rapid onset of transgene expression 
We then investigated whether dual glycan binding confers specific advantages to viral 
transduction in vitro and in vivo. Monitoring the time course of luciferase reporter expression 
in CHO Lec2 cells revealed that AAV2G9 mediates rapid onset and improved gene transfer 
in vitro (Figure 23). Live animal imaging studies were then carried out to monitor luciferase 
transgene expression following systemic administration of different AAV strains in BALB/c 
mice (Figure 24). Bioluminescent images and quantitative assessment of light output within 
the liver and the whole animal obtained at days 3, 7 and 18 post-injection correlate with in 
vitro data and support the notion that AAV2G9 can mediate rapid onset and enhanced gene 
expression (Figure 24B andFigure 24C). Interestingly, the kinetic profile displayed by 
AAV2G9 mirrors that of AAV9 but not AAV2. In contrast, the transduction profile/tissue 
tropism of AAV2G9 appears to be primarily hepatotropic, similar to AAV2 and unlike the 
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systemic tropism displayed by AAV9 as established previously 125,152,215,216. Thus, dual 
glycan receptor engagement appears to improve the transduction efficiency of AAV strains, 
but does not alter tissue tropism.  
Transduction and vector biodistribution profile of AAV2G9 in vivo 
To further evaluate the in vivo transduction and biodistribution profiles of AAV2G9, 
quantitative analysis of tissue lysates from BALB/c mice were carried out at days 3 and 18 
post-administration. Specifically, AAV2G9 displays markedly higher luciferase transgene 
expression in liver compared to AAV2 (nearly two log units) and AAV9 (~1 log unit) at 3 
days post-administration (Figure 25A). While AAV9 displays more than 10-fold higher 
transduction efficiency in heart than AAV2G9, a modest increase in cardiac transduction by 
AAV2G9 compared to AAV2 is also observed. At day 18, cardiac and liver tissues harvested 
from mice treated with AAV2G9 continue to demonstrate higher transgene expression, 
although AAV9 emerges as the most efficient strain at this stage. Specifically, transduction 
efficiencies in cardiac tissue by AAV2, AAV2G9, and AAV9 maintain a similar trend as 
observed 3 days post-administration. In the liver, the differences between luciferase 
transgene expression by AAV2, AAV2G9, and AAV9 diminish upon progressing to 18 days 
post-injection. Specifically, AAV9 demonstrates between 5 to 10-fold higher transgene 
expression when compared to AAV2G9 and AAV2, respectively.  
Quantitative analysis of vector genome copy numbers in liver and heart by AAV2G9 
and the parental AAV strains at 3 days post-administration (Figure 25B) is consistent with 
the trends observed for transduction efficiencies shown in Figure 5A. Specifically, AAV2G9 
accumulated to a higher extent in cardiac tissue compared to AAV2, but was still ~2 log units 
lower than AAV9. In liver, AAV2G9 copy number is comparable to that of AAV9, but over 
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one log unit higher than AAV2. At day 18, copy numbers for all serotypes were decreased 
presumably due to continuous cell turnover and degradation of single-stranded AAV 
genomes as reported previously 217,218.  
4.5 Discussion 
The current study demonstrates that grafting conformational receptor footprints from 
one AAV strain onto others is feasible and could result in novel chimeric AAV capsids with 
enhanced transduction profiles in vitro and in vivo. The dual glycan binding chimera 
AAV2G9 was synthesized by incorporating residues from within or around the Gal binding 
pocket on AAV9 onto the AAV2 capsids. Remarkably, a minor change in the primary amino 
acid sequence of the AAV2 VP3 subunit (~1.4%) was sufficient to impart Gal recognizing 
ability without affecting HS binding. These results are particularly unique from a structural 
perspective. For instance, in the case of influenza A, mutations within a single sialic acid 
binding site have been associated with altered recognition of glycan linkage specificities by 
new reassortant strains219,220. However, it is noteworthy to mention that the Gal and HS 
binding residues on AAV2G9 create two distinct footprints on the viral capsid surface. 
Further, AAV2G9 appears to utilize HS and Gal simultaneously and interchangeably. Based 
on similar rationale, our studies might provide design parameters for synthesizing a 
comprehensive panel of dual/multi-glycan binding AAV strains harboring various 
permutations and combinations of distinct glycan recognition patterns. 
Our results also provide insights into the biology of AAV receptor usage in vivo. First, 
the predominant determinants of AAV2G9 tropism in vivo appear to be dictated by one of the 
parental AAV serotypes (i.e., in this case, AAV2) which composes a majority of the capsid 
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structure. This would suggest that the Gal footprint on AAV2G9 is compatible with 
utilization of fibroblast growth factor receptor (FGFR), integrins and/or other co-receptors 
thought to play a role in AAV2 cell entry 152,193. An intriguing question that follows is 
whether interplay between primary glycan receptors and different AAV co-receptors are 
critical determinants of tissue tropism. Whether incorporation of a SA binding pocket onto 
AAV2 or HS binding sites on other SA/Gal binding AAV serotypes will yield viable 
chimeric strains remains to be determined. Further, as co-receptors for AAV serotypes 
continue to be identified, synthetic dual glycan binding strains might be extremely useful in 
understanding this specific aspect of AAV biology.  
Alternatively, the predominant hepatotropism displayed by AAV2G9 can possibly be 
attributed to a higher affinity for HS than Gal moieties. Indeed, we observed that 
incorporation of the Gal footprint into a HS-binding defective mutant (AAV2i8) yielded a 
liver-detargeted mutant displaying higher transduction efficiency in heart and skeletal muscle 
(mutant AAV2i8G9, Figure 26). In addition, while AAV2G9 did not exhibit systemic 
tropism similar to AAV9, the transduction efficiency of AAV2G9 in liver appears to be as 
high as AAV9. This explanation is further corroborated by earlier studies demonstrating the 
critical role played by HS interactions in liver tropism of AAV serotype 6 43. Thus, it is 
tempting to speculate that while HS binding by AAV2G9 primarily determines liver 
accumulation, recognition of a second glycan receptor (i.e., Gal) appears to promote 
increased tissue uptake and rapid onset of transgene expression.   
For the gene therapy community, the new technology reported herein provides a 
platform to develop improved clinical reagents. Dual glycan binding AAV vectors can 
initiate earlier gene expression that continues to increase at a faster rate and can sustain 
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higher transduction levels in comparison to naturally occurring parental strains. As a result, 
such lab-derived strains might help decrease the effective vector dose required for achieving 
therapeutically relevant transgene expression levels and help alleviate potential clinical 
concerns associated with vector dose-dependent toxicity 221. Whether such vector 
engineering approaches can help achieve higher transduction efficiencies upon synergistic 
integration with other major advancements in AAV technology, e.g., self-complementary 
vectors 222 or Tyr-to-Phe capsid mutations 84, which enable bypassing second strand DNA 
synthesis and proteasomal degradation, respectively remains to be seen. In addition to such 
studies, validation of synthetic dual glycan binding AAV strains in large animal models is 
forthcoming and likely to shed light on cross-species variation in AAV tissue tropism.  
In summary, rational engineering of capsid-glycan receptor interactions is a 
promising approach towards continued improvement of the preclinical/clinical portfolio of 
AAV vectors for gene therapy. Additional structural information pertaining to receptor 
binding footprints on different AAV capsids or other closely related parvoviruses could 
further expand the matrix of synthetic, dual glycan binding AAV vectors.  
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Figure 17. Three-dimensional models of the dual glycan binding AAV2G9 chimera and 
its parental strains AAV2 and AAV9. (A) Three-dimensional structural model of an intact 
AAV2G9 capsid with existing HS and “grafted” Gal binding sites colored in purple and 
orange, respectively. (B-D) Illustrations of the three-dimensional surface model of VP3 
trimers at the three-fold symmetry axes of AAV2 (B), AAV9 (C), and AAV2G9 (D) capsids. 
Residues involved in HS binding (AAV2 VP3 numbering: R487, K527, K532, R585, R588) 
and Gal binding (AAV9 VP3 numbering: D271, N272, Y446, N470, A472, V473, W503) are 
highlighted as in (A). Black triangles indicate the three-fold symmetry axes. 
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Figure 18. Structural alignment of AAV1, AAV2, AAV6, AAV8, and AAV9 VP3 
monomers. (A) Superposition of the VP3 monomers of AAV1 (purple blue), AAV2 (deep 
blue), AAV6 (light magenta), AAV8 (green), and AAV9 (brown) with loops I-IX labeled and 
axes of symmetry indicated.  (B) Close-up views of overlay of the galactose binding site on 
AAV9 and equivalent residues on AAV1, AAV2, AAV6, and AAV8. Amino acid residues 
are marked by the color code in (A). Coordinates were obtained from X-ray crystallography 
structure of VP monomers (PDB accession#: AAV1-3NG9, AAV2-1LP3, AAV6-3OAH, 
AAV8-2QA0, AAV9-3UX1). Structure alignment was performed and visualized using 
PyMOL. 
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Figure 19. In vitro characterization of the dual glycan binding AAV2G9 chimera. (A-C) 
Inhibition of AAV2 (A), AAV9 (B), and AAV2G9 (C) transduction on CHO Lec2 cells with 
FITC-ECL and soluble heparin. CHO Lec2 cells were pre-chilled at 4ºC and incubated with 
FITC-ECL, soluble heparin or both prior to infection with AAV2, AAV9 or AAV2G9 
packaging a CBA-luciferase reporter transgene cassette. Transduction efficiency was 
measured 24 hrs post infection as luciferase activity in relative light units (RLU). Percentage 
of transgene expression was calculated by normalizing transduction efficiency to RLU from 
controls. Results are presented as mean ± s.e.m. (n=4). (D-F) Competitive inhibition of cell 
surface binding of AAV2 (D), AAV9 (E), and AAV2G9 (F) on CHO Lec2 cells with FITC-
ECL and soluble heparin. Different AAV particles were bound to cells pre-chilled at 4ºC and 
unbound virions removed by washing with cold PBS. Bound virions were quantified using 
qPCR after viral genome extraction. Percentage of bound virions was determined by 
normalizing number of bound virions to that of corresponding controls. Results are presented 
as mean ± s.e.m. (n=5). Statistical significance was analyzed using the one-tailed Student’s t-
test (* p < 0.05; ** p < 0.01). 
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Figure 20. G-mutants utilize Gal as a novel glycan receptor to transduce cells in vitro. 
(A) Transduction efficiency of AAV1, 1G9, and AAV9 on Chinese Hamster Ovary (CHO) 
cell lines. Pro5 and Lec2 cells were pre-chilled to 4ºC for 30 minutes prior to AAV-CBA-
Luciferase infection at an MOI of 1000 vg/cell at 4ºC for 60 minutes. After removing 
unbound virions by three washes with ice-cold PBS, infected cells were cultured in 37ºC 
incubator for 24 hrs. Luminometric analysis was performed to quantify the luciferase 
transgene expression efficiencies from cell lysates. (B) Transduction efficiency of AAV2i8, 
2i8G9, and AAV9 on Pro5 and Lec2 cells. (C) Transduction efficiency of AAV6, 6G9, and 
AAV9 on Pro5 and Lec2 cells. (D) Transduction efficiency of AAV8, 8G9, and AAV9 on 
Pro5 and Lec2 cells. Results are presented as mean ± s.e.m. (n=4). Statistical significance 
was assessed using the one-tailed Student’s t-test (n.s., not significant; * p < 0.05; ** p < 
0.01). 
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Figure 21. Competitive inhibition of AAV2G9 transduction on Lec2 cells by AAV2 
capsids or AAV9 capsids. Lec2 cells were preincubated with (A) AAV2 or (B) AAV9-
CBA-tdTomato at multiplicity of infection (MOI) ranging from 500 to 100,000 vg/cell for 2 
hrs prior to infection with AAV2G9-CBA-Luc particles (MOI 1000 vg/cell). Percentage 
inhibition of AAV2G9 transduction was calculated by normalizing luciferase transgene 
expression levels to that of untreated control. Results are presented as mean ± s.e.m. (n=4). 
Statistical significance was analyzed using the one-tailed Student’s t-test (* p < 0.05; ** p < 
0.01).  
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Figure 22. Immunofluorescence of bound virions on Lec2 cell surface at 0 hrs post-
infection (hpi). CHO Lec2 cells were pre-chilled at 4ºC for 30 minutes, followed by 
infection with AAV2, AAV 2G9, and AAV9 at an MOI of 1000 vg/cell at 4ºC for 30 minutes. 
After removal of unbound virions, cells were fixed with 2% paraformaldehyde in 1xPBS. 
Intact virions were detected using the monoclonal antibodies (A20 for AAV2/AAV2G9 and 
ADK9 for AAV9). Alexa Fluor 594® goat anti-mouse IgG was utilized at a dilution of 
1:1000 in IFWB as the secondary antibody for immunofluorescent detection. Fluorescent 
micrographs were acquired using a Zeiss® 710 confocal laser scanning microscope equipped 
with a 63x oil immersion objective and a spectral detection system. Image processing was 
carried out using LSM® viewer and Image J® software. The red color represents intact viral 
particles, and the blue color from DAPI marks nucleus. The white scale bar indicates 10 µm.  
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Figure 23. Kinetics of transduction efficiency profiles of AAV 2G9 compared to 
parental AAV2 and AAV9 on Lec2 cells at indicated time points post infection. Pre-
chilled Lec2 cells were infected with AAV2, AAV2G9, or AAV9-CBA-luciferase vectors at 
an MOI of 1000 vg/cell as described earlier. At indicated time points (18, 24, 28, 42 and 54 
hrs) post-infection, cells were lysed prior to luminometric analysis. Luciferase transgene 
expression was measure by luciferase activities of cell lysates in relative light units (RLU) 
(n=5). Statistical significance was assessed using the one-tailed Student’s t-test (* p < 0.05; 
** p < 0.01). 
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Figure 24. AAV2G9 mediates rapid onset and enhanced transgene expression in vivo. (A) 
In vivo transgene expression kinetics of AAV2, AAV 2G9, and AAV9 vectors packaging 
CBA-luciferase transgene cassette. BALB/c mice (n=4) were administered AAV vectors at a 
dose of 1x1011 vg/animal through the tail vein and bioluminescent images collected at 3, 7, 
and 18 days post-injection using an Xenogen® Lumina imaging system. Representative live 
animal images are shown with bioluminescence on a rainbow colored scale (1x105-
1x106 photons/second/cm2/steradian). AAV2G9 maintains the hepatic tropism of AAV2, but 
demonstrates a more rapid and robust luciferase signal than both parental AAV strains. (B 
and C) Quantitation of the kinetics of light signal output (expressed as 
photons/second/cm2/steradian) was performed by marking regions of interest (ROIs) around 
images of the (B) liver region and (C) entire animals obtained at different time intervals 
(n=4). Statistical significance was assessed using the one-tailed Student’s t-test (n.s., not 
significant; * p < 0.05; ** p < 0.01). 
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Figure 25. Quantification of transgene expression and biodistribution profiles of 
AAV2G9 in mice. (A) Quantitation of luciferase transgene expression from heart and liver 
tissue lysates of AAV2 (black), AAV2G9 (grey), or AAV9 (white) treated animals at days 3 
and 18 (n=4). (B) Biodistribution of vector genomes in liver and heart lysates obtained from 
BALB/c mice administered with AAV2 (black), AAV2G9 (grey), or AAV9 (white) at days 3 
and 18 (n=4). At indicated time points, host genomic DNA and viral genomes were isolated 
from tissue lysates and quantified using qPCR with primer sets specific to mouse lamin gene 
and luciferase transgene. Results are presented as mean ± s.e.m. (n=4). Statistical 
significance was assessed using the one-tailed Student’s t-test (n.s., not significant; * p < 
0.05; ** p < 0.01).  
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Figure 26. In vivo transgene expression kinetics of AAV2i8, 2i8G9, and AAV9 vectors 
packaging CBA-luciferase transgene cassette. (A) BALB/c mice (n=4) were administered 
AAV vectors at a dose of 1x1011 vg/animal through the tail vein and bioluminescent images 
collected at 3, 7, and 18 days post-injection using an Xenogen® Lumina imaging system. 
Representative live animal images are shown with bioluminescence expressed on a rainbow 
colored scale (105-106 photons/second/cm2/steradian). (B) Luciferase transgene expression 
levels in tissue lysates obtained from (A) were quantified at 18 days pi. Data represents mean 
± s.e.m. (n=4). (C) The biodistribution of vector genome copies of AAV2i8, 2i8G9, and 
AAV9 at 18 days pi were analyzed using qPCR. DNA contents were extracted from tissue 
lysates in (A). Luciferase transgene copy numbers in each tissue were normalized to the 
corresponding copy numbers of mLam housekeeping gene. Data represents mean ± s.e.m. 
(n=4). 
 
CHAPTER 5  
Synopsis and Future Directions 
5.1 Summary  
The past thirty years witnessed the accelerating exploration of AAV as gene therapy 
vectors. Encouraging results from preclinical and clinical studies call for a comprehensive 
understanding of AAV biology as well as expedited generation of novel AAV-based vectors. 
In this dissertation, we sought to unravel the mysterious systemic phenotype of AAV9 by 
gaining insights into the first step of AAV9 infection---glycan receptor interactions. The 
identification of N-linked terminal galactose as the primary receptor of AAV9, in conjunction 
with deciphering the structure-function relationship of a random AAV9 library, provides 
important avenue for understanding and application of AAV9 in the clinical frontiers 52,95. 
The in vivo studies of how glycan-virus interactions affect the systemic and hepatic tropism 
of AAV9 expanded the interface between glycobiology and virology. In corollary with 
previous studies on influenza viruses, HCV, and many others, our results highlight the 
functional role of glycan receptors during viral infections in animal models. We also built the 
foundation to fine-tune and rationally design viral vectors with desired phenotypes by 
attributing virus tropism and blood circulation profiles partially to the binding avidity 
between viruses and their cognate glycans receptors. In addition, identification of key 
residues involved in galactose recognition enabled the molecular grafting of galactose 
binding footprint onto a series of well-studied AAV serotypes. The modularity of glycan 
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binding motif and flexibility of AAV backbone would further inspire the engineering of 
designer viral toolkits for future research and therapeutic advancement. 
Nevertheless, AAV vector development sees obstacles to attenuate safety concerns 
and meet higher expectations of transduction efficiency and specificity. Multiple aspects of 
AAV biology are yet to be elucidated.  
5.2 Glycan Receptors of AAV Serotypes  
In Chapter 2 of this dissertation, the glycan receptor for AAV9 was identified using a 
battery of glycobiology, biochemistry, biophysical assays. Enzymatic digestion of cell 
surface glycoconjugates enhances AAV9 transduction efficiencies on multiple cell lines by 
exposing the penultimate Gal moiety, the glycan receptor for AAV9. This result was counter-
intuitive. In case of HS- or SA-using viruses, heparinase or sialidase pre-treatment of cells 
prior to viral infection abrogates their infectivity due to the unavailability of attachment 
factors. However, as the first virus discovered to bind to terminal galactose, AAV9 
transduces host 10-1000-fold more efficiently. This enhancement of infectivity was also seen 
with well-differentiated ciliated human airway epithelia cells and the murine nasal airways. 
A temporary, moderate increase of the number of receptors available allows virus to engage 
productive infection.  
 To test whether sialidase could increase AAV9 transduction in situations similar to 
cell culture, we investigated the effects of combined injection of sialidase and AAV9 vectors 
with localized injections. The first trial was carried out in the context of the eye. The eye is 
spatially restricted, compared to other major organs where lymphatic and circulation systems 
are more readily available. Nevertheless, eye-related diseases have become a focus for gene 
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therapy research in the past few years, including Leber’s congenital amaurosis, color 
blindness, and macular degeneration 152. As shown in Figure 27, 1 ul of the mixture of 
sialidase and AAV9-CBA-Luciferase were intravitreously injected into the left eyes of 
BALB/c mice, while the right eyes were injected with PBS and AAV9. At 5 days pi, 
significant difference of gene expression levels was observed (Figure 27A). To our surprise, 
this disparate luciferase transgene expression maintained for 5 months pi at our last time 
point (Figure 27B). Dissection of these eyes revealed that the scleras were not transduced 
efficiently by AAV9 regardless of sialidase treatment, while sialidase co-injection enhances 
AAV9 transduction in retina by ~50-fold (Figure 27C).  
Another site of localized injection we tested was the joint space. Briefly, a mixture of 
sialidase or PBS (mock) and 1e9 vg of AAV9-CBA-Luciferase was injected into the joint 
space of the left leg on mouse. Two weeks pi, mice were sacrificed to harvest tissue samples 
from liver, leg muscle and the joint. According to luciferase assays on tissue lysates, the 
transgene expression in the joint pretreated with sialidase is ~500-fold higher than the one 
treated with PBS. Correspondingly, qPCR analysis also demonstrates an accumulation of 
AAV9 in sialidase treated joints, 40-fold higher than that in PBS treated ones. These results 
are corroborated with live-animal images shown in Figure 27D. In conclusion, results from 
murine nasal airway, ciliated HAE, murine retina, and joint support the notion that 
recombinant sialidase can be used as an adjuvant to enhance AAV9 transduction.  
Despite our focus on sialylated glycans, heparan sulfates, and galactose, the other 
structures and compositions of glycoconjugates are extremely complicated. In this 
dissertation, glycan specific lectins were applied to discern the glycan pattern alterations. 
More accurate methods include mass spectrometry, glycan microarray, as well as radioactive 
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labeling. With limited quantification and verification technologies available, manipulating 
and monitoring cell surface glycans has been very challenging. Given the intertwining 
networks of glycan biosynthesis in all three domains of life, the artificial biosynthesis of any 
given glycan structures is still under development 223. All the previous studies of the glycan 
receptors for pathogens are mainly focused on the terminal moieties of the long and complex 
glycoconjugates chains. However, the side chains, sulfate groups, the repeating disaccharide 
sequences might all play a role in glycan-protein interactions.  
From a series of mutant CHO-K1 cell lines, we started our endeavor to investigate 
how sulfation on glycoproteins and glycolipid affect AAV transduction. PgsA-745 is a CHO-
K1 mutant defective in GAG synthesis due to mutations in UDP-D-xylose:serine-1,3-D-
xylosyltransferase. PgsD-677 is only unable to synthesis heparan sulfate because of the 
deficiency of both N-acetylglucosaminyltransferase and glucuronyltransferase. Another 
CHO-K1 mutant is pgsE-606 that produces under-sulfated forms of heparan sulfate due to 
the deficiency in N-sulfotransferase 224-227.  Furthermore, the Esko group in UCSD developed 
two pgsA-745 derivatives pgsA-745-t26 and pgsA-745-t489, which are highly sulfated at the 
same sites as sialic acids 173. The underlying mechanism of this over-sulfated pgsA-745 is 
that the enzyme that transfer phosphoadenosine-5'-phosphosulfate to Galβ1-4(3)GlcNAcβ-O-
naphthalenemethanol is increased. In addition, a moderate concentration of sodium chlorate 
in culturing media could inhibit the incorporation of sulfate groups in glycoconjugates chains 
in many cell lines. Other than sulfation, fucosylation might also contribute to glycan-protein 
interactions as most polysaccharides are decorated with fucose groups. Pamela Stanley and 
coleagues developed CHO-LEC11 and LEC12 that does not express α-1,3-fucosyltransferase. 
Lec13, the hyper fucosylated CHO variant, was generated by transfecting plasmids 
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containing α-1,3-fucosyltransferase into CHO cells 228. Using an arsenal of cell lines with 
mutations or deficiencies in glycan synthesis, we are able to interrogate the impact of 
sulfation on parvovirus infection. Although no significant phenomena were observed with 
AAV1-9 on these cell lines compared to their parental cells (Shen Shen and Aravind Asokan, 
unpublished data), this collection of CHOs laid a roadmap for studies on emerging naturally 
occurring AAV and other parvoviruses. 
Our previous experience with pharmacokinetics analysis and hemagglutinin assay 
prompt the speculation that glycans on the erythrocytes might play a role in the transportation 
of AAV in their target tissues. The most dominant glycosylation forms on erythrocyte 
surfaces are the ABH(O) blood group antigens and the Lewis antigens Lea and Leb. ABH(O) 
blood group antigens present N-acetyllactosamines on O-linked glycans or glycolipid on the 
surface of erythorcytes and many other tissues. For example, they are expressed in the 
vascular endothelium and the epithelial of some salivary and exocrine glands. They can also 
be excreted into blood circulation. A hallmark of ABH(O) blood group antigens is the fucose 
groups transferred by α-1,2-fucosyltransferases. Lewis antigens Lea and Leb carry α-1,3- and 
α-1,4-fucose moieties. Unlike ABH(O) antigens, they are not synthesized by erythrocytes. 
Instead, Lea and Leb antigens are expressed on some epithelia and release to body fluids, 
where they are passively incorporated into erythrocytes. With a high sialylation rate and an 
enormous population on erythrocytes, these blood type antigens might contribute to the 
circulation of AAV vectors in vivo and serve as vehicles for tissue targeting.  
One intriguing characteristics of glycoconjugates in mammalian systems is its 
species-specificity. In 1962, Emile Zuckerkandl and Linus Pauling first postulated a 
hypothesis called “Molecular Clock Hypothesis” 229. In this hypothesis, the occurrence and 
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disappearance of molecules is viewed as part of evolution. The adaptation of the 
hemagglutinnin subunit of Influenza A from avian-like α2,3-SA to α2,6-SA specifically 
expressed in the small airway epithelia of human lung was attributed to the antigen drift of 
Influenza A. Therefore, this process is also considered an evolution of the HA subunit. 
Another species-specific glycol-moiety is N-Glycolyl-SA (Neu5Gc), which only exist in 
small quantity in human beings 209. Does any parvovirus have the specificity towards a 
species-specific glycol-moiety? How does this species-specific glycosylation pattern affect 
the translation of preclinical results generated from mice, dogs, nonhuman primates to be 
applied in curing human diseases? Many questions are yet to be answered. 
5.3 Understanding the Roles of Glycan in Animal Models  
A cornerstone of this dissertation is the analysis of glycosylation pattern on murine 
tissues using a series of lectins. Viral tropism is partially attributed to the differential 
distribution of glycan structures. Sialidase and heparinase (Shen Shen and Aravind Asokan, 
unpublished data) were injected systemically or locally to hydrolyze the terminal glycan 
moieties in animal. However, the effects of these enzymatic removals of glycan termini only 
persist for a short span of time. A great number of sialyltransferases, sialyltransporters, 
sulfotransferases, as well as polysaccharides obtained externally (i.e. through diets) 
reconstitute the lost glycan moieties back to the end of glycoconjugates chains. Therefore, 
mouse models with knockdowns of the key enzymes in glycan biosynthesis pathways would 
significantly elucidate the role of each glycan in a long-term observation.  
Given that protein and lipid glycosylation takes place in the Golgi compartments, it is 
compelling to speculate that the glycol-synthesis intermediates in cytoplasm could impact the 
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trafficking of AAV viral particles. This effect can be a double-edged sword, as it can affect 
the uptake and cytoplastic processing of AAV virions into the nuclei, as well as the 
packaging and release of newly synthesized AAV particles out of the nuclei. One technical 
hurdle to answering this question is the precise marking and analysis of glycan structures in 
each organelle and subcellular fraction. Quantitative imaging technology would be 
instrumental in studying this aspect of AAV biology, but the accurate labeling of individual 
glycans still remains challenging for now.  
5.4 Beyond the Glycans 
A central theme of this dissertation is to emphasize the significant function of glycan 
receptors in determining viral tropism. Results from Chapters 2-4 and Appendix I supports 
this notion in the context of AAV biology. However, the roles of the secondary receptor in 
viral transduction and tropism can never be underestimated. Over the past ten years, the list 
of secondary receptors for AAV serotypes has expanded, but the function of these receptors 
in vivo are yet to be unraveled. How does the distribution of PDGFR impact on the 
respiratory tropism of AAV5? Why do six amino acid changes allow AAV6 to bind EGFR, 
but not AAV1? How does the affinity towards EGFR of AAV6 contribute to its different 
tropism compared to AAV1? Although more secondary receptors for emerging AAV strains 
are to be discovered, the roles of these known receptors in AAV life cycles remain elusive.  
In attempt to dissect the systemic tropism of AAV9, a conserved integrin binding 
motif on AAV9 capsid was brought to our attention by sequence alignment. As shown in 
Figure 29A, the NGR motif common in all integrin α5β1 ligands are present on AAV1, 
AAV2, AAV3a, AAV3b, and AAV6-10. Homology simulation shows that this domain 
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resides on the concaved region immediately outside of the three-fold axes of symmetry 
(Figure 29B and Figure 29C). Site-directed mutagenesis on the arginine residue (R514A) 
yields mutant 9NGA, that is 10-100-fold less efficient in transducing Lec2 cells compared to 
the parental AAV9 (Figure 29D). Confocal laser scanning microscopy also suggests that this 
9NGA mutant is deficient in getting internalized into cells with high efficacy. At 0 hr pi, 
similar numbers of virions can be visualized on AAV9 and 9NGA infected Lec2 cells. In 
contrary, at 1 hr pi, a good amount of internalized viral particles can only be observed with 
AAV9-infected Lec2, not 9NGA-infected ones (Figure 29E). These results and 
quantification of internalized virions on Lec2 by qPCR (Shen Shen and Aravind Asokan, 
unpublished data) strongly suggest that 9NGA is an internalization deficient mutant. How 
does this loss-of-function affect AAV9 transduction in mice? Intravenous injection of AAV9 
and 9NGA into BALB/c mice was followed by live-animal bioluminescence imaging to 
monitor their transgene expression kinetics (Figure 29E). The systemic tropism of AAV9 
was absent in case of 9NGA, which demonstrates a decreased transduction efficiency in all 
major organs. As a corollary, this observation was substantiated by quantifying the luciferase 
transgene expression profiles in tissue lysates and the biodistribution of viral particles using 
qPCR (Shen Shen and Aravind Asokan, unpublished data). Taken together, our results show 
that the secondary receptor for AAV9 infection also plays a pivotal role in determining 
AAV9 tropism in vivo. How secondary receptors are further involved in intracellular 
trafficking and uncoating of AAV virions remains elusive. Whether this theory applies to 
other members of the AAV family would be of great importance for future studies.  
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5.5 Rational Engineering of AAV Vectors  
Although the collection of naturally occurring AAV strains are expanding, discovery 
of engineered AAV variants with higher transduction efficiency and improved 
immunogenicity is moving forward rapidly under the limelight. The first rational engineering 
of AAV capsid in pursuit of variants with novel properties was achieved by swapping a 
hexamer-peptide from the hepatotropic AAV8 to the partial heparan sulfate binding motif on 
AAV2 143. Chapter 4 of this dissertation focused on the synthesis of a dual-glycan binding 
AAV variant by grafting the Gal binding footprint and flanking residues from AAV9 to the 
corresponding region on AAV2 capsid. Our data first confirmed that the resulting 2G9 
chimera utilizes Gal and HS interchangeably by lectin and HS inhibition assay. In vitro and 
in vivo studies further described the transduction profiles and biodistribution patterns of this 
chimera. The phenotype displayed by 2G9 is the combination of the hepatotropism of AAV2 
and the transduction efficiency of AAV9. More interestingly, 2G9 also demonstrates an early 
onset of transgene expression. Furthermore, incorporation of the G9 footprint onto several 
other AAV serotypes (AAV1, AAV3, AAV6, AAV8, and AAV2i8) yielded similar results 
(Shen Shen and Aravind Asokan, unpublished data). This work not only demonstrated the 
modularity of Gal binding domain, but also laid the foundation of a novel strategy for AAV 
vector design. 
Our previous success with the G9 series suggests that a comprehensive understanding 
of structure-function relation of AAV strains is the prerequisite for rational reengineering of 
AAV vectors. During our endeavors to dissect the GH loops, three AAV9 mutants were 
constructed by swapping parts of the inner loop from AAV1 to the AAV9 backbone (Figure 
30A-C). The first region swapped from AAV1 (the iA stretch: 568-ATNPVATER 
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FGTVAVNF-584) starts from the N-terminal end of the inner loop. The resulting mutant was 
dubbed 9i1A (i stands for “inner loop”). The second stretch of amino acids swapped includes 
the iA stretch and 15 more residues to its C-terminal (the iB stretch: 568-ATNPVATERFGT 
VAVNFQSSSTDPA-592). The third variant, 9i1C has the entire inner loop of AAV1 
swapped onto AAV9 (the iC stretch: 568-ATNPVATERFGTVAVNFQSSSTDPATGDVHA 
MGA-601). Figure 30A-C depicts the altered domains in the context of AAV9 trimeric 
assemblies. In vitro transduction assay on Cos-1 cells (Figure 30D) shows a 10-fold 
enhancement of transduction efficiency of 9i1A compared to AAV9 regardless of sialidase 
treatment. Binding assays corroborated with this observation by showing a 100-1000-fold 
increase of binding ability of 9i1A compared to AAV9 on Cos-1 (Figure 30E). To our 
surprise, more components from the inner loops reduces the transduction efficiency of 9i1A 
to the level lower than the parental AAV9, suggesting more severe perturbations to the global 
conformation on viral capsids. Animal studies also show the consistent enhancement of 9i1A 
transduction profiles. At 3 days pi, 9i1A surpasses both AAV1 and AAV9 in transducing 
major organs (brain, heart, lung, and muscle) by 10-100-fold (Figure 30G). The 
biodistribution analysis of AAV9 and 9i1A in mice gave similar results, except a 5-fold 
increase of viral genome accumulation in liver which is absent in transduction assay (Figure 
30H).  The molecular mechanism of the superior infectivity of 9i1A is still under 
investigation. However, this study provides us with an AAV9 variant with startling 
transduction efficiency in both in vitro and in vivo settings. In addition, these results also 
imply the structural functions and the inadaptability of the inner loops at the three-fold axes 
of symmetry on AAV capsids. For future studies, more comprehensive mutagenesis attempts 
and structural approaches could be employed to identify the specific amino acids key to 
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AAV9 life cycle. In conjunction with G mutants, these results further testified the feasibility 
of incorporating multifunctionality into AAV capsid for a wide range of applications. 
In contrast with the rational vector design, directed evolution of AAV libraries starts 
from random mutagenesis or random mutations onto AAV capsid. As described in Chapter 1, 
directed evolution of AAV2 with random mutations or AAV shuffling libraries generated 
AAV variants with desired transduction specificity towards a given cell type or organ. We 
approach this directed evolution strategy from a different angle. Herein, we aim to evolve 
AAV9-based variants that bind to alternate glycan receptors. The synthetic dual-glycan 
binding 2G9 demonstrated the modularity of the Gal binding motif on AAV9 capsid. It is the 
minimum cluster of amino acid that is necessary to convert any AAV serotype binding to Gal. 
Instead of aiming to generate AAV9 variants targeting specific cell types or organs, we 
pursuit the idea of switching AAV9 to a HS binding isolate by introducing random mutations 
on the Gal binding motif.  
As shown in Figure 31A-C, random mutations were introduced onto three regions 
harboring residues critical for Gal-AAV interactions by NNN-induced site-directed 
mutagenesis: (i) 262-STSGGS-268; (ii) 498-NSEFAWP-504; (iii) 590-QAQTGW-595. 
These stretches cover the tips of the inner loops, middle loops, and outer loops near the three-
fold axes of symmetry on AAV9 capsids. Three AAV9 libraries, each with one stretch 
mutated, were combined to subject to elution on heparin columns. AAV2 serves as a control. 
The HS-binding AAV2 was eluted from heparin columns at a NaCl concentration of 450-500 
mM (Figure 31D). Therefore, after flowing through the combined AAV9 triple library 
through a heparin column, only the eluate at 450 mM were collected and amplified on 
HEK293 cells with the presence of Ad5. Four days later, viruses purified from this set of 
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HEK293 cells went through another selection on a heparin column. Again, only the eluate 
with 450 mM NaCl concentration was amplified on the next set of HEK293 cells. After one 
more “evolution” on the heparin column, the eluate at 450 mM NaCl concentration was 
preserved. As shown in Figure 31E, the initial AAV9 triple library has a mixed population 
of AAV9 variants with a wide range of HS affinities. QPCR of vg in each eluate with a 
varying NaCl concentration shows similar quantity of viral particles. As the “evolution” on 
heparin column proceeds, the population of AAV9 variants left in the triple library 
concentrates in the 450 mM NaCl fraction Figure 31F and 31G. This result indicates a shift 
of Gal preference towards a HS preference of those AAV9 mutants. Isolation of individual 
AAV9 variant from the preserved collection after the 3rd heparin column is ongoing. Once 
individual variants are identified, a series of in vitro and in vivo assays will be carried out to 
understand the phenotypes of these HS-binding AAV9 mutants.  
Considering the large size of this AAV9 triple library (206+207+206-3) in theory, a 
myriad of evolution or selection strategies can be readily applied in sarch for AAV9 variants 
with novel features. One possible strategy is to evolve this triple library back and forth on 
ferret airway epithelial cells and human airway epithelial cells. The aim of this strategy is to 
evolve AAV9 variants highly efficient in transducing airways for treating respiratory 
diseases, such as asthma and cystic fibrosis. Studies led by Yoshihiro Kawaoka and Ron 
Fouchier 219,220 generated H5N1 influenza mutants transmissible within ferret populations by 
acquired mutations during passages of airborne transmission. Successes in H5N1 influenza 
suggest a high likelihood of obtaining airway-tropicAAV9 mutants from this triple library.  
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5.6 Final Remarks  
Interaction with cell surface glycan receptors is the initial step of infection for most 
pathogens. AAV serotypes utilize three major categories of glycans to attach to host cells, 
sialylated glycans, heparan sulfates, and galactoses. In this dissertation, the terminal N-linked 
galactose was identified as the primary receptor for AAV9. Enhanced galactose binding 
ability by sialidase treatment leads to increased cell surface binding and transduction. 
Modulating this binding avidity between galactose and AAV9 in vivo by sialidase 
administration or mutation alters the pharmacokinetics profiles and systemic tropism of 
AAV9. Herein, we established the link between the glycan binding avidity of AAV and their 
respective phenotypes in animal. These results contribute to our understanding of the cross-
species differences of AAV tropism in general and aid the rational design and engineering of 
novel AAV variants with desired tissue-targeting/detargetting profiles. Further incorporation 
of Gal binding footprint demonstrates a new avenue to obtain vectors for enhance gene 
transfer. Although deciphering the exquisite infection pathways of AAV remains challenging, 
our study shed light on the AAV biology field and the utilization of AAV as gene therapy 
vectors to its full potential.  
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Figure 27. Sialidase can be used as adjuvant to enhance AAV9-mediated gene transfer. 
(A-B) PBS (left) or 1e9 vg of AAV9-CBA-Luciferase vectors were mixed with PBS (right 
eyes in the middle and right mice), sialidase (left eyes in the middle and right mice) were 
injected into female BALB/c mice intravitreally. To monitor luciferase transgene expression 
in animals, D-luciferin was administered through intraperitoneally at (A) 5 dpi and (B) 150 
dpi. (C) Eyeballs harvested from mice at 150 dpi were dissected. Luciferase expression was 
measured from lysates of retina or sclera. Error bars represent s.e.m. (n=4).  (D) 1e9 vg of 
AAV9-CBA-Luciferase vectors were injected into the joint space of the left leg in mice prior 
to PBS or sialidase through the same route. At 2 weeks post injection, luciferase expression 
profiles were recorded. Rainbow color represents quantification of RLU. Experiments were 
carried out with n=4. (E) Two weeks post AAV9 injection in the joint space, BALB/c mice 
were sacrificed to harvest tissues. Luciferase expression from liver, joint, and leg muscle 
were carried out. Error bars represent s.e.m. (n=4). (F) Viral genome copy numbers in liver, 
leg muscle, and joint from (E) were quantified using qPCR. Data are presented as 
mean±s.e.m. (n=4). 
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Figure 28. Lectin staining of a tissue array from multiple species. (A) FITC-MALI 
staining and (B) FITC-ECL staining of a tissue array of liver collected from 15 species 
(Amsbio #T6134149). 50 ul/ml FITC-MALI in 1xPBS were incubated with this slide of 
tissue array for 2 hours in rt prior to three washes with cold-PBS and covered with mounting 
media containing DAPI. Fluorescence images of individual tissue were obtained by imaging 
with a Zeiss 710 laser scanning confocal microscopy and an 40x oil objective at zoom 0.6. 
Representative images are shown here.  
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Figure 29. Integrin functions as co-receptors for AAV9. (A) Amino acid sequence 
alignment of AAV1-11 and human fibronectin reveals a conserved integrin binding domain 
close to the three-fold axes of sysmmetry. (B) Cartoon rendering of trimeric assembly of 
9NGA variant, with the point mutation R514A highlighted in red. (C) RIVEM roadmap 
model of the three-fold axes region on AAV9 with R514 marked in red. (D) AAV9 and 
9NGA packaging CBA-Luciferase cassette transduce Lec2 cells with MOIs ranging from 50 
to 100,000 vg/cell. Luciferase activity of cell lysates were obtained 24 hrs pi. Error bars 
represent s.e.m. (n=4). (E) AAV9 and 9NGA-CBA-Luciferase were added to pre-chilled 
CHO-Lec2 cells culture. 1 hr post infection, unbound virions were removed by three washes 
with ice-cold PBS prior to incubation in 37ºC for 0 or 1 hr. Cells were then fixed with 2% 
paraformaldehyde and penetrated with tween-20. Intact virions were detected with 
monoclonal antibody ADK9, followed by secondary antibody Dylight488 (green). DAPI 
stains nuclei. (F) AAV9- or 9NGA-CBA-Luciferase were injected into BALB/c mice 
through tail vein. Bioluminescence images of live animals were obtained at 2 weeks pi (n=4). 
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Figure 30. Swapping the inner loops from AAV1 onto AAV9 yields enhanced infectivity. 
(A-C) Surface models of the trimeric assemblies of (A) 9i1A, (B) 9i1B, and (C) 9i1C with 
AAV9 backbones colored as electrostatic potential (blue: positive charge, red: negative 
charge) and stretches from AAV1 highlighted in green (AAV9 VP1 numbering, 9i1A: 568-
ATNPVATERFGTVAVNF-584; 9i1B: 568-ATNPVATERF GTVAVNFQSSS TDPA-592; 
9i1C: 568-ATNPVATERFGTVAVNFQSSSTDPATGD VHAMGA-601). (D) Cos-1 cells 
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were pretreated with PBS or sialidase prior to infection with AAV9, 9i1A, 9i1B, 9i1C, and 
AAV1-CBA-luciferase at an MOI of 1000 vg/cell. 24 hrs pi, luciferase activities of cell 
lysates were obtained and quantified. Data represent mean ± s.e.m. (n=3). (E) Cos-1 cells 
pretreated with PBS or sialidase were infected with AAV9, AAV1 and chimeras at an MOI 
of 1000 vg/cell. After 1 hr incubation in 4 ºC, unbound virions were removed by three 
washes with ice-cold PBS. The amounts of virions bound to Cos-1 cell surface were 
quantified using qPCR. Data represent mean ± s.e.m. (n=5). (F) BALB/c mice were injected 
with AAV1, 9i1A, or AAV9 at a dose of 5e10 vg/mouse. 3 days pi, live-animal 
bioluminescence images were obtained using an Xenogen® Lumina imaging system. Live 
animal images are shown with bioluminescence expressed on a rainbow colored scale (105-
106 photons/second/cm2/steradian). (G) 1 month pi, mice from (F) were sacrificed to harvest 
tissue lysates from major organs. Luciferase transgene expression levels were measured and 
shown as mean ± s.e.m. (n=3). (H) Viral genome copy numbers from tissue lysates collected 
from mice in (F) at 1 month pi were quantified using qPCR. Biodistribution of viral particles 
were shown as number of viral genome copies normalized by housekeeping gene mLam. 
Data represent mean ± s.e.m. (n=3). 
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Figure 31. Construction and directed evolution of AAV9 libraries. (A) Surface model of 
an AAV9 full capsid with sites of random mutations (262-STSGGS-268, 498-NSEFAWP-
504, 590-QAQTGW-595) colored in blue, red, and green, respectively. (B and C) 
Visualization of surface models of an AAV9 trimer from (B) above and (C) side of the three-
fold axes of symmetry. Random mutations were introduced into three stretches highlighted in 
blue, red, and green separately to generate three AAV9 libraries. (D) Elution profiles of 
AAV2 from heparin columns. The red line with markers represents NaCl concentrations in 
elution buffer. The solid black line denotes quantity of AAV2 total vg in each eluate. (E-G) 
Elution profiles of the combined triple AAV9 library modeled in (A-C) on heparin columns. 
The combined triple AAV9 library was fractionized from a heparin column (E). The eluate at 
450 mM NaCl concentration was amplified on HEK293 with Adenovirus type 5, purified, 
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and eluted on a heparin column (F). After another round of amplification, purification, and 
fractionation on heparin columns, majority of this combined triple AAV9 library 
demonstrates high heparin binding affinity (G). 
 
APPENDIX I  
Sialic Acids Play a Multifunctional Role in Determining the Transduction Profile of 
Blood-Borne Adeno-Associated Virus Serotype 44 
AI.1 Overview 
Adeno-associated virus serotype 4 (AAV4) is one of the most divergent strains 
amongst natural isolates of AAV characterized by its low sequence homology of viral 
proteins, distinct antigenicity, and selective cardiopulmonary tropism in mice after systemic 
administration. 2,3-linked sialylated O-glycans or mucins have been identified as primary 
receptors for cell surface attachment of AAV4 in vitro. However, little is known about the 
roles of sialic acids in determining AAV4 transduction in vivo. In the current study, Jacalin 
lectin staining reveals that O-linked sialic acids are expressed abundantly in cardiac and lung 
tissues. Enzymatic removal of sialic acids in BALB/c mice completely abrogates the 
cardiopulmonary tropism of AAV4 in vivo after systemic administration. These results were 
further corroborated using two loss-of-function AAV4 mutants obtained by screening a 
randomly mutated AAV4 library. Specifically, the two mutants, 4.18 (K492E, K503E, 
N585S) and 4.41 (M523I, G581D, Q583E), were defective in binding, uptake, and 
transduction in African green monkey kidney cells (CV-1) in vitro. As a result, these mutants 
demonstrated decreased transduction efficiency and vector genome copy numbers in murine 
heart and lung. Ex vivo virus distribution assay in blood and hemagglutination assay showed 
that both 4.18 and 4.41 bind to sialylated glycans on murine erythrocytes with lower 
                                                 
4 This chapter includes the original manuscript in preparation: Shen, S., Troupes, N.A., 
Pulicherla, N., Asokan, A. Sialic Acids Play a Multifunctional Role in Determining the 
Cardiopulmonary Tropism of Blood-borne  Adeno-associated Virus Type 4. 
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affinities. Therefore, both 4.18 and 4.41 were cleared faster from the blood circulation in 
comparison with the parental AAV4, similar to the pharmacokinetics profiles of AAV4 in 
sialidase-treated mice. In conclusion, these results indicate that sialylated glycans on 
erythrocytes and tissues play a multifunctional role in determining blood residence time, 
tissue uptake and transduction profile of AAV4 in mice.   
AI.2 Introduction 
Adeno-associated viruses (AAV) are small, non-enveloped, single-strand DNA 
viruses 37. Several AAV serotypes have been developed into gene delivery vectors due to 
their diverse transduction profiles in vivo 152. In addition to naturally occurring AAV strains, 
genetically modified AAV variants have been generated by DNA shuffling and directed 
evolution as well as rational and combinatorial mutagenesis techniques 152.  As the AAV 
toolkit continues to expand, a better understanding of AAV biology is essential to ensure 
vector safety and efficacy in the clinic.   
Among more than one hundred isolates of AAV, AAV4 is particularly unique due to 
its divergent amino acid sequence of viral proteins (VPs), capsid topology 82,230, antigenicity, 
glycan receptor usage 46,47, and its systemic as well as CNS tropism in murine models 125,231. 
The Cap gene product of AAV4 shares only 58% homology with that of AAV2 in 
comparison with higher sequence similarities between AAV2 and most other prominent 
AAV serotypes. The core structure of the AAV VP monomer is a seven-stranded beta sheet 
interconnected by highly dynamic loops 82. The surface topology constituted by these highly 
dynamic loops on the exterior of AAV4 capsid is strikingly distinct when compared to other 
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AAV serotypes. This difference has been suggested as the underlying cause for the disparate 
properties of AAV4 in terms of receptor recognition, immunogenicity, and tissue tropism 212.  
The first step in the AAV life cycle involves recognition of primary cell surface 
receptors by the viral capsid 37. Currently known primary receptors for AAV serotypes 
include heparan sulfate for AAV2 40, AAV3 41,42, and AAV6 43, galactose for AAV9 52,53, and 
sialic acids for AAV1 44, AAV4 46,47, AAV5 45, and AAV6 44. Amongst all currently known 
dependoviruses, AAV4 appears to be the only strain that binds to O-linked sialic 
acids/mucins. A particular interesting feature of AAV4 is the distinct transduction profiles 
after systemic administration or direct injection into central nervous system. AAV4 
transduces heart and lung specifically after intravenous injection in mice 125. If administered 
directly into the lateral ventricle, AAV4-mediated transgene expression accumulates in 
ependymal cells and astrocytes in the subventricular zone and rostral migratory stream 
(RMS) 231. In addition, AAV4 also transduces specifically ependymal cells after intrastriatal 
injections 231. This property of AAV4 rendered it an ideal candidate for gene delivery of 
insulin-like growth factor 1 (IGF-1) and vascular endothelial growth factor (VEGF) into 
mouse models of amyotrophic lateral sclerosis (ALS) 232.  
Despite our growing knowledge of AAV4 in CNS, not much is understood pertaining 
to the biological mechanism behind its cardiopulmonary tropism. Meanwhile, reengineered 
strains of AAV have emerged for airway-specific transduction. For example, the pulmonary 
tropic AAV2.5T was discovered by directed evolution of combinatorial AAV libraries on 
well-differentiated Human Airway Epithelial Cells (HAE) 134. In addition, DNA shuffling of 
AAV1, 6, and 9 in combination with directed evolution also resulted in two chimera AAV 
strains with higher transduction efficiency on in vitro HAE culture 141 Therefore, a thorough 
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understanding of AAV vectors in cardiopulmonary system also promotes the design and 
engineering of AAV vectors with enhanced transduction profiles.  
In a recent study, we used AAV9 as model system to demonstrate that AAV-glycan 
receptor interactions are determining factors of hepatotropism and blood circulation profiles 
of AAV 51. Specifically, higher binding avidity between AAV9 and its cognate glycan 
receptor drives its accumulation in liver and depletes viral particles from blood stream 
rapidly. On the contrary, lower binding avidity between AAV9 and galactoses detargets 
AAV9 from liver and leads to a longer blood retention time. In the current study, we 
hypothesized that O-linked sialylated glycans serve as a key determinant in AAV4 infectious 
pathway after cell surface attachment. To dissect the functional roles of sialylated glycans in 
AAV4 lifecycle, AAV4-sialic acid interactions were disrupted using two strategies: (1) 
enzymatically removal of sialic acids in mice, and (2) characterization of AAV4 mutants 
deficient in sialic acid binding in vitro and in vivo. Our data support the notion that sialylated 
glycans are indispensable for the cellular binding and uptake of AAV4 both in vitro and in 
vivo. These results also reveal that sialic acid-mediated interactions between AAV4 and 
erythrocytes are indispensable for the blood circulation and cardiopulmonary tropism of 
blood-borne AAV4 in mice. 
AI.3 Materials and Methods 
Random Mutagenesis. AAV4 helper plasmid (pXR4), containing Rep2 and Cap4, 
was obtained from UNC vector core. Random mutations were introduced to the GH loop 
(amino acids 428-617 on VP1, GeneBank no.: U89790.1) by error-prone PCR using the 
GeneMorph II EZ clone domain mutagenesis kit (Agilent Technologies, Santa Clara, CA). 
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Briefly, forward primer 5’-AACCCTCTCATCGACCAGTAC-3’ and reverse primer 5’-
TCCATCGGTATGAGGAATCTT-3’ (IDT, Coralville, IA) were utilized in PCR cycles 
according to manufacturer’s instruction to amplify regions on Cap4 encoding GH loop with 
random mutations. Individual pXR4 mutant clones were sequenced by the University of 
North Carolina Genome Analysis facility, and sequence alignments were carried out using 
VectorNTI software (Invitrogen, Carlsbad, CA). 
Molecular Modeling. Surface models of AAV4 were displayed as a full icosahedral 
capsid or trimers using the crystal structure of AAV4-VP3 from RCSB Protein Data Bank 
(PDB-ID: 2G8G) in PyMOL. Homology models of 4.18 and 4.41 were obtained using the 
SWISS-MODEL online server (http://swissmodel.expasy.org/) 213 with the crystal structure 
of AAV4-VP3 (PDB-ID: 2G8G) as a template. Three-dimensional models of the three-fold 
axes of 4.18 and 4.41 were generated using the oligomer generator utility in VIPERdb 
(http://viperdb.scripps.edu/oligomer_multi.php) 214, and visualized in PyMOL Molecular 
Graphics System (Schrödinger, LLC., New York, NY).  
Cell Culture. HEK293 cells were obtained from UNC Vector Core and cultured in 
Dulbecco’s Modified Eagle’s Medium supplemented with 10% fetal bovine serum (FBS), 
100 U/ml of penicillin, 100 µg/ml of streptomycin, and 2.5 µg/ml of amphotericin B (Sigma-
aldrich, St. Louis, MA). CV-1 cells (African green monkey fibroblast) were a gift from Dr. 
Jude Samulski (UNC-Chapel Hill) and propagated in Eagle's Minimum Essential Medium 
with 10% FBS, 100 U/ml of penicillin, 100 µg/ml of streptomycin, and 2.5 µg/ml of 
amphotericin B. All cell cultures were maintained in 5% CO2 at 37°C. 
Virus Production, Purification, and Quantification. Recombinant AAV4 and 
mutants were generated by triple-plasmid transfection method as described earlier 166. All 
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three plasmids were obtained from UNC vector core unless mentioned otherwise. Briefly, a 
log-phase culture of HEK293 cells were transfected with the following three plasmids using 
polyethylene imine (Polysciences, Warrington, PA): (1) the AAV4 helper plasmids, pXR4, 
or mutant pXR4 generated from random mutagenesis described earlier, (2) pXX6-80 
expressing Adenoviral helper genes, and (3) pTR-CBA-Luciferase, CBA-promoter-driven 
firefly luciferase transgene flanked by two Inverted-Terminal-Repeats (ITR) from AAV2. 
60-72 hrs post transfection, HEK293 were pelleted by centrifugation and supernatant was 
collected. A stock solution of 40% [wt/vol] polyethylene glycol 8000 (PEG8000) and 2.5M 
NaCl was added in the supernatant to a final concentration of 8% PEG8000 and 0.5M NaCl. 
After overnight incubation at 4ºC, the precipitate was sedimented by centrifugation at 10k 
rpm for 30 min. This precipitate from supernatant and cell pellet were combined and 
subjected to cesium chloride untracentrifugation at 55k rpm in 17ºC overnight in a T-890 
rotor (Thermo Scientific). Peak fractions with highest luciferase activity were collected and 
dialyzed against 1xPBS twice prior to titration of viral genome with quantitative PCR using a 
Roche Lightcycler 480 (Roche Applied Sciences, Pleasanton, CA). Quantitative PCR primers 
were designed to specifically recognize luciferase gene (forward 5’-AAA AGC ACT CTG 
ATT GAC AAA TAC-3’; reverse 5’-CCT TCG CTT CAA AAA ATG GAA C-3’). A virus 
stock with a previously known titer was included in qPCR as an internal control for viral 
genome titration. 
 In Vitro Transduction Analysis, Cell Surface Binding Assay, Internalization 
Assay. CV-1 cells were seeded in 24-well plates at a density of 1e5 cells/well 18 hrs prior to 
experiment. The cells were first pre-chilled at 4ºC for 30 min, and then AAV4, 4.18, and 4.41 
packing CBA-luciferase transgene were incubated on CV-1 cell surface at 4ºC for 60 min 
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followed by three washes with ice-cold 1x phosphate-buffered saline (1xPBS) to remove 
unbound virions. For transduction assays, 0.5 ml of DMEM with 10% FBS was replaced 
onto CV-1 cells before they were moved back to 37ºC incubator with 5% CO2. 18 hrs later, 
cells were lysed to quantify the luciferase transgene expression in a Victor2® luminometer 
(Perkin Elmer, Waltham, MA).  
For binding assays, after removal of unbound virions by washes with cold PBS as 
descried above, 200 µl of ddH2O was added to each well. Cells went through three freeze-
thaw cycles followed by DNA extraction using DNeasy kit (Qiagen, Germantown, MD). The 
amount of transgene in each well was titrated by quantitative PCR as previously described. 
In internalization assays, CV-1 cells were seeded at a density of 1e5 cells/well in 24-
well plates the day before experiment to allow for attachment to the plates. During the 
internalization assay, cells were first chilled to 4ºC in cold room before adding viruses at an 
MOI of 1000 vg/cell. After incubation of viruses on cell surface at 4ºC for 60 min, unbound 
viruses were wash away by three changes of cold 1xPBS, and fresh DMEM was replaced for 
each well. Cells were brought into 37ºC incubator to synchronize virus internalization. 1 hour 
later, cells were treated with 150 µl/well of 0.25% trypsin at 37ºC for 5 min to release cell 
surface-associated AAV. Trypsinization was quenched by adding 150 µl/well of DMEM 
with 10% FBS into each well, followed by three washes of cell pellets with ice-cold PBS. 
DNA was extracted from cell pellets using DNeasy kit, and viral genome copy numbers were 
measured using qPCR as previously described in binding assays. 
Hemagglutination Assay. All our animal experiments were performed on 6-8 weeks 
old female BALB/c mice purchased from Jackson Laboratories (Bar Harbor, ME). Animals 
were maintained and treated in accordance with National Institutes of Health guidelines and 
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as approved by Institutional Animal Care and Use Committee (IACUC) at UNC at Chapel 
Hill. 6-8 weeks old female BALB/c mice were anesthetized using 1.25% avertin through 
intraperitoneal injection before blood was drawn using cardiac puncture. Murine erythrocytes 
were collected by centrifugation at 5k rpm for 5min, washed three times in 1xPBS, and 
diluted by 10-fold with Alsever’s solution (2.05% [wt/vol] glucose, 0.8% sodium citrate, 
0.055% citric acid, 0.42% sodium chloride, pH 6.1).  Hemagglutination assay was carried out 
on a V-bottomed 96-well clear plate in cold room. Briefly, 1e11 vg of AAV4, 4.18, and 4.41-
CBA-luciferase were serially diluted in 2-fold steps with 1xPBS, respectively. 50 µl of 10% 
murine erythrocytes were added into each well, and incubated with virus for 1 hour in cold 
room. Hemagglutination titer was determined as the lowest fold-of-dilution of virus stocks 
that disrupt hemagglutination. 
Ex Vivo Blood Cell Binding Assay. Whole blood from BLAB/c mice were collected 
as described above. Whole blood were mixed with two volumes of Alserver’s solution to 
prevent coagulation, and further diluted into 10% with 1xPBS and kept in 4ºC. 2e10 vg of 
AAV4, 4.18, and 4.41-CBA-luciferase were incubated with 100 µl of 10% whole blood on 
ice for 1 hour, followed by separation of plasma and blood cells by centrifugation. Blood 
cells were subjected to three washes with ice-cold 1xPBS prior to viral genome extraction 
from both blood cells and plasma using DNeasy kit. The amount of viral genome in each 
fraction was measured using qPCR with primers specific to luciferase transgene. 
Transduction and Biodistribution Assays in Live Animals. To investigate the 
effect of sialic acid in AAV4 tropism in vivo, BALB/c mice were injected with either 400 
mU/mouse of sialidase (Type III, from V. Cholera, Sigma) or 1xPBS through tail vein 3 hrs 
prior to administration of AAV4-CBA-luciferase (1e11 vg/mouse) via the same route. To 
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track luciferase transgene expression pattern in mice at indicated time points, aminals were 
anesthetized with 2% isoflourane prior to intraperitoneal injection of D-luciferin (120 mg/kg, 
Nanolight, Pinetop, AZ), and imaged using an Xenogen IVIS Lumina® imaging unit (Perkin 
Elmer/Caliper Life Sciences, Waltham, MA) at indicated parameters. To test transduction 
profiles of AAV4 mutants, 5e10 vg of each AAV4 variant was injected intravenous into 
BALB/c mice. Luciferase transgene expression in live animals was imaged as described 
above at indicated time points.  
To quantify luciferase expression in individual organs, the same group of mice from 
imaging experiment was sacrificed to harvest about 50 mg tissues from indicated organs. 150 
µl of 2x passive lysis buffer (Promega, Madison, WI) was added to each tissue before lysing 
them on a Tissue Lyser II 352 system (Qiagen, Valencia, CA). Tissue lysates were pelleted 
using centrifugation. 50 µl of supernatant from each lysate was subjected to luciferase assay 
on a Victor2® luminometer (Perkin Elmer, Waltham, MA). 2 µl of supernatant was used in 
Bradford assay (BioRad, Hercules, CA) to determine protein content in each sample.  
For biodistribution analysis, a second group of BALB/c mice were injected with the 
same viruses and killed at 3 days post administration to harvest organs. 50 mg of tissue from 
each organ were pretreated with proteinase K prior to being homogenized in a Tissue Lyser. 
DNA was extracted from tissue lysates using DNeasy kit (Qiagen, Germantown, MD). Viral 
genome copies were measured using qPCR with primers binding to Luciferase transgene, 
while number of cells in each lysate sample was quantified using qPCR with primers specific 
to mLamin housekeeping gene. Data were shown as viral genome copies normalized by cell 
numbers. 
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Pharmacokinetics Assay. BALB/c mice were pretreated with intravenous sialidase 
or PBS as previously described. 3 hrs post administration, 1e11 vg copies of AAV4, 4.18, or 
4.41-CBA-Luciferase were injected into animals through tail vein. 10 ul of blood was 
collected by tail nicking at the following time points post injection: 5 min, 15 min, 30 min, 1 
hour, 3 hrs, 6 hrs, 24 hrs, 30 hrs, 48 hrs, and 72 hrs. DNA was extracted from each blood 
sample using a DNeasy kit, and viral genome copy numbers were measure using qPCR as 
described previously. 
AI.4 Results 
Intravenous sialidase abrogates the cardiopulmonary transduction profile and 
biodistribution of AAV4 in mice. To investigate how interactions with sialic acids impact 
on AAV4 tropism, a broad-spectrum sialidase from Vibrio cholerae was administered 
intravenously into BALB/c mice to remove cell-surface exposed sialic acid moieties on 
major organs. Previous study demonstrated that the density of terminal galactose on the 
surface of major organs increased significantly after systemic administration of this 
sialidase 51. This increase of galactose-terminated glycans was accompanied by moderate 
decrease of terminal sialic acids in the same organs, as shown by Erythrina Cristagalli Lectin 
(ECL) and Maackia Amurensis Lectin I (MAL I) staining  51. 3 hrs post sialidase treatment, 
AAV4 packaging chicken beta-actin promoter-driven firefly luciferase transgene (CBA-
Luciferase) was injected into BALB/c mice intravenously. Bioluminescence images were 
obtained at 7 days post administration. As shown in Figure 32A, transgene expression of 
AAV4 is localized specifically in lung and heart regions in PBS-treated BALB/c mice, and 
this transduction profile is absent in mice pretreated with sialidase. This observation was 
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corroborated with luciferase expression assay and biodistribution analysis of tissue lysates 
from the same group of animals. In consistent with bioluminescence images, luciferase 
transgene expression (Figure 32B) in heart and lung shows stark decreases by ~300-fold and 
600-fold respectively in sialidase-treated group compared to PBS mock-treated group. The 
decrease of luciferase expression was also observed in leg muscle (~15-fold), spleen (~2.5-
fold), and kidney (~12-fold), but transgene expression in liver remained at the same level in 
sialidase-treated mice compared to PBS-treated group.  
Quantitative analysis of viral genome copy numbers in major organs demonstrates the 
effect of sialidase on the biodistribution of AAV4 viral particles (Figure 32C). Normalized 
to the copy numbers of mouse genomic DNA, the biodistribution profiles of AAV4 reflects 
the trend displayed by the aforementioned transduction efficiency profiles. Specifically, there 
are > 250-fold and ~400-fold decreases of viral genome accumulation in heart and 
pulmonary system in sialidase-treated mice, respectively. Modest reductions of viral genome 
copies per cell were seen in leg muscle (~17-fold), spleen (~3-fold), and kidney (~12-fold) 
due to intravenous injection of sialidase, while no statistically significant changes observed 
in hepatic tissues. These results indicate that sialic acids play a critical role in mediating 
efficient infection of AAV4 in the cardiopulmonary system in mice.  
O-linked sialic acids are highly expressed in the cardiopulmonary system in mice. 
To interrogate the underlying mechanism of the differential transgene expression profiles and 
biodistribution patterns of AAV4, we hypothesized that glycan receptors plays a critical role 
in determining the tropism of AAV4. Using lectin staining, the endogenous distribution of 
the primary receptor for AAV4 – O-linked sialylated glycans – was analyzed in murine heart, 
lung, and liver. Briefly, sections of heart, lung and liver from BALB/c mice underwent 
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immunostaining by fluorescein labeled Jacalin lectin (FITC-Jacalin). Jacalin is a lectin 
isolated from jackfruit Artocarpus integrifolia 233. It specifically recognizes glycopeptides 
that contain O-linked oligosaccharides with a disaccharide core of Galactose-(N-Acetyl-
)Galactosamine (Gal-GalNAc) covalently linked to serine or threonine residues 234. Therefore, 
Jacalin has been widely used as markers for O-glycosylation, such as mucins. As seen in the 
left panel of Figure 33, FITC-Jacalin shows markedly higher staining on the ciliated mouse 
airway epithelial lining and the alveoli. Similar intensity of FITC staining is evenly present in 
the cross-section of murine hearts (middle, Figure 33), indicating the outlines of 
cardiomyocytes. On the contrary, FITC-Jacalin does not stain liver sections with comparable 
intensity uniformly (right, Figure 33). Only the endothelial side of blood vessels in murine 
livers is stained by FITC-Jacalin, leaving both parenchymal and nonparenchymal cells 
unstained. Together with the aforementioned cardiopulmonary tropism of AAV4, these data 
suggest a pivotal role of O-glycosylation in the transduction profiles and biodistribution 
patterns of AAV4. 
An AAV4 library was constructed by random mutagenesis on the GH loop near 
the three-fold axis of symmetry. The three fold axes of symmetry on AAV capsids have 
been claimed to be responsible for receptor recognition by AAV1, AAV2, AAV3b, AAV6, 
and AAV9 43,83,90,92-94,165,198. The protrusion and spike structures surrounding the three fold 
axes are composed of highly dynamic loops connecting seven strands of the core β-sheet 
structure. These loops share low amino acid sequence homology among AAV strains, and 
demonstrates high flexibility according to X-ray crystallography 81,82,165,198,212,235-237. To 
identify key residues involved in sialic acid binding at three-fold axes on AAV4 capsids, a 
random library of AAV4 was generated by introducing mutations on the GH loop connecting 
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the G and H strand of the core beta sheet in VP (highlighted in blue in Figure 34A). 48 
individual clones of plasmids encoding Rep from AAV2 and mutated Cap from AAV4 
(pXR4) were selected arbitrarily from this library reservoir. By structural modeling, mutant 
isolates with the following features were excluded from further analysis: silent mutations, 
frame-shifts, deletions, mutations buried inside tertiary structure, or mutations only exposed 
on the interior side of capsid. As a result, 9 variants were selected out of 48 mutant AAV4 
isolates for further characterization (Table 7). A collection of mutations on these 9 variants 
were clustered on the exterior of spikes forming the three-fold axes, as highlighted in blue in 
Figure 34.  
4.18 and 4.41 are deficient in sialic acids binding and cellular internalization. In 
order to identify AAV4 mutants that are unable to bind to sialic acids, we carried out an in 
vitro screening of infectivity on CV-1 cells. CV-1 cells, kidney fibroblasts from African 
green monkey, are highly permissiveness to AAV4 infection. In this screening, CV-1 cells 
were infected with mutant AAV4 capsids packaging CBA-Luciferase reporter gene. 
Luciferase transgene expression was measured as the indicator of infectivity. As 
demonstrated in Figure 35A, the infectivities of both 4.18 and 4.41 are more than one log 
unit lower than that of the parental AAV4 in CV-1. To investigate the fundamental reasons 
for this loss of infectivity displayed by 4.18 and 4.41, cell surface binding and internalization 
assays were carried out on CV-1 cell cultures. As shown in Figure 35B (grey bars), both 
4.18 and 4.41 displayed 2-4 –fold lower binding capacity on CV-1 cells surface. More 
interestingly, the differences between the internalization efficiencies of 4.18/4.41 and that of 
AAV4 (white bars, Figure 35B) are more significant. At the multiplicity infection (MOI) of 
1000 vg/cell, there are 20 AAV4 bound onto CV-1 surface on average, 10 of which are 
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further internalized after 1 hour incubation in 37°C. In contrary, at the same MOI, only ~ 10 
viral particles of 4.8/4.41 are bound to CV-1 surface, and ~1 virion is internalized later on 
average. This percentage of internalization depicted in Figure 35C strongly supports the 
notion that 4.18/4.41 are deficient in both cell surface binding and cellular uptake in an in 
vitro setting. Together with results from the infectivity screening, these data suggest that 
AAV4 mutants with low sialic acid binding affinity demonstrate less cellular attachment and 
uptake, which further leads to reduced infectivity in vitro.   
  4.18 and 4.41 are incapable in transducing the cardiopulmonary system in vivo. 
While the in vitro screening of AAV4 mutants were carried out, the same set of AAV4 
variants were subjected to in vivo characterization by monitoring their transgene expression 
after intravenous injections. At 1 month post injection, bioluminescence images were 
collected, and two types of transduction pattern were observed: (1) Cardiopulmonary 
transduction similar as that of parental AAV4, such as 4.7, 4.15, 4.19, 4.29, 4.31, 4.38, and 
4.49 (Figure 36A); (2) Lost of transduction efficiency in vivo, as displayed by 4.18 and 4.41 
(Figure 36A). The classification of these two phenotypes was verified by luciferase assays 
on tissue lysates isolated from the same group of animals (Figure 36B). Compared to 
parental AAV4, only 4.18 and 4.41 demonstrate decreased luciferase activity across all major 
organs, including heart, lung, leg muscle, liver, and spleen (Figure 36B). Specifically, in 
case of 4.18, transduction efficiency in heart dropped by more than two orders of magnitude, 
while that in lung decreased by over a log; in case of 4.41, more dramatic lost in transduction 
efficiency was observed in lung tissue (>100-fold), while there was only a 10-fold decrease 
of transduction efficiency in heart.  
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These results are further corroborated by the biodistribution of viral genome of 4.18 
and 4.41 as compared to AAV4 (Figure 36C).  Consistent with the trend of transduction 
efficiency shown in Figure 36B, 4.18 and 4.41 displayed ~5-10 -fold decrease in viral 
genome accumulation in heart and lung compared to the parental AAV4. Similar loss of viral 
genome copies was also observed in muscle and kidney. The biodistribution of both 4.18 and 
4.41 in hepatic tissues remain unaltered, while only 4.41 showed ~10-fold reduction in 
biodistribution in spleen. Taken together, these results suggested that 4.18 and 4.41 are 
unable to entry and transduce the cardiopulmonary system in mice due to surface exposed 
mutations on the three-fold axes. According to in vitro data on CV-1 cells, the loss of 
function of 4.18 and 4.41 results from their inability to bind and enter cells in target tissues 
marked by high O-glycosylation. 
4.18 and 4.41 bind to erythrocytes with lower avidity. To correlate the in vitro 
binding and internalization data of 4.18 and 4.41 with their in vivo transduction profiles, an 
ex vivo blood binding experiment and hemagglutination assays were carried out with blood 
and erythrocytes from BALB/c mice, respectively. After incubating viruses with freshly 
prepared whole blood on ice, plasma and blood cells were separated using centrifugation, and 
the amount of viral genome distributed in each fraction were measured with qPCR. With the 
total amount of recovered viral genome as total virions, 75% of AAV4 was associated with 
blood cells, while only 25% of 4.18 and 40% of 4.41 were recovered from the fractions with 
blood cells (Figure 37). The majority of 4.18 and 4.41 remained in plasma. This observation 
reveals that 4.18 and 4.41 do not bind to blood cells as efficiently as AAV4.  
These observations prompted us to carry out hemagglutination assays (Table 7) to 
quantitatively compare the avidities between 4.18/4.41 viruses and murine erythrocytes. As 
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negative control that does not bind to sialic acids, AAV2 has an HA titer of 2, the same as 
that of PBS. Consistent with previous publications 46, AAV4 has an HA titer of 128, 
indicating a high binding affinity towards sialic acids. Both 4.18 and 4.41 only showed HA 
titers of 4, suggesting that they do not bind to sialylated glycans as efficiently as the parental 
AAV4. This sialic acid binding deficiency leads to less association with blood cells (Figure 
37), which are decorated with a spectrum of sialylated glycans. In corollary, 4.18 and 4.41 
are taken up by tissues and organs with lower efficiencies in vivo, leaving most virions 
cleared from reticuloendothelial system (RES).  
Lower erythrocyte binding avidity leads to faster blood clearance profiles of 
AAV4 in mice. In order to further understand the role of sialic acids in AAV4 infection in 
vivo, pharmacokinetics analysis of AAV4 in mice with and without sialidase treatment was 
performed (Figure 38A). At 24 hrs after virus administration, AAV4 viral genome in the 
blood of PBS-treated mice is more than 2-fold higher than that in the blood of desialylated 
mice. This difference became ~20-fold when it comes to 72 hrs post virus dosing. These 
results reveal that the availability of sialic acid receptors in vivo also alters the adsorption of 
AAV4 from blood to tissue, together with its clearance from blood circulation through 
unidentified routes. We then carried out pharmacokinetics analysis of 4.18/4.41 and AAV4 to 
elucidate the mechanism of their different biodistribution profiles (Figure 38B). Within 24 
hrs post virus administration, the amount of viral genome in total blood for both 4.18 and 
4.41 are notably lower than that of AAV4, indicating fast clearance rate from blood 
circulation. Therefore, lower erythrocytes binding avidity, resulted from either less sialic acid 
receptors or disruption of glycan receptor footprints on viral capsids, leads to faster 
pharmacokinetic profiles of AAV4 virions.  
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AI.5 Discussion 
Sialylated glycans function as cellular attachment receptors for a broad spectrum of 
viruses, including influenza, rotaviruses, coxsackieviruses 1,192. In the Dependoviridae genus 
of the Parvoviridae family, AAV4 is the only serotype that binds to O-linked 2,3-sialic acids, 
the polymeric form of which is called “mucin”. Mucin, produced by goblet cells on the 
epithelia of tracheobronchial, gastrointestinal, and genitourinary tracts, constitutes a 
defensive mechanism against exogenous pathogens. Even though both AAV4 and AAV5 can 
hemagglutinate red blood cells by binding to cell surface sialic acids, only AAV4 can be 
efficiently inhibited from infecting well-differentiated human airway epithelial (HAE) cells 
from the apical side 47. If infecting from the basolateral side, AAV4 transduces HAE 
efficiently through sialic acid-dependent pathway(s) 47. Given the specific cardiopulmonary-
tropism of blood-borne AAV4, the roles of sialic acids in AAV4 infectivity drew our 
attention. 
The role of glycan receptors in virus lifecycles is to determine the host tropism and 
interspecies transmissibility of viruses. Pathogenic respiratory viruses, such as influenza 
viruses and rhinoviruses, evolved to recognize specialized forms of sialic acids on upper 
airway epithelial cells to initiate their infectious pathways in host 11,238. Hepatitis B, C, and E 
viruses employ heparan sulfates, which is abundant on hepatocytes, to infect human liver 34-36. 
A good example of how glycan binding profile of AAV translates into tropism difference is 
AAV1 and AAV6 43. By a difference of six out of >700 amino acids on VP1 sequence, 
AAV1 binds only to N-linked sialic acids, while AAV1 binds to both N-linked sialic acids 
and heparan sulfates. As a result, besides muscle and lung for AAV1, AAV6 also transduces 
hepatocytes with moderate efficiency. Our recent study indicates that the systemic 
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transduction profile of AAV9 is driven by the low glycan binding avidity and the low 
availability of cognate glycan receptors 51. In current study, by disrupting sialic acid-AAV4 
interactions, the endogenous cardiopulmonary transduction profile of AAV4 is completely 
lost, with pharmacokinetics profiles altered. Our data bridges the in vitro results of AAV4-
erythrocytes interactions with its behaviors in vivo. After systemic administration, AAV4 
enters the blood circulation, and has a preferential affinity towards organs expressing O-sialic 
acids abundantly. Upon intravenous injection of sialidase, the interactions between AAV4 
and cell-surface sialic acids are interrupted. Therefore, AAV4 are unable to bind to blood 
cells or internalized into tissues, and eventually end up cleared from the blood circulation 
faster. The same reasoning also applies to AAV4 mutants with disrupted sialic acid binding 
footprint.  
For the first time, it is suggested that sialylated glycans play a multi-facet role in the 
infectious pathway(s) of AAV4 in vivo. Reconstitute of sialic acid moieties on desialylated 
rhesus erythrocytes by α-2,3-O-sialyltransferases, but not α-2,3-N-sialyltransferases recovers 
the sialic acid binding avidity of AAV4  46. It suggests that polysaccharides linked to Ser/Thr 
residues on glycopeptides are critical for cell surface attachment of AAV4. However, the 
protein receptor(s) involved in the cellular uptake of AAV4 has yet to be determined. Of 
other sialic acid-binding AAV serotypes, platelet-derived growth factor receptor (PDGFR) 
and epidermal growth factor receptor (EGFR) were determined to be the secondary receptors 
for AAV5 and AAV6, respectively 102,103. In addition, there is no integrin binding motif 
(RDG or NGR) on AAV4 capsid either. Based on the internalization assay of 4.18 and 4.41, 
it is tempting to speculate that sialylated glycans are also a determining factor in mediating 
the cellular internalization of AAV4. 
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Another critical finding in this study is the identification of key amino acids involved 
in glycan-AAV4 interactions. In case of heparan sulfate-binding AAV2, there is a basic strip 
(R484, R487, K532, R585, R588) on the protrusions of three-fold axes which is critical in 
interacting with glycans 83,89,90,92. When it comes to AAV6, its heparan sulfate binding ability 
can be attributed to a single amino acid, K531 43. Sequence alignment of several heparin-
binding proteins suggests a typical heparin-binding motif was proposed: XBBXBX or 
XBBBXXBX, where B is lysine or arginine, X is any other amino acids 2. Unlike heparan 
sulfate binding motif, no conserved binding site for sialic acid has been discovered across 
several viruses, or different strains of AAV. Based on structure-function studies of canine 
parvoviruses (CPV) 239 and minute virus of mice (MVM) 240, amino acid residues at similar 
position as basic residues on AAV2/AAV6 are responsible for sialic acid binding 43,83,89,90,92. 
From this current study, key residues on proposed sialic acid binding footprint is focused on 
K492, K503, M523, G581, Q583, N585 near the three-fold axes. By sequence alignment and 
structural comparison, G581-N585 geographically equivalent to the basic stretch on AAV2. 
K492 and K503 both constitute dominant basic patch on the exterior of protein shell at 
locations close to its counterpart on AAV2 capsid. Mutations at these positions, but not 
around 450-465 or 588-610, significantly affect the sialic acid binding profile of AAV4. 
Mutagenesis study with individual residues would provide more information on this region. 
Our attempts to dissect the functions of variable regions on AAV4 capsid by random 
mutagenesis provides substantial aids in understanding the structure-function relationship of 
AAV in general. 
In conclusion, our study provides new insights into the functional roles of sialylated 
glycans in AAV4 biology. Sialylated glycans not only serve as attachment factors for AAV4, 
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but also induce its cellular uptake in both in vitro models and in vivo models. Thus, 
interactions between AAV4 and its cognate glycan receptors are indispensable for its 
infection in cardiopulmonary system. In addition, we also identified key residues (K492, 
K503, M523, G581, Q583, N585) on the three-fold axes of AAV4 capsid that compose part 
of sialic acid binding motif, and reconfirmed that trimer-forming GH loop is critical in 
receptor binding of AAV. With this random library of AAV4, more aspects of AAV4, such 
as immunogenicity determinants, can be studied to facilitate AAV4-based vector design. 
Furthermore, this study might also contribute to our understanding on the mechanism of how 
AAV4 transduces ependymal cells and astrocytes in CNS. 
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Table 7. List of AAV4 Mutants 
Number Point Mutations on AAV4-VP3 
4.7 T454S 
4.15 T496S, S515C, L564P, L588M, R593G, M603V, I610T 
4.18 K492E, K503E, N585S 
4.19 K479N, L501F, A569P 
4.20 T446A, S584G 
4.31 L588Q 
4.38 T463A, W514L, Q537L, G581C  
4.41 M523I, G581D, Q583E 
4.49 R593D 
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Table 8. The Ability of AAV4 and Mutants to Hemagglutinate Murine Erythrocytes 
Virus Hemagglutination Titer 
PBS < 2 
AAV2 < 2 
AAV4 < 128 
4.18 <4 
4.41 < 4 
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Figure 32. Enzymatic removal of sialic acids in vivo disrupts AAV4 transduction. (A) 
Live animal images of AAV4-mediated luciferase transgene expression in BALB/c mice. 
Mice (n=4) were injected with PBS or sialidase from Vibrio Cholera (400 mU/mouse) 
through tail vein 3 hrs prior to AAV4-CBA-Luciferase (1e11 vg/mouse) injection via the 
same route. At 7 days post infection, live animal bioluminescence images were recorded with 
an Xenogen IVIS Lumina Imaging System. Scale stands for relative light units (RLU) as 
photons per sec per cm2 per steradian. (B) Luciferase transgene expression in tissue lysates at 
7 days post infection. PBS or sialidase were injected intravenously into BALB/c mice (n=4) 
3 hrs before AAV4-CBA-Luciferase administration. At 7 days post infection, heart, liver, 
lung, leg muscle, spleen, and kidney were harvested from animals. Luciferase transgene 
expression in each tissue lysate was measured using a bioluminescence plate reader. Values 
were expressed in RLU normalized to amount of protein in each lysate sample. Data are 
shown as mean ± s.e.m. (n=4). (C) Biodistribution of AAV4 viral genomes in BALB/c mice. 
DNA contents in tissue lysates from experiment in (B) were isolated and subjected to 
quantitative PCR analysis, as described in Materials and Methods. Viral genome copies were 
normalized to copy numbers of housekeeping gene mLamin. Data are shown as mean ± s.e.m. 
(n=4). Statistical significance was analyzed using the one-tailed Student’s t-test (* p < 0.05; 
**p < 0.01). 
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Figure 33. Expression of sialylated O-glycans in murine lung, heart, and liver. Lung, 
heart, and liver tissues harvested from BALB/c mice were stained with FITC-Jacalin, a lectin 
specific to O-linked polysaccharides. Confocal micrographs were obtained using a Zeiss 710 
Confocal Laser Scanning Microscope with a 20x objective at zoom 0.6. Scale bar = 100 µm.  
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Figure 34. Three dimensional models of AAV4 capsid and trimer models of 4.18 and 
4.41. (A) Three-dimensional structural model of an intact AAV4 capsid with its backbone 
colored in red and GH loops (VP1 numbering: 428-617) highlighted in blue, respectively. (B 
 150 
 
and C) Visualization of AAV4 trimeric assembly from exterior of the capsid. The GH loops 
(B) or the cluster of point mutations (C) introduce by random mutagenesis are marked in 
blue. (D -L) Surface representations of the VP3 trimers of individual AAV4 mutants from 
the random mutagenesis library, respectively. Residues mutated from the parental AAV4 are 
highlighted in blue. Models were visualized and generated using PyMOL. 
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Figure 35. Infectivity, binding and internalization assays of AAV4, 4.18, and 4.41 on 
CV-1 cells. (A) Infectivity of AAV4, 4.18, and 4.41 on CV-1 cells. AAV4, 4.18, and 4.41-
CBA-Luciferase (MOI=1000 vg/cell) were incubated on pre-chilled CV-1 cells for 1 hour 
before three washes of PBS to remove unbound viral particles. 18 hrs later, cells were lysed 
to quantify luciferase transgene expression using bioluminescence plate reader. Data were 
presented as mean ± s.e.m. (n=4) in RLU. (B) Binding (grey bars) and internalization (white 
bars) of AAV4, 4.18, and 4.41 on CV-1 cells. Viruses packaging CBA-Luciferase transgene 
were allowed to bind on prechilled CV-1 cells for 1 hour. After three washes with ice-cold 
PBS, cells were either lysed to measure numbers of bound virions using qPCR, or moved 
into 37ºC incubator to allow for internalization. 1 hour after 37ºC incubation, viral particles 
not internalized were removed by trypsin. Trypsin-resistant viral particles in CV-1 cells were 
quantified using qPCR. Data were shown as mean ± s.e.m. (n=4) in vg/cell. (C) Percentage 
of internalization of AAV4, 4.18, and 4.41. The amount of internalized virions (B, white bars) 
was normalized to the amount of bound virons (B, grey bars) for AAV4 and mutants to show 
differences in internalization efficiency on CV-1 cells. Statistical significance was analyzed 
using the one-tailed Student’s t-test (* p < 0.05; ** p < 0.01). 
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Figure 36. Transduction profiles of 4.18 and 4.41 in vivo. (A) Live animal images of 
luciferase transgene expression mediated by AAV4, 4.18, and 4.41. AAV4 and mutants 
packaging CBA promoter-driven Luciferase transgene were injected into BALB/c mice 
(5e10 vg/mouse) through tail vein. At 1 month post infection, luciferase expression profiles 
in live animals were obtained using Xenogen IVIS Lumina Luciferase Imaging System (n=3). 
Scales represents RLU as photons per sec per cm2 per steradian. (B) Luciferase expression in 
tissue lysates. Animals shown in (A) were sacrificed at 1 month post infection to harvest 
heart, liver, lung, leg muscle, and spleen tissues. After lysing, luciferase expression in these 
tissues was recorded using bioluminescence plate reader. Data are shown as mean mean ± 
s.e.m. (n=4) in RLU. (C) Biodistribution of 4.18 and 4.41 in BALB/C mice at 3 days post 
infection. AAV4, 4.18, and 4.41 (5e10 vg/ul) packaging CBA-Luciferase transgene were 
injected into BALB/c mice intravenously. 3 days post infection, heart, liver, lung, leg muscle, 
and spleen were collected from animals to extract DNA. Viral genome copy numbers were 
obtained using qPCR, and normalized to number of mLamin genomic DNA copy numbers. 
Data are plotted as mean mean ± s.e.m. (n=4). Statistical significance was analyzed using the 
one-tailed Student’s t-test (* p < 0.05; ** p < 0.01). 
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Figure 37. Distribution of AAV4 and mutants in blood ex vivo. 2e10 vg of AAV4, 4.18, 
or 4.41-CBA-Luciferase was incubated with 100 µl of 10% blood collected from BALB/c 
mice on ice for 1 hour. Plasma and cells were separated by centrifugation. Blood cells were 
washed with PBS three times to remove loosely bound virions. Amount of virus particles in 
plasma and cells were analyzed using qPCR after DNA extraction from both phases. Data 
were presented as percentage of total virions as normalized to total viral particles recovered. 
Error bars represent s.e.m. (n=5). Statistical significance was analyzed using the one-tailed 
Student’s t-test (* p < 0.05; ** p < 0.01). 
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Figure 38. Sialic acid binding avidity affects the blood clearance profiles of AAV4. (A) 
Kinetics of AAV4 clearance in blood within 72 hrs post infection. PBS or sialidase from 
Vibrio cholerae (400 mU/mouse) was intravenously injected into BALB/c mice (n=4) 3 hrs 
prior to AAV4-CBA-Luciferase administration via the same route. 10 µl of blood was 
collected from tail vein at indicated time points post AAV4 injection: 5 min, 15 min, 30 min, 
1 hr, 3 hrs, 6 hrs, 24 hrs, 48 hrs, and 72 hrs. Viral genome copies in blood samples were 
quantified using qPCR with primers annealing to Luciferase transgene. Data are shown as 
mean ± s.e.m. (n=4). (B) Blood clearance profiles of 4.18 and 4.41. AAV4, 4.18, and 4.41 
(1e11 vg/mouse) were administered into BALB/c mice via intravenous injections. 10 µl of 
blood was collected through tail vein at following time points post injection: 5 min, 15 min, 
30 min, 1 hr, 3 hrs, 6 hrs, 32 hrs, 48 hrs, and 72 hrs. Amount of viral genome in each blood 
sample was quantified using qPCR recognizing Luciferase transgene. Data are shown in vg 
in total blood as mean ± s.e.m. (n=4).  
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